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Abstract
The biomedical and pharmaceutical communities are experiencing a growing demand for
new druggable targets. On the other hand, many marketed drugs are being repurposed for their
newly uncovered pharmacological activities. In fact, off-target drug effects can either lead to
adverse events or new marketable indications. As the healthcare industry moves closer toward
systems biology and precision medicine, comprehensive profiling of small molecule-protein
interactions has become increasingly crucial. Chemical proteomics is a powerful set of
bioanalytical approaches that utilize small molecule chemical probes and affinity capture mass
spectrometry to study proteome-wide actions of reactive small molecules like drugs, toxins, and
metabolites.
This dissertation discusses multiple technical and methodological aspects of chemical
proteomics as a multidisciplinary subject. It presents two projects that exemplify the development
of chemical probes and implementation of chemical proteomics in two distinct directions known
as compound-centric and activity-based. Within both studies, the modification-specific data
processing principle has provoked awareness and thoughts on tailoring bioinformatics tools for
chemical proteomics.

Lei Wang – University of Connecticut, 2020

The 2-nitroimidazole-indocyanine green (2-nitro-ICG) project features the deployment of
a novel compound-centric chemical probe that answers how 2-nitroimidazole targets tumor
hypoxia. This study concludes that 2-nitro-ICG and its reduced fragments modify mouse albumin
as the primary target, but at two distinct sites via two different mechanisms. The development and
application of 2-nitro-ICG also demonstrate various analytical benefits, challenges, and pitfalls in
the compound-centric direction of chemical proteomics.
The α-methylene-β-lactone (MeLac) project presents an innovative activity-based probe
with multiple electrophilic sites. This study explores the significance of broad probe reactivity in
activity-based chemical proteomics. It concludes that MeLac is reactive to amino, hydroxyl, and
thiol groups on proteins. Moreover, the discovery of MeLac-alkyne glutathione adduct reveals a
potential shortcut for customizing compound-centric probes. Therefore, the multi-electrophilic
MeLac moiety creates both a versatile activity-based probe and a scaffold for assembling
compound-centric probes.
Overall, chemical proteomics has established its irreplaceable position in chemical biology.
Researchers exert efforts to make chemical proteomics technologies more applicable. The
chemical tools, analytical workflows, and bioinformatics support continue to improve. The field
of chemical proteomics will expand faster as more innovations emerge at its cutting edge.
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Chapter 1 Introduction to Chemical Proteomics
This chapter begins with a briefly introduction to the omics concept and its application in
modern biomedical and pharmaceutical research. Afterwards, it mainly focuses on a
comprehensive overview of bottom-up proteomics. The discussion touches multiple technical
aspects on sample preparation, analytical instrumentation, chemical tools, analytical
methodologies, and bioinformatics throughout a typical mass spectrometry-based bottom-up
proteomics workflow. Finally, the discussion extends to the introduction to chemical proteomics
involving application of these chemical tools and analytical approaches for studying proteomewide activity of small molecule compounds. The final discussion covers several challenges and
their related prospects in the field of chemical proteomics.

1

1.1 Multi-Omics as a Promising Path to Precision Healthcare
The universal detection and measurement of whole sets of biomolecules shape the
technological fundamental of omics research. The principle that a complex biological system can
be understood better if treated as a whole defines the characteristic methodology of the omics
approach.
Modern biomedical and pharmaceutical research often generates and tests hypotheses by
exploring the context of organelles, cells, tissues, organs, and organisms at the molecular level.
These explorations scrutinize functions and compositions of individual biological molecules and
address their interactions, relationships, and combined influence on an organism’s growth and
development. The omics approach is particularly suitable for those explorations. In hypothesisgenerating experiments, the omics approach acquires and analyzes all available data to construct
a hypothesis. In hypothesis-testing experiments, the omics approach highlights nuance, models
trends, and builds connections among various subsets of multiple complex biological samples. It
often discovers missing pieces from the existing knowledgebase. Moreover, the holistic datasets
accumulated in omics research are ready for retrograde analyses if necessary, even for completely
irrelevant objectives.
Thus, omics research naturally produces archivable data with great long-term values. A
complete biological sample only provides four sets of biological molecules, DNA/genes (genome),
mRNA (transcriptome), proteins (proteome), and metabolites (metabolome). From the genome to
metabolome, the volume of information expands as molecular diversity increases. (Figure 1.1)
Given the biological and chemical differences and similarities among these molecules, omics
research uses a variety of bioanalytical strategies and techniques. While genomics and
transcriptomics primarily rely on high-throughput sequencing technology using fluorescence
2

detection, proteomics and metabolomics employ liquid chromatography-tandem mass
spectrometry (LC-MS/MS) as the main analytical platform.
The principle of omics dates to the early 2000s with the completion of the Human Genome
Project.1 The establishment of automated high-throughput DNA sequencing and synthesis
pipelines formed the technological foundation for modern genomics research.2,3 Meanwhile, the
introduction of complementary DNA (cDNA) microarray and mass spectrometry-based protein
profiling technologies also enabled the quantitative analysis of the differential global gene
expression at messenger RNA level and protein level.4 These powerful tools marked a historical
milestone in transcriptomics and proteomics research. On the other hand, the growing availability
of spectroscopy, mass spectrometry, and nuclear magnetic resonance instruments allowed
functional analysis at the metabolite level, which was initially referred to as metabolic profiling
and metabolic control analysis.5 It was remarkable that the concept of complete multi-omics study
on the yeast model was reported as early as 1998.5,6
Nowadays, proteomics and metabolomics research frequently contribute to the
development of biomolecular indicators known as biomarkers7,8 for disease diagnosis9,
progression monitoring10, drug absorption, distribution, metabolism, and excretion (ADME) in
pharmacokinetics and pharmacology (PK/PD)11 studies. (Figure 1.2) Moreover, proteomics
platforms are also implemented with chemical tools that facilitate the analyses of intermolecular
interactions of proteins with other molecules. For instance, covalent chemical probes that react and
label proteins can analyze small molecule drug candidates’ effects on the target protein activity in
various stages of drug development, such as evaluating drug-target engagement, revealing offtarget effect, and assessing drug toxicity.12 Protein cross-linking reagents that react and conjugate
proximate protein pairs and assemblies can analyze protein-protein interactions and reveal
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biological roles of protein complexes.13 Complementary to genomics and proteomics platforms,
advanced metabolomics platforms rapidly expand knowledgebase of biochemical pathways and
metabolic networks in various organisms, which has led to recent achievements in studies on gut
microbiome-related regulations of human immune system.14
Analytically, omics samples are essentially mixtures of diverse biomolecules that require
pre-analysis preparation. Depending on the specific analytical goal, separation/extraction
techniques, which preserve a subgroup of these biomolecules as analytes of interest and remove
the rest as interference, are practiced accordingly. The protein or metabolite analytes in the
prepared samples are then resolved and measured at molecular level on liquid or gas
chromatography-mass spectrometry (LC-MS or GC-MS) systems. While high-resolving
power/accurate-mass (HR/AM) mass spectrometers enable unambiguous measurements of
biomolecules, ultra-high-performance liquid chromatography (UHPLC) systems provide extra
separation of various analytes online. Advanced mass spectrometers are often equipped with
instrumental components that can break down ions of analytes into fragments for tandem mass
spectrometry (MS/MS) measurements. These fragments contain more useful information as
molecular fingerprints. The capability of generating and measuring gas-phase fragments further
reinforces the analytical impact of mass spectrometers on the omics research. In fact, researchers
routinely use selective measurement of fragment ions generated in the gas phase as the method of
choice for quantifying biomolecules of interest in quantitative proteomics and metabolomics.
Apparently, the LC-MS/MS, a hyphenated analytical technology, has become the technological
core of the proteomics and metabolomics research.
Overall, contemporary multi-omics platforms (genomics, transcriptomics, proteomics, and
metabolomics) together with advanced bioinformatics tools and high-performance computing

4

systems are driving the fast advancement of multidisciplinary biomedical subjects such as systems
biology, synthetic biotics8 and translational medicine15, which ultimately enact precision and
personalized medicine as the state-of-the-art approach to healthcare.

5

1.2 The Bottom-up Proteomics Workflow

1.2.1 Overview of proteomics
Proteomics is the comprehensive study of proteins. It deciphers protein structures, posttranslational modifications (PTMs), cellular functions, biological/pathological significances, and
interactions with other molecules. Since proteins are the most important cellular machinery and
building blocks, proteomics investigations are being conducted at an escalating rate to explore
pathologies of a wide range of diseases and medical conditions including but not limited to
cancer7,16,17, neuro-degenerative disease18,19, infectious disease20,21, metabolic disorders22,23,
autoimmune disease24,25, and cardiovascular disease26. Proteomics studies routinely involve the
large-scale experimental analysis of proteins.
Depending on the specific study objective, proteins are analyzed either in their original
forms (native, slightly reduced, or denatured) or proteolytically cleaved forms. This analytical
choice further splits proteomics into two strategic divisions as top-down proteomics and bottomup proteomics (also known as shotgun proteomics27). Each of them has its unique sets of
experimental practices and analytical emphases. In general, the top-down strategy is more suitable
for protein structure elucidation of purified protein samples. It has the potential to access complete
protein sequences and ability to locate and characterize PTMs. It also eliminates the protein
digestion step that is most time-consuming but mandatory part of the sample preparation for
bottom-up proteomics. However, top-down proteomics is a relatively young field.28 It requires the
most advanced instrumentation and higher operation costs while suffering from a large number of
analytical limitations. In comparison to the top-down strategy, the bottom-up strategy is the
method of choice for analyzing complex protein samples with higher reliability and lower costs.
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Nevertheless, all proteomics experiments often require constant development and
implementation of effective analytical techniques. The present collection of various technical
disciplines that contributes to proteomics include gel electrophoresis, chromatography, affinity
pull-down/immunoprecipitation, spectrophotometry, fluorophotometry, fluorescence imaging,
immunoblotting, and most importantly mass spectrometry. In general, a typical bottom-up
proteomics workflow (Figure 1.3) consists of three major steps as sample preparation,
instrumental sample analysis, and data processing for biological inferences.

1.2.2 Sample preparation
The proteomics workflow begins with preparation of complex biological samples. The
overall purpose of proteomics sample preparation is to collect analytes of interest from the samples
and convert them into instrument-compatible forms. The implementation of a specific sample
preparation workflow entails a balance of method efficiency, reproducibility, and cost. A typical
proteomics sample preparation workflow is a four-step procedure that involves a series of physical
and chemical processes. These four steps are cell lysis, protein separation/clean-up, proteolytic
cleavage/digestion, and peptide separation/clean-up.
1.2.2.1 Cell lysis
As the first step, crude biological samples, such as cell culture pellets, animal tissues, and
organs, are physically homogenized in a lysis buffer that consists of buffering agents, protease
inhibitors, and a surfactant such as octyl phenoxypolyethoxylethanol (NP-40) or Triton X-100 at
refrigeration temperature. Although homogenization can be a manual process that takes place in a
Dounce tissue grinder, advanced mechanical forces introduced by focused bursts of ultrasonic
waves or high-frequency bead beating are usually preferred for extraction of whole-cell protein
contents. The lysis process disturbs the cellular membrane while preserving and solubilizing
7

cellular protein contents. Particulates are usually removed from the samples either via high-speed
centrifugation or filtration through 0.2 μm filters. Additional cell fractionation is necessary for
more efficient extraction of low-abundance proteins. Mild surfactants such as saponin and
digitonin are suitable for the extraction of cytosolic proteins. In contrast, strong ionic surfactants
such as sodium dodecyl sulfate and sodium deoxycholate are required for the extraction of nuclear
proteins. However, these ionic surfactants can denature proteins and are incompatible with
experiments that require protein integrity.
For some special human or animal proteome samples such as plasma and sera, the initial
preparation steps generally focus on the depletion of high-abundant proteins rather than
solubilization of the whole proteome. Plasma samples consist of mainly high-abundance proteins
such as albumin, haptoglobin, hemopexin, immunoglobulins, which are usually not the target
proteins of interest. Large quantities of immobilized antibodies on agarose resins are usually used
to scavenge these high-abundance inference proteins. These immunodepleting materials are
commercially available at relatively high costs.
1.2.2.2 Total protein quantitation assay
It is crucial to measure the total protein concentration of lysates. Although the
concentration of a protein solution can be directly determined from spectrophotometric
measurements at 280 nm for its UV absorption, reagent and dye-based assays are preferred for
higher analytical performance. Several conventional protein assay techniques are available. The
bicinchoninic acid (BCA) assay29 and Lowry assay30 are redox reaction-based assays, where the
protein reduces copper(II) ions to copper(I) ions that form a colored complex. It strongly absorbs
light at a specific wavelength (562 nm for BCA assays and 660 nm for Lowry assays).
Alternatively, Bradford protein assay31 is a colorimetric dye-based assay, where the Coomassie
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Blue G-250 dye undergoes a light absorption spectrum shift upon binding to proteins. Therefore,
the absorbance at 595 nm is proportional to the amount of protein-bound dye, and thus to the
sample’s protein concentration. Reagents for these assays are commercialized and used routinely
in proteomics research. In a total protein quantification assay experiment, reagents are mixed with
protein solutions to produce a measurable color change in proportion to the protein amount. The
total protein concentration of a lysate is determined by referring to a calibration curve constructed
with the assay readout of several known concentrations of a purified reference protein, such as
bovine serum albumin. The BCA assay features compatibility with surfactants and less protein-toprotein variation while the Bradford assay features easy preparation and compatibility with
chaotropic and reducing agents. Therefore, the BCA assay is the most popular choice in lysate
protein quantitation because of the surfactants in lysate samples.
1.2.2.3 Size-exclusion chromatography
Frequently, it is necessary to remove certain small molecule interference, such as assay
incompatible surfactants, buffering agents/salts, excessive reagents, reducing agents, and
chaotropic agents, from the lysate sample matrix while retaining its protein content. The sizeexclusion chromatography (SEC) is the most efficient technique to perform a buffer exchange,
which replaces the entire sample matrix of small molecules with one compatible to downstream
processes. The buffer exchange SEC is usually performed in spin column format. The lysate
sample is gradually loaded to the resins packed in a spin column, where small molecules will enter
the resin matrix and become retained while large molecules will bypass the resin matrix and elute
early. Alternative techniques, including molecular filtration using micro-spin filters and dialysis
using semi-permeable membrane inside a cassette, are also available. However, compared to SEC,
these techniques are usually less effective and more time-consuming.
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1.2.2.4 Gel electrophoresis
Within the polyacrylamide gel, the porous gel matrix retains proteins and isolates them
from the sample matrix. Driven by electrophoretic forces in the electric field, proteins undergo
differential migration and thus separation in the polyacrylamide gel matrix with an appropriate
buffer composition according to their size (sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, SDS-PAGE), charge (isoelectric focusing-polyacrylamide gel electrophoresis,
IEF-PAGE), or a mixed factor of the size, charge, and shape (native polyacrylamide gel
electrophoresis, native PAGE). The two-dimensional gel electrophoresis is essentially a serial
implementation of IEF-PAGE and SDS-PAGE as orthogonal separation techniques to resolve
different proteins in a lysate sample. Gel electrophoresis techniques are used for both analytical
and preparative purposes in proteomics research. Analytical protein gel electrophoresis provides
an expedited way to visualize the global protein composition of the sample upon colorimetric
staining and validate target proteins upon affinity/reaction-based fluorescence detection, which
can be used as both an upstream sample preparation checkpoint and supplementary data to the
mass spectrometry-based proteomics profiling result. On the other hand, preparative protein gel
electrophoresis provides an interactive approach to purify protein analytes and isolate proteins of
interest with on-spot verification. The (fluorescence imaging) verified target protein gel bands or
spots can be excised and undergo the in-gel protein digestion process to prepare enriched MScompatible analytes.
1.2.2.5 Affinity capture
When proteins of interest are distinguishable from the rest of proteins within the sample
matrix, affinity capture (also known as affinity pull-down or affinity enrichment) techniques can
be used to concentrate analytes and simplify the sample matrix. Engineered avidin immobilized

10

on agarose or magnetic beads can enrich proteins chemically labeled with the biotin affinity tag.
Monoclonal antibodies immobilized on magnetic beads can also capture specific target proteins
with or without engineered amino acid sequence tags (such as polyhistidine tags) via
immunoprecipitation (IP) or protein complex immunoprecipitation (Co-IP) processes.
The biotin-(strept)avidin system serves as the technological core of an enormous number
of approaches to analyze and manipulate molecular interactions within complex biological
matrices. It has been decades since the discovery and first laboratory application of this tightest
protein-ligand binder (Kd ~ 10-15 M) that nature ever creates. Yet, its prevalence in biological
sciences never seems to diminish.32,33 Despite nuances among the strategies of its specific
applications, the four-step general principle remains the same: (a) Tag the target with biotin,
directly or indirectly, covalently or non-covalently. (b) Conjugate the (strept)avidin to a reporter
group (for detection) or immobilizing matrix (for isolation), directly or indirectly, covalently or
non-covalently. (c) Remove irrelevant species by fractionating a reaction mixture of the tagged
target and its complementary (strept)avidin conjugate. (d) Analyze and recover relevant remnants
by monitoring and alternating its physicochemical environment, such as photochemical response,
pH, redox, etc.
1.2.2.6 Protein digestion
Bottom-up proteomics focuses on the analysis of proteolytic products of protein mixtures.
It requires at least one protease to cleave protein analytes into shorter peptides. LC-MS/MS
analyzes the resulting complex peptide mixture. Among all naturally occurring or engineered
proteases, trypsin is usually the protease of choice for protein digestion in bottom-up proteomics.
As a serine protease found in animal small intestines, trypsin is highly specific and only cleaves
protein amide bonds at the carboxyl side of arginine and lysine residues except those before the
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proline. The resulting tryptic peptides carry either a C-terminal arginine or lysine, both of which
are highly basic and easily carry positive charges, leveraging their ionization efficiency and thus
detectability by mass spectrometers. Less frequently, alternative proteases such as chymotrypsin,
LysC, LysN, AspN, GluC, ArgC, etc. are also used in proteomics.34
1.2.2.7 Offline peptide fractionation
In proteomics profiling, a complex lysate digest can be prepared into several fractions
before the LC-MS/MS analysis to improve the overall analytical performance. Similar to twodimensional online LC, offline fractionation also utilizes an additional chromatographic
mechanism that is orthogonal or semi-orthogonal to the online reverse-phase chromatography.
Popular peptide fractionation methods include strong cation exchange (SCX)35 chromatography,
hydrophilic interaction chromatography (HILIC)36, and high-pH reversed-phase fractionation
(HpH)37. These methods have been successfully implemented in large-scale proteomics studies to
greatly improve the protein sequence coverage and PTM hits.

1.2.3 Liquid chromatography
In theory, mass spectrometry is perceived as the central technology that allows
identification and quantitation of thousands of peptides in a complex proteome digest. Liquid
chromatography (LC) is recognized as the indispensable tool that provides high-performance realtime separation of those peptides. HPLC relies on fluidic pumps to pressurize liquid solvents
(mobile phase) that carry a sample mixture of analytes through a column packed with a solid
sorbent material (stationary phase). Governed by its physicochemical properties, each analyte in
the sample interacts differently with the stationary phase as the sample mixture travel through the
column. The separation of analytes occurs when the retention differences of analytes within the
sorbent matrix are distinguishable. Apart from the column length, the LC separation efficiency
12

depends on several physical parameters. With a given set of these parameters, the separation
efficiency per unit column length can be described as the reciprocal of theoretical plate height
which is modeled by the van Deemter equation38. For a specific LC column, the smaller the
theoretical plate height, the larger the theoretical plate number, and thus the higher the separation
efficiency. As exemplified in Figure 1.4, the van Deemter equation is a hyperbolic function that
predicts the plate height from a linear velocity of mobile phase as the variable and three
contributing terms as constants. This model implies it is possible to maximize the separation
efficiency for a specific column by just tuning the flow rate of the LC for the optimal linear velocity
of the mobile phase.
In practice, LC serves as the last but best step of separation that reduces proteomics sample
complexity prior to mass spectrometric analysis. Although the LC separation plays a critical role
in bottom-up proteomics for protein/peptide identification and quantitation, LC methods are
developed and implemented in a relatively conservative and standardized manner. A typical
bottom-up proteomics LC setup consists of a nanoflow LC system, a nanoflow reverse-phase
column (usually packed with C18 stationary phase) coupled to a compatible emitter interfacing the
ESI inlet, and a binary mobile phase system (usually comprised of 0.1 to 0.2% of formic acid in
water as the weak solvent and 0.1 to 0.2% of formic acid in acetonitrile as the strong solvent).
Such nanoflow reverse phase LC setups are empirically known, heavily tested, and experimentally
justified for the optimal peptide resolution and sensitivity as well as practicability. In addition to
the simple reverse-phase LC setup, the multidimensional protein identification technology
(MudPIT) was designed to integrate an SCX column and a reversed-phase column in a biphasic
LC system for a higher number of resolvable peptides by the mass spectrometer.39 However, these
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multidimensional LC setups gradually become less desired as mass spectrometers become more
powerful in separating and resolving ions in the gas phase.

1.2.4 Mass spectrometry instrumentation and implementation in
proteomics
The general principle of mass spectrometry (MS) is to generate ions of analytes from
samples and measure them via an optimal analytical method. Capable of ionizing analytes,
separating, and detecting ions in the gas phase, all mass spectrometers share the basic setup
consisting of an ion source where solution-phase molecules are converted to gas-phase ions, mass
analyzer(s) where gas-phase ions are separated, and detector(s) where signals from the ions are
measured. The readouts of mass spectrometers are mass-to-charge ratio (m/z) values and their
abundance-correlated signal intensities over the period of measurement. MS datasets can provide
two types of extracted data: mass spectra and ion chromatograms. While a plot of intensity vs. m/z
values at a specific time provides a mass spectrum, the plot of ion intensity (sum of
intensity/current within a given m/z range) vs. time presents an ion chromatogram. Subsequently,
mass spectra are generated for compound identification, but chromatograms are derived for analyte
quantitation. In addition to the basic MS setup, advanced mass spectrometers are also equipped
with collision cell(s), where deliberate gas-phase fragmentation of target ions can take place. These
instruments offer multi-stage experimental setups that enable breaking down analyte ions into
fragments in the gas phase for further analysis. These setups are defined as tandem mass
spectrometry, MS/MS (MS2), or MSn, where “n” is the number of fragmentation stages. In bottomup proteomics, it is the MS/MS that serves as the technical fundamental to sequence peptides and
identify proteins.
1.2.4.1 Ion sources
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Mass spectrometry is the study of gas-phase ions and their chemistry. The ion source
generates these ions. Since the downstream components in a mass spectrometer such as mass
analyzers and detectors can only handle charged species, ionic forms of analytes in the gas phase
must be created from analyte molecules in solutions. Although a wide range of ionization methods
are available, proteomics primarily uses electrospray ionization (ESI) and matrix-assisted laser
desorption/ionization (MALDI) due to their preferred “softness” for ionizing peptide and protein
analytes while causing minimal in-source fragmentation of these analyte ions.
ESI is known as the softest ionization technique for solution-to-gas phase conversion of
analytes. Due to its ionization softness and universal compatibility to LC systems, ESI is the
method of choice in analyzing peptides and proteins.40 At the ESI source, the pressurized sample
solution (either from LC or from a syringe pump) is forced to pass through an electrospray emitter
(a needle made of either metal or metal-coated glass) at a flow rate ranging from hundreds of
nanoliters per minute to microliters per minute. The emitter is constantly charged and holds an
electric potential of 2 to 6 kV relative to the ion inlet. During the ESI process (Figure 1.5), the
electrically sprayed aerosol, comprised of microscopic droplets, is generated. These droplets,
which carry electric charge on the surface, gradually shrink and disintegrate due to the evaporation
of solvent and desorption of ions from the solution. Analyte ions are generated via two
mechanisms: Coulombic fission and surface evaporation. The former mechanism assumes that the
increase of charge density of a droplet, due to solvent evaporation, causes the droplet to split into
multiple smaller ones, which ultimately form individual ions in the gas phase. The latter assumes
that the increase of charge density of a droplet, resulting from solvent evaporation, escalates
Coulombic repulsion, which eventually overcomes the surface tension of the liquid, causing the
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release of ions from the surface of droplets. This process is usually accelerated by heat and
countercurrent streams of nitrogen gas at microliter flow rates of sample infusion.
MALDI ionizes the dried samples mixed with a suitable crystalline matrix such as sinapinic
acid and ferulic acid on a metal plate via pulsed laser (Figure 1.5). It is known only to generate
singly charged ions. In proteomics, MALDI-MS is normally used for the fast identification of
reconstituted protein samples isolated from gel electrophoresis, size exclusion chromatography,
and ion exchange chromatography.41 Unlike ESI, which interfaces with LC systems at the
atmospheric pressure, the MALDI source usually requires the prepared sample matrix plate placed
in a vacuum chamber where the ionization takes place. The potential uneven distribution of
analytes on the matrix plate makes MALDI a less quantitative ionization method compared to ESI.
Therefore, the application of MALDI is normally limited to the qualitative protein analysis in the
top-down proteomics while the ESI is more versatile.
1.2.4.2 Mass analyzers
In a mass spectrometer, the mass analyzer separates ions in the gas phase before the
detector measures the m/z values of these ions. The separation of gas-phase ions can be either
spatial or temporal, according to the physics of the mass analyzer. The resolving power of a mass
analyzer describes its ability to separate ions with similar m/z values. The higher the resolving
power, the smaller the distinguishable differences among m/z values. Quadrupole (Q) and ion trap
are two types of low-resolving power mass analyzers used in proteomics. Time-Of-Flight (TOF),
Fourier-transform ion cyclotron resonance (FT-ICR), and Orbitrap are three types of highresolving power mass analyzers used in proteomics. Both quadrupole and TOF separate ions in
space. The ion separation occurs in a quadrupole via its alteration of the electric field that enforces
selective transmission of ions within a defined m/z window. Therefore, a quadrupole mass analyzer
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is also referred to as a quadrupole mass filter or mass selector. The ion separation occurs in a TOF
mass analyzer via the amplification of the m/z dependent ion differential flight distances in the
vacuum after the initial acceleration in the electric field. The TOF mass analyzer features the
intrinsic compatibility to the MALDI source and a wide measurable m/z range at a high spectrum
acquisition rate; its use is mostly preferred in top-down proteomics. By trapping ions in an
alternating electric field in the vacuum, the ion trap, FT-ICR, and Orbitrap separate ions in time.
Detection of trapped ions in an ion trap requires the selective release of ions with specific m/z
values and the physical contact of these ions with the detector. However, the detection of trapped
ions in the FT-ICR and Orbitrap does not require the physical contact of any ion with the detector;
its detection is achieved via electromagnetic induction. In practice, the FT-ICR is known for its
highest resolving power but low scan rate, which is only suitable for top-down proteomics analysis.
Orbitrap is becoming the gold standard for proteomics due to its tunable performance balance
between the resolving power and scan rate, which can be used in both top-down and bottom-up
proteomics.
1.2.4.3 Gas-phase peptide fragmentation and tandem mass spectrometry
The MS/MS process can be simply perceived as two-stage mass analysis of analyte ions.
This process thus involves two mass analyses, with the first mass analysis selecting ions within a
specific m/z window. This m/z value is characteristic of a pre-defined analyte precursor from the
sample mixture. These precursor ions then pass through a gas-pressurized compartment where they
are activated and break into fragments that are also known as product ions. The fragmentation can
be achieved via different mechanisms. Collision-induced dissociation (CID; also known as
collisional activation dissociation, CAD) and higher-energy collisional dissociation (HCD) are two
most used mechanisms, where accelerated precursor ions collide with neutral gas molecules to
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accumulate thermodynamic energy for their dissociation. The resulting product ions are further
subjected to the second mass analysis, following by ion detection for compiling a structure-specific
mass spectrum for the precursor.
Unlike those of proteins and small metabolites, fragmentation patterns of peptides that
provide the sequence information are well documented and highly predictable. The trait makes the
bottom-up proteomics results more credible and reproducible than others. The interpretation of a
peptide MS/MS spectrum involves assignments of six types of fragment ions generated from the
peptide backbone. When the cleavage of an amide bond on a positively charged peptide occurs, b
and y ions are produced. The apparent cleavage of a Cα-C bond annotates a and x ions. When the
cleavage of an N-Cα bond occurs, c and z ions are produced. The a, b, and c ions have a positive
charge on the N-terminus while the x, y, and z ions have a positive charge on the C-terminus. The
number of amino acids contained in the fragment ion is noted in a subscript, for instance, b3 as the
N-terminal ion produced by the cleavage of the 3rd amide bond counting from the N-terminus, and
y6 as the C-terminal ion produced by the cleavage of the 6th amide counting from the C-terminus
(Scheme 1.1). Systematic analysis of mass spectra containing information on these product ions
forms the technological basics of mass spectrometry-based peptide sequencing.
In addition to CID and HCD, other fragmentation mechanisms such as electron-transfer
dissociation (ETD), electron capture dissociation (ECD), and ultraviolet photodissociation
(UVPD) are also used in proteomics for studies of PTMs, intact proteins, and cross-linked protein
complexes. ETD and ECD fragmentation mechanisms are known to preserve PTM information
better than CID and HCD. In comparison to CID and HCD that primarily produce b and y ions
from peptides, ETD and ECD can produce a predictable, homologous series of c and z ions that
are absent in CID or HCD-based MS/MS spectra.
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1.2.4.4 Modes of spectral data acquisition in bottom-up proteomics
The bottom-up proteomics pipeline begins with proteomics profiling experiments to
characterize complex proteome samples and discover proteins of interest from identification and
quantitation of individual protein components. The data-dependent acquisition (DDA, Figure 1.6)
mode is the classic LC-MS/MS method for measuring protein samples in a proteomic profiling
experiment.42,43 In the LC-MS/MS profiling experiment, LC column-separated tryptic peptides are
introduced to the mass spectrometer and converted to protonated gas-phase ions at the ESI source.
The mass spectrometer loops the measurement of these peptide ions in duty cycles. In each duty
cycle, the instrument first performs a quick MS1 survey scan for all the detectable ions. Second,
the instrument identifies “top N” (according to the pre-set “N” value in the instrumental method)
precursor ions with the highest intensities as targets for gas-phase fragmentation and MS2
analyses. Third, the instrument performs a series of MS2 scans for all these target ions. During
each MS2 scan, the instrument isolates, fragments, and measures the product ions of each preselected target ion, generating target-specific MS2 spectra. Moreover, programmable DDA filters
(such as charge state inclusion/exclusion, dynamic exclusion, and isotope pattern matching) are
used routinely to maximize the detectability and MS2 analyses of peptide analytes. However, due
to the stochastic ion sampling, limited scan rates of mass spectrometers and inadequate peak
capacities of LC44, DDA data usually fails to provide a complete picture of the sample.
In recent years, data-independent acquisition (DIA) has been gaining popularity45-49, thanks
to faster computers and sophisticated data mining algorithms50-54. In contrast to DDA, DIA (Figure
1.6) does not rely on the MS1 survey scans that trigger the selection of detected precursor ions for
gas-phase fragmentation and subsequent MS2 scans of their product ions. In a DIA mode, the mass
spectrometer is programmed to alternate periodically either the collision energy (all-ion-
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fragmentation, AIF55; MSE56) or precursor ion isolation window (MSX-DIA57,58, SWATH59) so
that each duty cycle can cover a broad range of spectral information. However, such information
is usually not immediately available and requires in-depth post-acquisition processing of resulting
DIA datasets containing complex spectra of fragment ions.50,60 While the analysis of DIA data can
be tricky, each dataset provides a more complete and less biased depiction of the sample.61 When
incorporated with internal standard peptides for retention time normalization, a DIA method was
shown to outperform a typical DDA method in both the number of consistently identified peptides
across multiple measurements and quantitation of proteins with various abundance.62 Furthermore,
archived DIA datasets hold more value than DDA datasets in retrospective analyses60,63 when the
knowledge of previously-unknown analytes becomes available. However, DIA methods lack the
ability of generating high-quality precursor-specific MS2 spectra, thus may suffer from poorer
specificity of identified peptides than that of DDA methods. Because every scan of DIA contains
multiple groups of fragment ions (corresponding to different peptidyl precursor ions) recorded on
a single MS2 spectrum in a convoluted manner while DDA scans are designed only to measure
the fragment ions generated from a single defined precursor ion in principle.
In the downstream segment of the bottom-up proteomics pipeline, protein targets of interest
are usually analyzed as tryptic peptides in a target-specific manner that ignores or removes
everything other than the target analytes from the sample. The targeted proteomics relies on two
acquisition modes known as selected reaction monitoring (SRM; also known as multiple reaction
monitoring, MRM) on the triple quadrupole (QqQ) tandem mass spectrometer and parallel reaction
monitoring (PRM) on the quadrupole-orbitrap (Q-Orbi) tandem mass spectrometer. When a QqQ
instrument operates in the SRM mode (Figure 1.7), its first mass analyzer (Q1) selectively
transmits precursor ions of a particular m/z corresponding to a pre-selected target analyte. These

20

precursor ions are then subject to CID in a collision cell (q2) filled with neutral gas regulated with
proper instrumental settings. This process produces a variety of fragment ions of the target analyte.
However, only a few pre-selected fragment ions with high intensity and specificity are, once again,
selectively transmitted through the second mass analyzer (Q3). The transmitted ions finally reach
the detector in the mass spectrometer, and detected signals are recorded as an ion chromatogram
for a precursor-fragment ion pair, which is known as a transition in the SRM MS experiment.
Transitions are pre-determined during the experiment design stage. Notably, new QqQ mass
spectrometers are faster and can analyze a larger number of transitions within a duty cycle. The
duration of a duty cycle is defined as the cycle time, while the time the instrument spends on
scanning each transition is defined as the dwell time. The cycle time heavily depends on the LC
gradient profile, which affects the chromatogram peak widths of peptides because a good
quantitation method usually implements 12 to 20 data points per LC peak and 3 to 5 transitions
per peptide.64 Moreover, with robust LC instrumentation and known LC retention profiles of target
peptides, the SRM acquisition can be scheduled for a limited number of expected transitions at
each specific time window. This scheduled SRM method can greatly leverage the total number of
transitions per run. Overall, selective ion transmission features SRM MS analysis with excellent
limits of quantitation (LOQs), high specificity, and a wide dynamic range at a lower cost.
In contrast to SRM, the PRM mode is the next-generation ion monitoring technique
exclusive to high-resolving power and high-mass accuracy hybrid tandem mass spectrometers like
quadrupole-orbitrap.65-68 The principle of PRM MS is comparable to SRM MS (Figure 1.7).
Briefly, the quadrupole mass analyzer of these tandem instruments selects precursor ions. These
precursor ions then undergo high-energy collisional dissociation (HCD) in a collision cell.
Compared to CID, HCD generates a broader spectrum of fragment ions, which provides a higher
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global detectability of peptide analytes.69 These fragment ions are transmitted to an orbitrap mass
analyzer for gas-phase separation and detection at MS2 level with high resolving power and high
mass accuracy. Unlike the SRM, which records the signal for one fragment ion of the selected
precursor at a time, the PRM simultaneously detects a full range of fragment ions of one precursor.
Therefore, the number of fragment ions does not restrict the speed of such a full scan, which is
instead limited by the orbitrap mass analyzer’s resolving power. The LOQ of analytes in the PRM
mode can be improved by summing intensities of multiple fragment ions, which makes up the
sensitivity loss due to compromised transmission of individual fragment ions (compared to SRM).
Moreover, the full scan of fragment ions can eliminate the need for selecting best precursor-tofragment ion pairs before LC-MS/MS measurements. For the PRM data processing, the mass
accuracy (in ppm) and isotope distribution patterns of each measured fragment ion can be
incorporated as part of data-refinement algorithms to minimize the background interference and
false detection. The implementation of PRM-based quantitation methods can be easier than SRMbased methods due to the fact that targeted proteomics methods are usually built based proteomics
profiling data, which are mostly acquired on the same Orbitrap-based mass spectrometers used in
PRM MS experiments due to the growing trend of Orbitrap-based proteomics practice. Overall, in
addition to its SRM-comparable target quantification capability, the PRM technique offers more
analyte multiplexity and an easier LC-MS/MS-based assay development workflow.

1.2.5 Bioinformatics of database search and peptide identification
The rapid advancement of mass spectrometry-based proteomics has shifted large-scale
studies of protein sequences from the genomics/transcriptomics-based prediction towards direct
analysis of complex protein mixtures. The practice of mass spectrometry-based protein
identification also relies heavily on the development of computer algorithms and software tools.
22

These software tools identify proteins by referring to and searching sequence databases acquired
from the genomics sequence infrastructure. In a typical bottom-up proteomics profiling
experiment, MS/MS spectra are acquired from peptides generated from trypsin digestion of
complex protein mixtures. These MS/MS spectra are stored as two-dimensional arrays of signal
intensity (integers) versus m/z (floating point numbers) values. Each of these MS/MS spectral
datasets is also tagged with its corresponding precursor ion m/z, charge state, and retention time
on the LC column. In general, a computer program splits the database search process into four
steps to assign a peptide identity to such a MS/MS spectrum. These four steps are input preprocessing, in silico protein digestion, peptide mass filtering, and peptide-spectrum
matching/scoring. (Figure 1.8)
1.2.5.1 Input pre-processing
A database search program initiates a new task by reading and extracting information from
two pieces of input data: the protein sequence database predicted from genomics and raw MS/MS
data (usually acquired by an HR/AM mass spectrometer in DDA mode). The former is stored in
FASTA format as a single text-based file compiling all known protein sequences from the
proteome of a specified organism. For each protein entry, the first line in a FASTA file starts with
a”>” (greater-than) character that followed by the entry title consisting of the protein name and
comments parsed by other special characters. The second line is the actual protein sequence itself
in the standard single letter code for amino acids. The raw LC-MS/MS data are stored in
proprietary formats (e.g., RAW, and WIFF) that are convertible to open-source formats (e.g.,
mzML, and MGF). The program either directly reads raw data files in their proprietary formats or
requires third party software for the conversion to an open-source format. After the import of raw
data, the database search program separates MS/MS spectra from MS survey spectra and performs
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spectral data reduction with a series of calculations that convert the raw MS/MS spectra to searchcompatible ones. These calculations include centroiding, mass rounding, de-isotoping, and charge
state reduction. The centroiding refers to calculations that extract apex m/z values of continuously
sampled data points in the interval recording (profile or continuum) mode of the mass
spectrometer. The mass rounding refers to calculations that round the m/z values to less precise
figures according to a pre-defined mass accuracy threshold. The de-isotoping refers to the practice
that merges multiple m/z peaks and isotope clusters that feature the same fragment ion in different
charge states on the sample MS/MS spectrum. The charge state reduction is always performed as
part of the de-isotoping, which preserves only the m/z peaks of singly charged fragment ions on
processed MS/MS spectra. These pre-search MS/MS spectrum processing measures can greatly
facilitate down-stream search algorithms by reducing data complexity and increase the overall
computational efficiency.
1.2.5.2 in silico protein digestion
Similar to the process of the actual enzymatic digestion of proteins, the in silico protein
digestion refers to calculating and indexing theoretical m/z values from protein sequences fetched
from the database. For each protein, the digestion algorithm predicts a list of peptides according
to the specified protease and its empirical enzymatic cleavage sites (such as cleavage at the Cterminal side of lysine or arginine for trypsin) as well as a pre-defined number of missed cleavage
(usually 1 to 3). Theoretical masses of these peptides are then calculated from their predictable
elemental compositions based on their amino acid residues, pre-defined chemical modifications,
PTMs, and secondary fragment ions with neutral losses. Additional constraints such as maximum
and minimum peptide lengths/masses are also pre-defined as included in configurable search
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parameters. The resulting theoretical m/z values are compiled as theoretical MS/MS spectra for
later uses.
1.2.5.3 Peptide mass filtering
Before the search program can match an experimental MS/MS spectrum to a theoretical
one and score it for a peptide hit, the theoretical spectra are filtered at the MS level. For each
experimental MS/MS spectrum tagged with its precursor mass, the filtering algorithm extracts
theoretical MS/MS spectra that have identical masses within a pre-defined mass accuracy
threshold (usually ± 5 to 10 ppm). The search program may perform additional search enginespecific filtering that dynamically removes low-intensity peaks from an experimental MS/MS
spectrum to improve its overall spectrum quality.
1.2.5.4 Peptide-spectrum matching and scoring
The peptide-spectrum matching (PSM) algorithm is the core algorithm that compares
candidate sequences to experimental MS/MS spectra with appropriate precursor masses. Different
spectra may have different maximum numbers of detectable fragment ion masses, numbers of
peaks with different quality, and signal-to-noise ratios. Therefore, successful identification of an
observed MS/MS spectrum depends on several factors, including the number of matching peaks,
mass accuracy, overall spectrum quality, and the uniqueness of the underlying peptide within the
whole proteome. To report meaningful PSM results, search engines usually adopt mathematical
and statistical models to score peptide-spectrum matches (PSMs) and systematically describe the
statistical significance and confidence of these PSMs before they report them in the final result. A
target-decoy strategy,70 where a decoy database (consisting of either reverse or scrambled protein
sequences) is generated from the input database and used together for PSM, is implemented to
estimate the false-discovery rate (FDR, usually 1% as the cutoff) for the quality control and last-
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step filtering of the final result. Different search engines implement the PSM scoring system
differently. Table 1.1 summarizes some key features of five popular search engines that are heavily
used in the field.
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1.3 Tools and Strategies in Chemical Proteomics
The mass spectrometric analysis in most proteomics studies has extended beyond the
profiling of protein expression. The investigation and utilization of modified proteins and peptides
have become major topics in proteomics research. A modification can be broadly defined as an
observable positive delta mass (mass increase) on the protein or peptide. It can be a result of either
the chemical alteration or biological manipulation of proteins as different modifications are
introduced to or exist intrinsically within a proteome. Some modifications can be products of
chemical probes that label a specific number of target proteins. Some can be metabolic labels or
chemical tags introduced to proteins and peptides during the sample preparation to achieve
analytical objectives. Others may simply exist naturally as part of cell signaling and regulation
processes where enzymes and biochemical pathways are activated. Although conducted for diverse
chemical or biological principles, these modification-specific proteomics studies share similarities
in multiple analytical perspectives of sample preparation, analyte detection, and data
interpretation.
Chemical proteomics or chemoproteomics can be defined as a proteomics-based systematic
approach to study the interaction between small molecule compounds and proteins in complex
biological systems. In contrast to the conventional “one-on-one” strategy used in studying small
molecule-protein interactions such as ligand binding assays, chemical proteomics emphasizes
multiplexed protein analysis with the inclusion of the biochemical complexity in the experimental
model, where the small molecule-protein interactions take place. Therefore, compared to
traditional methods in chemical biology and drug discovery studies, chemical proteomics profiling
is more suitable for discovering protein targets of small molecule compounds, measuring target
engagement, understanding mechanisms of action, and evaluating off-target effects. Chemical
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proteomics relies on chemical probes that introduce detectable chemical modification and/or
distinguishable analytical traits of proteins that interact with the small molecule of interest.
Consequently, the preparation of probe-treated protein samples, detection of probe-modified
peptides, and analysis of probe-reacted protein depends on a dedicated set of chemical tools and
analytical strategies.

1.3.1 Compound-centric vs. activity-based probes
Chemical proteomics studies usually involve one of two probing strategies (Figure 1.8).
The compound-centric strategy features the use of chemically modified, either tagged71 or
immobilized,72 compounds of interest as either covalent or non-covalent chemical probes. These
chemical probes are introduced directly as baits to capture target proteins from a complex
proteome. In contrast, the activity-based strategy depends on covalent probes. These activity-based
probes (ABPs) are capable of irreversibly binding, reacting with, and labeling target proteins from
a complex proteome, which is pre-treated with compounds of interests. The subsequent elucidation
of target activity relies on the measurement of probe-target adducts in competitive binding assays.
Presumably, the compound-centric strategy is straightforward for studying the proteomewide activity of a known drug molecule. It mandates a boutique probe created by installing a
reporting group on the drug molecule. However, the construction of a drug-derived probe often
bears high synthetic costs. The application of such a compound-centric probe also suffers from the
consequence of chemical modifications; any structural changes made to the drug molecule may
significantly alter the parent molecule’s potency and selectivity profile.73 The more sophisticated
strategy is activity-based chemical proteomics, which emphasizes the use of a covalent probe.
Activity-based competitive chemical proteomics, also technically known as competitive activitybased protein profiling (ABPP), offers a versatile bioanalytical platform.74,75 Such a platform can
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effectively decipher proteome-wide actions of different underivatized drugs and other reactive
molecules like environmental toxins and reactive metabolites from the human microbiota.76-79
Opposing to the design of compound-centric probes, ABPs are designed to show little or no
specificity to proteins. They capture proteome-wide “snapshots” visualizing drug-protein
interactions by permanently occupying available active sites post drug treatment on the model
proteome. As illustrated in Figure 1.8, a competitive ABPP platform depends on its ABP to
measure the proteome-wide action of an underivatized drug.80,81 Competitive ABPP’s distinctive
technological advantage is that a single ABP with broad proteome coverage can establish a
versatile analytical platform capable of evaluating different drugs or drug candidates on different
subsets of a single proteome. Therefore, ABPs with a broad spectrum of reactivity can fully
unleash the enormous potential of competitive ABPP technology.

1.3.2 Chemical tagging on peptides
The quantitative analysis of in vitro drug dose response is challenging. It demands not only
identification but also accurate and precise quantitation of biochemically altered proteins from
proteome samples treated at various drug concentrations. Fortunately, several types of peptide
derivatization reagents are available for label-based quantitation. These versatile derivatization
reagents tag multiple protein digest samples that are combined for simultaneous analysis, which
enhance both the accuracy and sample throughput. These chemical tags can be either stable
isotope-based or non-isotopic.
Stable isotope-based peptide tagging involves either isobaric82-84 or mass-difference85-94
derivatization reagents. These reagents tag peptides and incorporate stable isotope labels
differentially. In comparison to mass-difference derivatization reagents, isobaric reagents are more
popular because they are commercially available, more reliable, and constantly being updated for
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additional multiplexity: 4-plex iTRAQ,83 6-plex TMT84, 8-plex iTRAQ95, 11-plex TMT96,97, and
16-plex TMT98. Using tandem mass tag (TMT™) reagents as an example, peptides derivatized
with isobaric reagents have the same precursor ion masses but produce product ions with
differentiable masses only after gas-phase fragmentation (Figure 1.10A). Therefore, tandem mass
tags enable the concurrent measurements of chemical proteomics samples. The LC-MS/MS
measurements of pooled TMT-labeled samples minimizes unwanted run-to-run variations in target
quantitation. Because these tandem mass tags multiply the abundance of a peptide precursor ion
by the number of combined samples. This analyte abundance boost has little effect on the
spectrometric complexity during the MS precursor ion scan of a DDA profiling experiment. Only
the reporter ions are measured for peptide quantitation during the MS/MS product ion scan, which
significantly mitigates chemical interference. Besides, signal intensities of sequence ions from
different samples are additive. This feature ensures that combining multiple samples for a single
LC-MS/MS run enhances the detectability of peptide sequence ions and has a minimal negative
impact on the sample matrix. As illustrated in Figure 1.10B, the 10-plex TMT-based chemical
proteomics workflow can provide a powerful shortcut to quantify dose responses of small molecule
compounds of interest within a complex proteome.
It is also possible to use mass-difference derivatization reagents for incorporating peptides
with stable isotope labels.86,87,90,92,94 For instance, the reductive methylation of peptidyl amines is
a commonly practiced method for multiplexed proteomic quantitation.85,88,89,91,93 It features a
simpler derivatization procedure, lower cost,91 and the potential for automation.88,99 However, it
can only be applied for labeling up to five different samples. The quantitation of methylated
peptides is based on fragment ions generated from tagged peptides with different precursor
masses., resulting in a relatively higher chemical background and spectrometric complexity.
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Non-isotopic derivatization reagents leverage the analytical performance of a
chemoproteomics platform in a slightly different way. These reagents are designed to provide a
cost-effective solution to improve the sample throughput in targeted proteomics quantitation rather
than analyte multiplexity in untargeted proteomics profiling. This technology is proposed as ultrathroughput MRM MS, or uMRM MS.100,101 This method re-allocates the scan capacity of fast
contemporary QqQ instruments from a large number of pre-selected peptides in a single sample102
to several key peptides of interest from a large number of samples in a single experiment.100,101 As
demonstrated on Figure 1.11, once integrated with stable isotope by amino acids in cell culture
(SILAC), the open-source uMRM MS technology can also greatly facilitate the development of
chemical probes and chemical proteomics by enhancing the quantitation performance in the
scaling analysis of proteome-wide reactivity of activity-based chemical probes.103

1.3.3 Metabolic labeling on proteins
Metabolic labeling methods incorporate stable isotope labels biologically into a model
proteome during the cell culture (SILAC) or small animal feeding process (stable isotope labeling
by amino acids in mammals, SILAM).104 These powerful labeling methods are residue-specific
and rely on the natural metabolism of a living system to produce heavy copies of proteins.105
Although commonly used in a heavy/light duplex fashion, up to five samples can be pooled for
concurrent proteomic quantitation.106 Compared to chemical tagging, the most significant
advantage of metabolic labeling is the potential of introducing the labeled proteins at an earlier
stage of proteomic sample preparation workflow. Thus, the reduction of sample complexity at the
protein level can be implemented for high accuracy and precision proteome quantification, with
little differential protein loss.107 By only supplying heavy amino acid feed to an organism,
organism-wide labeling is achievable. The SILAC technology is widely used for investigating
31

disease mechanisms and identifying biomarkers in human samples.108-112 Similar to the massdifference tagging, the use of metabolic labeling suffers from analyte dilution and increased
sample complexity. Nevertheless, as demonstrated on Figure 1.11, once integrated with the opensource uMRM MS technology, SILAC the can also greatly facilitate the development of chemical
probes and chemical proteomics by enhancing the quantitation performance in the scaling analysis
of proteome-wide reactivity of activity-based chemical probes.103
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1.4 Challenges and Opportunities in Chemical Proteomics

1.4.1 Alternative bio-orthogonal affinity tags and trypsin-resistant
affinity binders
In most cases, biotin-(strept)avidin system-based techniques are versatile and fit
seamlessly in their applicable experimental workflow. However, when being used for affinity
enrichment of probe-reacted proteins, this pair of binders often delivers poor enrichment efficiency
due to the mandatory harsh conditions for releasing captured targets, such as prolonged heating
and use of chaotropic agents at an extremely low pH for analyte elution. While these harsh
conditions can disturb the strong biotin-(strept)avidin interaction, they may also inflict undesired
damages on both the solid-matrices and captured analytes, thus increasing the sample’s complexity
and decreasing the analyte’s recovery. In comparison to biotin (Kd ~ 10-15 M), the desthiobiotin
has been developed as a synthetic biotin analog with a deliberately-reduced avidin affinity (Kd ~
10-11 M) to afford less chemical disruption for its release.113 The desthiobiotin affinity tag also has
its unique advantages as a xenobiotic tag, which is chemically unique and bio-orthogonal with a
biological system. Its mass signature is distinguishable by mass spectrometric analysis. It also is
not part of any biochemical reactions. On the other hand, biotin-specific antibodies with lower
affinities (Kd ~ 10-8 M) have also been developed to serve as an affinity enrichment platform for
higher analyte recovery.114
Nevertheless, protein-based macromolecular binders share a significant drawback. That is
chemical orthogonality. As proteins, these macromolecular binders are prone to biochemical
manipulations that affect proteins. Trypsin digestion is often implemented in technically distinct
ways (Figure 1.12) in a chemical proteomics profiling workflow.115 It is practiced as an adaptive

33

step within the sample processing workflow according to specific analytical strategies, which
would provide distinct advantages and drawbacks. Compared to the other two methods, the onbead digestion approach provides an uncompromising shortcut to protein-level enrichment.
Because the captured probe-protein adducts do not leave the solid matrix until the very end, fewer
steps and less analyte loss are expected. However, in practice, there is always an intangible tradeoff between the trypsin digestion efficiency and contamination from tryptic (strept)avidin peptides.
Even after meticulous optimization, an on-bead digestion protocol frequently leads to an
overwhelming number of either miscleaved analyte peptides or (strept)avidin contaminant
peptides. In some applications, co-existence of the enrichment media and trypsin is required,
particularly known as the on-surface (on-bead) trypsin digestion strategy115,116. In this case,
trypsin’s proteolytic activity can also affect the macromolecular binders, which causes inevitable
contamination and loss of analytes.
In recent years, the significance of ligand-binding capability of oligonucleotides has
attracted a tremendous amount of attention. Due to several substantial advantages over antibodies,
aptamers have gradually gained ground in clinical applications.117 In comparison to antibodies that
are biologically-produced large-sized (150kDa for IgG made in animals or cell lines) protein
molecules, aptamers are chemically-synthesized small-sized oligonucleotides (24kDa for 80-NTs
ssDNA, made on automated chemical synthesizer) that are easy to create, use, and manipulate.
Therefore, it is possible and will be beneficial to develop alternative affinity-capturing platforms
consisting of immobilized aptamers and non-biotin affinity tag-based chemical probes. These
novel affinity capturing systems may provide superior flexibility, robustness, compatibility, and
efficiency for affinity pull-down of target proteins labeled by chemical probes.
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1.4.2 Reactivity and selectivity of chemical probes
In contrast to ideal covalent drugs that react with target proteins selectively and sensitively,
ideal chemical probes may occupy both ends of the selectivity spectrum. While a successful
compound-centric probe must recreate the high selectivity of its drug template, a versatile ABP
would react with a wide range of proteins at their active sites, which are targeted respectively by
various drugs to be analyzed. Covalent inhibitors and drugs have prolonged selective engagement
with their targets and improved pharmacodynamic properties, but they react unavoidably with offtarget proteins, leading to toxicity and safety concerns.118 During the drug development, chemical
proteomics are increasingly used to reveal selective covalent inhibitors early, identify toxicity
liabilities, and help mitigate the risk of late-stage failures.74,119
ABPs are also uniquely useful in chemical proteomics for measuring the proteome-wide
action of all sorts of reactive molecules other than covalent drugs to understand their biological
consequences.74,79,119,120 These molecules include environmental toxins, natural products, reactive
metabolites from the human microbiota. At the low end of the selectivity spectrum, broadly
reactive ABPs77,78,121 are used as measurement probes in ABPP platforms that can be flexibly
adapted for the (re)activity analysis of underivatized reactive molecules. The platform adaptability
relies on the reactivity coverage of the measurement probe—the number of proteins and the type
of amino acid residues with which the probe reacts. The broader the coverage, the higher the
adaptability.
It is challenging for a warhead to cover a large fraction of a proteome reactivity’s domain.
Individual proteins differ in molecular composition and structure. Their reactions with small
molecules are distinct from site to site, domain to domain, and protein to protein. The diversity of
these reactions further increases due to the large number and abundance range of proteins in a
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proteome. When designed to be broadly reactive, an ABP does not carry a binding/recognizing
group and depends on its warhead for its reactivity and proteome coverage.122-124 Exemplified by
iodoacetamide (IA)-alkyne, the IA warhead reactivity represents the proteome coverage of a class
of broadly reactive probes,76 which react with large numbers of proteins in a proteome, but
primarily targeting cysteine residues.77,119 On the other hand, warheads that target multiple amino
acid residues are also available. For instance, ABPs that are developed on the acrylate warhead125
or sulfonyl fluoride126 warhead are utilized to target nucleophiles, including amino, hydroxyl, and
thiol groups. Although being useful in some cases, probes based on these warheads may limit their
applications due to storage, sample compatibility, and experimental reproducibility issues caused
by their cytotoxicity, background reactions, and instability. The large extent of nonspecific
background reactions usually compromises competition assay-based proteomics analysis of the
probe-reacted proteins. Therefore, novel warheads with moderate electrophilicity and reaction
rates but a high coverage of residue types are still in high demand for developing activity-based
measurement probes. These probes are expected to lessen background reactions and establish more
versatile platforms of competitive (re)activity-based proteomics.
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1.4.3 Bioinformatics for modification-specific proteomics
Chemical proteomics utilizes chemical probes to study biological functions of proteins and
small molecule-protein interactions within a highly complex biological sample. Direct LC-MS/MS
analysis of a total protein digest prior to any offline analyte separation is typically futile because
of the competition between analytes and interfering non-target peptides for ionization and
stochastic sampling resource in the mass spectrometer. Fortunately, only a fraction of peptides are
actual analytes that should be selected for LC-MS/MS analysis. The selection/enrichment of these
analytes is achieved via the affinity tagging approach, where only peptides modified by the
chemical probe that carry an affinity tag are retained for further analysis. This intrinsic trait has
shifted the analytical focus from all peptides onto probe-modified peptides, which characterizes
chemical proteomics as modification-specific proteomics akin to large-scale PTM studies.
It is challenging to analyze modification-specific proteomics data. Conventional
proteomics database search engines handle search requests for modified peptides by expanding the
peptide sequence pool using a list of modification masses. These modification masses are set as
search parameters before the search workflow initiates. When the numbers and locations of
specific chemical modification are unknown (known as a variable modification), this approach has
to enumerate all possible instances of such modification on native peptides. It also appends
modified peptides to the native ones to create an exponentially larger peptide sequence pool as the
search space. Problems occur when multiple variable modifications are introduced because the
inclusion of combinatory modified peptide variants artificially inflates the search space with more
isobaric peptide masses, resulting in a much larger candidate peptide list. Compared to search
without modifications, the subsequent iterative peptide-spectrum matching and scoring algorithm
using such an inflated candidate peptide list usually results in increased computational cost,
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elevated error rates, and compromised sensitivity. Moreover, some chemically modified peptides
may undergo secondary chemical reactions during sample preparation or LC-MS/MS analysis.
Others may simply be unknown or mispredicted during exploration of novel chemical probes and
biochemical reactions. It is also possible that modified peptides will be less detectable due to their
erratic gas-phase behaviors such as low ionization efficiency, poor fragmentation, and unusual
fragmentation patterns. On the other hand, existing software packages are developed ubiquitously
for analysis of all peptides and proteins. They often offer limited support for post-search processing
of modification-specific data. These packages usually frustrate end-users by presenting proteomics
profiling reports adulterated with a large volume of information on native proteins and peptides
that are irrelevant to the research objectives. Therefore, novel search algorithms and post-search
data processing tools remain to be developed. Together with novel chemical probes and analytical
innovations, these bioinformatics tools will greatly accelerate advancement of chemical
proteomics field.
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1.5 Chapter 1 Figures

Figure 1.1 The omics pyramid.
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Figure 1.2 Overview of omics pipeline.

Note: Figure adapted with permission from (Wang, L., McShane, A. J., Castillo, M. J. & Yao, X. in
Proteomic and Metabolomic Approaches to Biomarker Discovery (Second Edition) (eds Haleem J. Issaq
& Timothy D. Veenstra) 261-288 (Academic Press, 2020).). Copyright (2020) Elsevier Inc.
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Figure 1.3 Overview of the bottom-up proteomics workflow
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Figure 1.4 Example van Deemter plot with the equation and contributing
terms.
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Figure 1.5 Schematic overview of ESI and MALDI sources.
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Figure 1.6 LC-MS/MS acquisition modes for untargeted proteomics.
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Figure 1.7 LC-MS/MS acquisition modes for targeted proteomics.
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Figure 1.8 Bioinformatics workflow for database search and peptide
identification
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Figure 1.9 Schematics of the compound-centric probe vs. activity-based probe.
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Figure 1.10 TMT enabling accurate and multiplexed target quantitation in
chemical proteomics.
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Figure 1.11 Ultra-throughput MRM MS for quantitative scaling of proteomewide reactivity of activity-based chemical probes.

*Note: plot adapted with permission from (Li, S. et al. Scaling Proteome-Wide Reactions of Activity-Based
Probes. Analytical Chemistry 89, 6295-6299). Copyright (2020) American Chemical Society.
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Figure 1.12 Three different affinity capturing approaches used in chemical
proteomics.

Note: (A) general workflow chemical proteomics, (B) in-solution trypsin digestion procedure for peptidelevel target enrichment, (C) in-gel trypsin digestion procedure for protein-level target enrichment, and (D)
on-bead trypsin digestion procedure for protein-level target enrichment
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1.6 Chapter 1 Schemes

Scheme 1.1 Six types of sequence ions in gas-phase peptide fragmentation.
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1.7 Chapter 1 Tables

Table 1.1 Overview of top 5 most popular database search engines.
Software package
Algorithm name

Scoring system
implementation
•

Convert observed and theoretical spectra to

Comet128 (open source),
frequency domain by fast Fourier transform
Tide/Crux129 (open
•

SEQUEST127

Cross-correlation, reporting ratio between

source), Proteome
zero-offset alignment and nearby
Discoverer (commercial)
alignments
•

Count matching fragment ions (b and y ions
only) on the observed spectrum

•

Calculate dot product using ion intensities

Parallel Tandem131 (open
and the number of matching ions
source),
•

X!Tandem130

Calculate “hypercore” by multiplying with

Trans-Proteomic
factorials of the number of assigned b and y
Pipeline132 (open source)
ions (hypergeometric distribution)
•

Build a histogram of scores per spectrum
and report its expectation value

•
MOWSE133

Mascot (commercial)

Calculate the probability (P) if a PSM occurs
by chance

•

Report the score as -10log10 (P)

•

Convert peptide P and spectrum S into

MS-GF+ (open source),
MS-GF+134

peptide vector P* and spectral vector S*.
ProteoSAFe (web-based)
•

Calculate dot-product Score(P, S) = P*·S*
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•

Filter top q peaks per 100 Da mass interval
on the theoretical spectrum

•

Count matching fragment ions (k) on the
observed spectrum to all possible
theoretical ions (n)

Andromeda135

MaxQuant136 (freeware)

•

Score each mass interval as -10log10 of the
probability of matching at least k out of the n
theoretical masses by chance (binomial
distribution)

•

Score the spectrum as the highest mass
interval score
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Chapter 2 Investigation of Covalent Protein Adducts of 2Nitroimidazole-ICG as a Hypoxia-targeting Probe in Mouse
Tumor
2-Nitroimidazole is a well-known chemical probe targeting hypoxic environments of solid
tumors, and its derivatives are widely used as imaging agents to investigate tissue and tumor
hypoxia. However, the underlying chemistry for the hypoxia-detection capability of 2nitroimidazole is still unclear. This chapter reports the deployment of a biotin conjugate of 2nitroimidazole-indocyanine green (2-nitro-ICG) for the investigation of in vivo hypoxia-probing
mechanism of 2-nitro-ICG compounds. Mass spectrometry-based proteomics and exhaustive data
mining concluded that 2-nitro-ICG and its fragments modified mouse serum albumin as the
primary protein target, but at two structurally distinct sites, possibly via two different mechanisms.
The identification of probe-modified peptides not only contributes to the understanding of the in
vivo metabolism of 2-nitroimidazole compounds but also demonstrates a competent analytical
workflow that enables the search for peptides with undefined modifications in complex proteome
digests.
The Journal of Mass Spectrometry published this study under the title “Treasure hunt for
peptides with undefined chemical modifications: Proteomics identification of differential albumin
adducts of 2‐nitroimidazole‐indocyanine green in hypoxic tumor” as a research article.137 The
reuse of its content in this Chapter 1s permitted by John Wiley and Sons and Copyright Clearance
Center under the license number 4816640832152.
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2.1 Introduction

2.1.1 Tumor hypoxia and its detection
Hypoxia is a well-renowned vicious low-oxygen condition that that is a salient feature of
most tumors. Tumor hypoxia occurs because of a cumulative micro-environmental imbalance
between diminished oxygen supply and elevated demand in the region of a fast-growing
tumor.138,139 As a consequence of inefficient local vascular network and hyperactive cellular
metabolism, tumor hypoxia is often responsible for severe inhibition of immune cells, strict
exclusion of therapeutic agents, and malignant progression of tumors.140 Thus, detection and
measurement of tumor hypoxia can provide invaluable clinical information for initialization and
evaluation of anti-cancer therapy.141-143
Selectively monitoring an exogenous bio-reducible and traceable marker is one of the
mainstream methods for hypoxia assessment, where 2-nitroimidazole derivatives are typically
used as the hypoxia tracer for indirect measurements.144 In contrast to 2-nitroimidazole derivatives
as established radiotracers for positron emission tomography (PET) to image tumor hypoxia,
indocyanine green (ICG) conjugates of 2-nitroimidazole are a novel class of near-infrared (NIR)
fluorescent

tumor

hypoxia

tracers

demonstrating

superb

in

vivo

detectability

and

biocompatibility.145-150 Built on a fluorophore analogous to the commercial ICG as the scaffold
structure, this class of compounds has evolved for three generations as ICG conjugates differing
in linker and imidazole structures, as shown on Scheme 2.1.
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2.1.2 A brief history of nitroimidazole-ICG probes
On Scheme 2.1, all of these nitroimidazole-ICG probes were synthesized at Dr. Michael
Smith’s laboratory at Department of Chemistry, University of Connecticut, referred to as
Generation I145,146, Generation II147-149, Generation IIIa150, Generation IIIb151, and Generation IIIc
(to be used this study) dye. Regarding the lower reduction potential and toxicity of some 4nitroimidazole derivatives, the initial work focused on the development of 2-nitroimidazole
derivatives as chemical probes that target tumor hypoxia, based on the scaffold compound, biscarboxylic ICG (compound 1).145,148,152-154 In a continuous effort to develop the best probe, the
first-generation dye conjugate using an ethanolamine linker (compound 1-1)146, and the secondgeneration dye conjugate using a piperazine linker (compound 1-2)147-149 were prepared. In both
cases, previous in vivo studies showed that the dye conjugate was retained in hypoxic tumors,
allowing imaging by the NIR fluorescence technique.145 For the third-generation dye-conjugates,
apart from the 2-nitroimidazole-based probes (compound 2-1 and 1-5-1), the unsubstituted
imidazole derivative (compound 1-3) and the 4-nitroimidazole dye-conjugate (compound 1-4)
were also reported in a recent study.151
Despite numerous cases where 2-nitroimidazole derivative-assisted tumor hypoxia
detection techniques have been successfully established, a comprehensive understanding of
explicit biochemistry for the hypoxia-detection capability of 2-nitroimidazole is still absent. In the
early 1980s, Dr. Raleigh and his colleagues demonstrated that misonidazole, a 2-nitroimidazole
derivative, could undergo oxidoreductase-catalyzed degradation in a cell-free experimental
system.155 The same research team later illustrated that the 2-nitroimidazole derivative could
covalently bind to macromolecules after reductive activation by high-energy photoirradiation.156
This study also suggested the activated 2-nitroimidazole possessed a higher selectivity for proteins
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compared to nucleic acids and the highest reactivity to thiol groups among any other nucleophiles
on bovine serum albumin in solution. Over the years, a predominant number of in vitro and in vivo
studies on mammalian cells have been dedicated to analyzing 2-nitroimidazole’s metabolites.157160

According to some recent studies, the hypoxia-detection capability of 2-nitroimidazole-

mediated imaging methods mostly arose from the regional accumulation of specific 2nitroimidazole metabolites, such as the glutathione conjugate of 2-aminoimidazole.158,159
However, macromolecular adducts of 2-nitroimidazole have not been thoroughly examined since
the initial study in the 1990s.156,161

2.1.3 MS-based proteomics to identify 2-nitroimidazole targets
To unleash the full potential of 2-nitroimidazole derivatives and similar compounds for
targeting tumor hypoxia at a higher efficiency, accuracy, and biocompatibility, it has become
imperative to re-examine the reactivity of 2-nitroimidazoles from the proteomics perspective.
Related questions (Scheme 2.2a) are: (1) which proteins 2-nitroimidazole-indocyanine green (2nitro-ICG) probes preferentially bind to; (2) how these hypoxia-driven probe-protein reactions
initialize, progress, and terminate; and (3) to what extent these reactions can perturbate the
proteome of tumor cells in vivo. Therefore, a biotinylated version of the 2-nitro-ICG probe (biotin
dye, Scheme 2.2b) was developed and applied to facilitate a modern mass spectrometry-based
proteomics investigation (Scheme 2.2c) of the chemistry for in vivo hypoxia-probing mechanism.
Nonetheless, given the large molecular weight of 2-nitro-ICG probes, target analytes
(proteins modified by 2-nitro-ICG in vivo and digested by trypsin) are potentially labile while their
affinity enrichment efficiency may be low. Substantial degradation of probe-protein adducts may
occur during sample preparation. It is usually prudent to project a data utility loss of 80% to ensure
sufficient analysis of the resulting highly convoluted proteomics profiling data. In an attempt to
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accomplish an ambitious objective aiming at the identification of modification sites, the
investigator is likely to experience extraordinary challenges when both the target proteins and their
measurable modification (regarding the increase in mass of the peptide after its modification by
the chemical probe) are undefined. Consequently, the data often remains uninterpretable for
identifying probe-modified peptide via the typical data processing workflow used in a shotgun
proteomics experiment.162,163 While the direct identification of covalent adducts appears
unachievable, the “gray area” of the profiling data, where a large volume of valuable information
on modified peptides deposits as unassigned spectra, can offer a second chance.164 As the task of
“rescuing” spectra featuring probe-modified peptides is extraordinarily labor-intensive and
frustrating, methods to alleviate such arduousness for the identification of undefined covalent
adducts are in immediate demand.
Herein, this study introduces a front-to-end analytical workflow that dictates the successful
discovery of a primary protein target and its modification sites for a 2-nitroimidazole-based in vivo
chemical probe. In this workflow, probe-reacted proteins are detected as target analytes using
fluorescence imaging and isolated using avidin affinity pull-down in conjunction with multiple
techniques of gel electrophoresis. These electrophoresis techniques include the sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing-polyacrylamide gel
electrophoresis (IEF-PAGE), and a combination of the two as the two-dimensional gel
electrophoresis (2-DE). The isolated target analytes are measured as tryptic digests using LCMS/MS. The profiling data is processed and interpreted using an approach of product-ion-oriented
data mining for the identification of the target protein and its modification sites. In general, this
approach bypasses the search restriction on peptidyl precursor ions at MS level, weights the
detection of surrogate peptidyl product ions and probe fragment ions at MS/MS level, bridges the
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gap between MS and MS/MS data with chromatographic information, reconciles MS data for
evidence supporting the assignment of peptide identities, thus distinguishes otherwise
unassignable spectra featuring probe-modified peptides. This work broadens the perspective on
the hypoxia-probing mechanism of 2-nitroimidazole compounds. More significantly, it conveys a
practical troubleshooting guideline for similar chemical proteomics studies routinely conducted
during the research and development of new active pharmaceutical ingredients, where the
measurable chemical modifications on target and off-target proteins are usually unknown or
mutable.165
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2.2 Experimental

2.2.1 Materials
Solvents, reagents, stock buffer solutions, and equipment were purchased from Bio-Rad
Laboratories Inc (Los Angeles, CA), Fisher Scientific Co LLC (Hanover Park, IL), Life
Technologies (Grand Island, NY), Sigma-Aldrich Inc (St. Louis, MO), and Thermo Fisher
Scientific LLC (Asheville, NC). Details of materials, mouse tumor model preparation, and
fluorescence imaging are included in the supplemental information.

2.2.2 Tumor lysis and protein extraction
The excised solid mouse tumors had approximate dimensions of 1 cm x 1.5 cm x 0.2 cm.
For each tumor sample, the solid excision was homogenized in a 7-mL Dounce tissue homogenizer
(Bellco Glass, Vineland, NJ) with 1 mL of a working lysis buffer (WLB) on ice until visually
homogeneous. A 5-mL sterile disposable syringe with a 20-gauge needle (BD, Franklin Lakes,
NJ) was used to assist the disruption of cellular membranes. The WLB contained 1% of Halt™
EDTA-free 100X protease inhibitor cocktail in Pierce™ IP Lysis Buffer. The homogeneous
suspension was split and transferred to 1.5-mL microcentrifuge tubes. The collection tube of the
homogenizer was washed with 200 μL of WLB, which was combined with the suspension. For
maximal extraction of the cellular protein content, the suspension underwent two freeze-thaw
cycles (frozen at -80 °C and thawed on ice), three rounds of centrifugation and resuspension. In
each round, the homogeneous tumor suspension was centrifuged for 1 h at 16100 rcf, 4 °C. In total,
an additional 1 mL of WLB was used to resuspend the pellets. All the supernatants were collected
and combined as a whole crude lysate for each tumor sample. Both the crude lysate and pellets
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were saved for further analyses. Next, the crude lysate was purified with Zeba™ Spin Desalting
Columns to remove its small-molecule content by following the manufacturer’s instruction. For
each sample, approximately 2 mL of purified lysate was collected as a protein extract. Each extract
was quantified via the standard BCA assay protocol and aliquoted into new 1.5-mL
microcentrifuge tubes, which were stored at -80 °C before further analyses. The final protein
extracts had a concentration of approximately 7 mg/mL.

2.2.3 Affinity enrichment of covalent adduct
For each avidin affinity pull-down experiment, a 100-μL aliquot of protein extract was
diluted for a protein concentration of 2 mg/mL with freshly-prepared WLB and mixed with an
equal volume solution of 8 M urea in WLB, resulting in a pre-binding solution (PS) containing 1
mg/ml proteins and 4 M urea. Afterward, the PS was mixed with either Pierce™ NeutrAvidin™
agarose resins or Pierce™ high-capacity streptavidin agarose resins (Thermo Fisher Scientific)
according to the proper the protein amount vs. binding capacity ratios. After overnight incubation
at 4 °C with constant agitation on the HulaMixer, appropriate washing steps were performed based
on the manufacturer’s instruction manual. Briefly, the adduct-bound resins were washed with three
different washing buffers, which were prepared in situ. Washing buffer 1 (WB1) was prepared as
4 M urea in Pierce™ IP lysis buffer. Washing buffer 2 (WB2) was prepared as 5% isopropanol in
PBS (pH 7.4). Washing buffer 3 (WB3) was prepared as a solution of 20 mM of Tris-HCl, 50 mM
of NaCl, whose pH was adjusted to 8.0. The adduct-bound resins were washed three times of WB1
and WB2, twice of WB3, with either 20X volume of the settled resins for the high-capacity
streptavidin-agarose or 10X volume of the settled resins for the NeutrAvidin-agarose. After
resuspension of resins in the washing buffers via brief vortexing, centrifugation was performed for
5 min at 2000 rcf, 4 °C, to pellet the resins. Supernatants were collected as washes and stored at 62

20 °C for checkpoint analyses. For releasing resin-bound adducts, an equal resin-volume of a
freshly prepared working elution buffer (WEB) was added to each 1.5-mL microcentrifuge tube
that contained washed adduct-bound resins. The WEB was prepared by mixing 2-mercaptoethanol,
Laemmli sample loading buffer, and a stock solution of biotin in WB3. The resulting resin
suspension included 2.5% of 2-mercaptoethanol, 1X Laemmli sample loading buffer, and 4 mM
of biotin, considering the volume of resins. The microcentrifuge tube was then heated in a hot
water bath at 95 °C for 15 min and cooled down to room temperature, protected from the light.
The heated resin suspension (HRS) was either used immediately or temporarily stored at 4 °C for
either analytical or preparative gel electrophoresis experiments.

2.2.4 Gel electrophoresis and fluorescence detection
For the analytical SDS-PAGE, a small portion of each sample (5 to 20 µL of either protein
extract, washes from affinity pull-down experiments, the supernatant of HRS, or whole HRS) was
loaded onto a Mini-PROTEAN® TGX™ precast gel (1.0-mm, 10-well, Bio-Rad). For the
preparative SDS-PAGE, approximately 90 µL of whole HRS was loaded into each well of an inhouse prepared gel (1.5-mm, 5-well). The gel consisted of a top stacking layer and a bottom
resolving layer with a volume ratio of 2:8. The stacking layer was cast with 4% acrylamide/bisacrylamide in a buffer of 0.5 M Tris-HCl and 0.4% SDS, whose pH was adjusted to 6.8. Whereas,
the resolving layer was cast with 12% acrylamide/bis-acrylamide in a buffer of 0.5 M of Tris-HCl
and 0.4% SDS, whose pH was adjusted to 8.8. Together with the samples, 5 µL of either SeeBlue™
Plus2 pre-stained protein standard (Life Technologies) or Precision Plus Protein™ dual color
standards (Bio-Rad) was loaded to the gel as molecular weight reference protein standards. The
subsequent electrophoresis was performed either at constant 120 V for 90 min or at a two-step
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setting of 120 V for 40 min and 200 V for 20 min until complete migration of the fronting band to
the bottom of the gel.
For the implementation of preparative 2-DE, we adopted a high-compatibility but low-cost
protocol.166 This protocol seamlessly merged two distinct gel electrophoresis techniques: vertical
isoelectric focusing-polyacrylamide gel electrophoresis (vIEF-PAGE) and SDS-PAGE, with
minimal instrumentation requirements. As the first part of this 2-DE procedure, vIEF-PAGE was
performed according to its manufacturer’s instruction. Briefly, 20 µL of protein extract was mixed
with 20 µL of provided IEF sample buffer at room temperature. The resulting 40 µL sample
solution was loaded to a provided precast IEF gel in a cassette assembly accommodated in the
electrophoresis cell. The three-step electrophoresis was operated at 50 V for 60 min, 200 V for 60
min, and 500 V for 30 min. Afterward, the IEF gel was incubated in 20% TCA for visualization
of white bands via protein precipitation and sliced into strips along the edge of each well, parallel
to the well-dividers, with a piece of thin glass on a clean glass surface. The gel strips were
dehydrated in acetonitrile until turning opaquely white and rehydrated in a solution of 2.5% 2mercaptoethanol in the stacking gel buffer. As the second part of this 2-DE procedure, the prepared
strip was loaded onto an in-house-cast gel (1.5-mm, single-well, 10% polyacrylamide). The
following SDS-PAGE was performed in the same manner as previously described.
After electrophoresis, the protein bands were fixed with a solution of 10% acetic acid and
50% methanol in water. The gels were imaged with an LI-COR Odyssey imaging system (LICOR, Inc. Lincoln, NE) with setting as a dual channel (700 nm and 800 nm; the 700-nm channel
was monitored for visualizing the reference protein ladder), 0.75 mm focus offset, 7.0 intensity,
and highest quality. After successful detection of the fluorescent protein band, the gels were
stained with QC Colloidal Coomassie Stain (Bio-Rad), placed in a clear resealable plastic pouch,
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and imaged with a document scanner. Finally, the target protein band or spot was excised and
diced into 1 mm x 1 mm cubes with a sterile scalpel on a clean glass surface. Gel cubes were
transferred to clean 1.5-mL microcentrifuge tubes either for immediate preparation for in-gel
digestion or temporary storage at 4 °C.

2.2.5 In-gel trypsin digestion
The excised gel bands or spots were washed with acetonitrile for destaining, treated with
DTE for reduction, IAA for alkylation, and incubated overnight with trypsin for digestion. Refer
to Text S6 for details. Afterward, peptides were extracted with an appropriate amount of
acetonitrile from the post-digestion gel dices, concentrated in SpeedVac, and acidified with formic
acid (to pH ≤ 3) for desalting with the solid-phase extraction (SPE) technique. For desalting peptide
samples, Pierce™ C18 StageTips (Thermo Fisher Scientific) were used. The SPE procedure was
performed according to the manufacturer’s instructions. The desalted tryptic digests were
concentrated in the SpeedVac, lyophilized, and reconstituted to 10 µL.

2.2.6 LC-MS/MS analysis
The in-gel tryptic digests were analyzed on a Q Exactive HF mass spectrometer equipped
with the nanospray ionization (NSI) source coupled with an UltiMate 3000 UHPLC system
(Thermo Fisher Scientific).
For the LC part, a nanoEase M/Z Peptide BEH C18 column (25 cm length, 75 μm diameter,
1.7 μm particle size, and 130Å pore size) was used for peptide separation. The autosampler
temperature was 4.0 °C. Column oven temperature was 50.0 °C. Sample injection volume was 1.0
µL. Mobile phase flow rate was set as 300 nL/min. Solvent A was 0.1 % formic acid in water, and
solvent B was 0.1 % formic acid in acetonitrile. The complete 90-min LC method consisted of a
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10-min sample-loading period, a 50-min mobile phase linear gradient period, and a 30-min postgradient column flushing and equilibration period. Specifically, the method profile (% for Solvent
B at runtime) was 4% at 0 to 10 min, 30% at 50 min, 90% at 60 to 70 min, and 4% at 72 to 90 min.
For the mass spectrometer part, Xcalibur v2.8 software controlled the instrument. The mass
spectrometer operated in DDA mode for monitoring positive ions at a spray voltage of 1500 V.
For MS1, the mass range was from 300 to 1800 m/z. The Orbitrap mass analyzer was set with a
resolution of 60,000, an AGC target of 1e6, and a maximum ion time of 60 ms. For data dependent
MS2, the quadrupole was set with an isolation window of 2.0 m/z. The Orbitrap was set with a
resolution of 15,000, an AGC target of 1e5, and a maximum ion time of 40 ms. This DDA method
allowed up to 20 MS/MS scans per duty cycle, and a stepped normalized collision energy (NCE)
of 27. Precursors that triggered MS/MS scans were dynamically excluded from repetitive MS/MS
scans for 40 s. Charge state exclusion was enabled to reject precursor ions with charge states
beyond the range of +2 to +8. Peptide match option was set at preferred. MS/MS spectra were
collected as the centroid data type.

2.2.7 LC-MS/MS data processing
For peptide and protein identification, the mass spectral data were searched against a mouse
reference proteome database (Swiss-Prot, Mus musculus, UP000000589, last modified on October
22, 2018) containing 16,997 mouse proteins. Database searches were performed with both
MaxQuant (version 1.6.1.0) and MODa (version 1.60).
For MaxQuant-based searches, essential parameters were set as follows: 1% peptide-level
false discovery rate (FDR), 1% protein-level FDR, 1% modification site FDR, a minimum peptide
length of 5, a minimum score of 0 for unmodified peptides, a minimum score of 10 for modified
peptides, a minimum unique peptide number of 0, a minimum razor peptide number of 1, an
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MS/MS mass error tolerance of 20 ppm, a peptide length range of 8 to 25 for unspecific search, a
maximum missed peptide cleavage of 3, a maximum peptide mass of 8000 Da, and a revert decoy
mode. For the setting of modification inclusion list, oxidation on methionine, acetylation on
protein N-terminus were set as variable modification. Besides, carbamidomethylation, biotinyl
piperazine-2-nitroimidazole-ICG (original form, +1284.5250 Da), biotinyl piperazine-2aminoimidazole-ICG (reduced form 1, +1254.5519 Da), or biotinyl piperazine-2-aminoimidazoleICG (reduced form 2, + 1239.5410 Da) on cysteine was set as a variable modification. Up to 5
variable modifications per peptide were allowed.
MODa-based searches were performed in single-blind mode (maximum one modification
per peptide). Key parameters are two enzymatic termini, no missed cleavage, a modification mass
range of 150 to 1500, no fixed modification, a fragment ion tolerance of 0.01 Da, no precursor ion
auto-correction, and a precursor mass tolerance of 2 Da. FDR of 1% was enforced for separate
searches against the database appended with reverted decoy protein sequences. Additional data
processing was performed with the assistance of ProteoWizard Toolkit167 for conversion of data
format, visualization, and extraction of ion chromatograms and spectral binary datasets from the
raw data files.

2.2.8 Mouse serum albumin modeling and molecular docking
The sequence of mouse serum albumin (AlbM, P07724) was obtained from UniProt protein
data repository in FASTA format.168 The AlbM structural model was built using the SWISSMODEL (https://swissmodel.expasy.org), based on target-template sequence alignment and
homology.169 After the template database query with the sequence of AlbM as the input, all 42
available templates were sorted by their global model quality estimation (GMQE) scores. With a
GMQE score of 0.86 being the highest among 42 available serum albumin templates, the X-ray
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crystal structure of rabbit serum albumin (PDB accession: 3V09)170 was selected as the template
to generate the three-dimensional (3D) structure of AlbM in PDB format.
The virtual probe-protein binding (docking) study was performed using AutoDock Vina171
and AutoDock Tools version 1.5.6172. For docking model preparation, the 3D structure of AlbM,
water molecules were removed, and polar hydrogen atoms were added. The 3D structure of biotin
dye was constructed in two-dimensional MOL format using ChemDraw Prime 16.0.1.4 and
converted to three-dimensional MOL2 format using Avogadro173. The following 3D structure of
biotin dye was prepared for docking by assigning torsional bonds. For peptide
LPCVEDYLSAILNR, the grid box with a size of 60 × 30 × 36 Å was allocated at the center of the
binding cavity with x, y, and z coordinates of 30, 15, and 12. For peptide DTCFSTEGPNLVTR,
the grid box with a size of 30 × 30 × 30 Å was centered on the cysteine residue with x, y, and z
coordinates of 32, 60, and 20. Other parameters were set as default values. The docked models
with the highest affinity (-8.5 kcal/mol for LPCVEDYLSAILNR and -6.1 kcal/mol for
DTCFSTEGPNLVTR) were selected result to demonstrate the probe-protein interaction before
the formation of covalent adducts.
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2.3 Results and Discussion

2.3.1 The biotinyl 2-nitroimidazole-ICG
By conjugating a biotin moiety to the previously reported 2-nitro-ICG chemical
probe,148,150 we designed biotinyl 2-nitroimidazole-ICG (referred to as the biotin dye, Scheme
2.2b) as a “dual-functional” chemical probe. In comparison, most chemical probes used in
proteomics contain one of two groups for detection: a fluorescence reporter group or biotin
“affinity handle.174 Ideally, the “dual-functional” design of the biotin dye would offer multiple
analytical advantages including flexible and confident detection, leveraged sensitivity, and surface
chemistry-compatibility.
With its exceptional affinity to avidin (Kd ~ 10-15 M), the biotin moiety is routinely used as
a propagable “affinity handle” on the chemical probe for flexible detection and enrichment of
probe-reacted proteins. The downstream sample preparation is supported by a broad range of
commercially available products for avidin-based immunoprecipitation and detection.175 By
design, biotin dye allows solid-phase affinity pull-down of probe-reacted proteins from complex
tumor tissues. Besides, the biotin moiety on the adducts can be detected by Western Blot analysis
(Figure 2.1), offering a complementary detection approach to the fluorescence based on the ICG
fluorophore of the probe-modified proteins.
The optical absorption and emission peaks, as well as the extinction coefficient of the biotin
dye, were measured (Table 2.1) by the Zhu group at Department of Biomedical Engineering,
University of Connecticut. The absorption and fluorescence emission peaks were similar to those
of previously reported ICG probes, while its extinction coefficient was about half of that of the

69

“fully-loaded” 2-nitro-ICG probe and two-thirds of that of the “half-loaded” 2-nitro-ICG probe, in
agreement with the reduced conjugation system in the biotin dye.

2.3.2 Selective protein modification by biotinyl 2-nitroimidazole-ICG in
hypoxic mouse tumor
In vivo fluorescence intensity for tumor peaked between minute 5 to 15 post-injection and
declined rapidly afterward (Figure 2.2a). The average tumor fluorescence intensity in a range of
1 to 60 minutes for the biotin dye was the lowest compared with other ICG probes (Figure 2.3).
This observation was likely due to the optical property of the probe and its diffusion physics in
solution and intercellular translocation within the tumor tissue.176 After 60 minutes, the
fluorescence signal intensity from the biotin dye converged towards that of the “half-loaded” 2nitro-ICG probe, yet remained weaker than that of the “fully-loaded” 2-nitro-ICG probe (Figure
2.3 and Figure 2.4), which might be explained by the halved stoichiometry of the hypoxia targeting
2-nitroimidazole functional group.
The biotin dye remained highly fluorescent in either the free molecule or adduct forms at
all three analytical levels (Figure 2.2). At the in vivo level, fluorescence images of the probeinjected mouse indicated that the dye molecules circulated throughout the cardiovascular system
of the mouse after a short period upon the injection. At the ex vivo level, only the tumor, kidneys,
and liver exhibited fluorescence in the specified optical condition 48 hours post-injection. As
expected, the majority of dye molecules underwent fast excretion via the renal route while a
smaller population of them sustained delayed elimination and probable enzymatic degradation
through the biliary and hepatic routes.154,177 It is known that 2-nitroimidazole derivatives are
reactive and predominantly retainable under hypoxic conditions in cells,144 which is consistent
with the tumor fluorescence images. Accordingly, the biotin dye successfully reproduced an
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imaging profile of in vivo and ex vivo fluorescence akin to those previously reported for original
2-nitro-ICG probes.148,150
At the tumor lysate level, proteins separated by SDS-PAGE were analyzed for fluorescence
emission at 800 nm. Notably, there was only a single protein band with a molecular weight of
about 70 kDa (left, Figure 2.2b) showing intense fluorescence signal, despite the high complexity
of its sample matrix as a whole lysate of the tumor (right, Figure 2.2b). Furthermore, this band
remained intense upon Coomassie Blue staining, compared to intensities of other bands in the
entire lane (right, Figure 2.2b). These observations suggested that (1) the biotin dye was attached
to one protein as the primary target, or less likely a few co-migrating proteins, (2) the probe-protein
adducts were covalent because the denaturing condition of SDS-PAGE did not dissociate the
adducts, and (3) the protein target would probably be of high abundance.

2.3.3 Identification of protein targets for modification by biotinyl 2nitroimidazole-ICG
To identify the probe-modified protein, we performed proteomics profiling for two
preparations of tumor lysates upon treatment with the biotin dye. One sample (Sample 1) was from
the lysate of fluorescent tumor tissue. The lysate was enriched using immobilized avidin and then
resolved by SDS-PAGE. The other sample (Sample 2) was from 2-DE-resolved proteins without
the affinity enrichment. LC-MS/MS profiling data of peptides from in-gel digestion of both
samples were searched against the mouse proteome database (Swiss-Prot, Mus musculus,
UP000000589, last modified on October 22, 2018), using Andromeda of MaxQuant.163 The top
hit for both samples was AlbM with 47 peptides identified for the Sample 1 and 55 for Sample 2,
among which 34 peptides were shared for both samples (Table 2.2). Co-migrating proteins were
also identified. In total, MaxQuant search identified 376 peptides corresponding to 75 proteins for
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Sample 1 and 377 peptides corresponding to 155 proteins for Sample 2. Among these identified
proteins, only 29 proteins (Table 2.3) were shared by both samples. No oxidoreductase was on the
identified list of proteins. Oxidoreductases play an indispensable role as the bio-reductive activator
in the metabolic pathway of 2-nitroimidazole, a prerequisite for the detection of hypoxia.155,178
This observation was not surprising. The sample preparation workflow of this study targeted
proteins with detectable fluorescence, and the number of fluorescence adducts of reduced forms
of the probe and oxidoreductases could be too low to call for proteomics profiling.
The inclusion of the theoretical masses of both biotin dye and its anticipated reduced form
(biotinyl 2-aminoimidazole-ICG)156 as variable modifications on cysteine for the database search
did not identify peptides with either modification (Scheme 2.3). Presumably, the reducing
environment of hypoxic tumor favors the reduction of 2-nitroimidazole to 2-aminoimidazole that
has increased electrophilicity for forming covalent adducts with nucleophiles on the protein.156
Since Andromeda of MaxQuant is a commonly used restrictive search engine for proteomics
profiling,163 MaxQuant requires an input of specified searching constraints for expected
modifications to be either fixed or variable.

2.3.4 A general data analysis workflow for identifying peptides with
defined and mutable modifications
To identify probe-carrying peptides, we performed an alternative database search using
MODa179 (Scheme 2.3). MODa is an unrestrictive or “blind” search algorithm that is based on the
alignment of peptide sequence tags. It was developed for discovering unknown protein posttranslational modifications (PTMs) without any prerequisite knowledge on modification targets or
modification-induced peptide mass shifts.179 Briefly, MODa first performs in silico digestion,
which converts protein sequences from a proteome database into tryptic peptide sequences, and
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calculates theoretical m/z values for b and y ions of each peptide to construct two theoretical
MS/MS spectra, respectively. In contrast, restricted database search engines, like the Andromeda
of MaxQuant, enumerate all possible fragment ions and combine their m/z values altogether to
generate complex theoretical MS/MS spectra for in-depth statistical analyses and comparisons to
experimental MS/MS spectra.163 Second, MODa creates short sequence tags of 3 to 4 amino acid
residues in length, using consecutive theoretical b or y ions, for all the in silico peptides. Third,
MODa compares the resulting short tags with ion patterns in observed MS/MS spectra. Based on
the Needleman–Wunsch algorithm,180 MODa scores peptide-spectrum matches (PSMs) according
to numbers of sequence-tag matches, mismatches, and gaps, and assigns up to five candidate
peptides with highest scores to each experimental MS/MS spectrum. The precursor mass value of
the spectrum is then compared with calculated masses for the candidate peptides to examine for
any possible mass shift that is potentially attributed to a peptide modification, followed by further
verification based on sequence-tag gaps in the previous analysis. When there is no mass shift, the
peptide is assigned as a native one. Finally, to improve the specificity of the peptide identification,
a pre-set FDR threshold is ready to be implemented if decoy protein sequences are appended to
the input proteome database. For the FDR-based filtering, MODa examines the statistical
distributions of sequence tag-matching scores assigned to co-identified decoy peptides and actual
peptides, respectively, adjusts the score cut-off for the peptide candidate output according to their
score distributions, and eliminates a large number of low-quality peptide candidates. In contrast to
the original candidate pool, the FDR-filtered candidate pool is less inflated and delivers the
identification result with higher confidence at the cost of sensitivity.181
MODa identified 25 peptides corresponding to 15 proteins for Sample 1 at 1% FDR and
125 peptides corresponding to 51 proteins for Sample 2. Sample 1 contained 5 peptides for AlbM,
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while Sample 2 contained 16 peptides (Table 2.4). In comparison, MODa and MaxQanut results
shared 10 proteins for Sample 1 and 44 proteins for Sample 2 (Table 2.5 and Figure 2.5).
However, Samples 1 and 2 only shared 3 identified proteins by both searches: serum albumin
(AlbM, P07724), hemoglobin subunit beta-1 (P02088), and heat shock protein HSP 90-beta
(P11499).
Notably, the capability of MODa for aligning short sequence tags assigned the candidacy
to an AlbM peptide (LPCVEDYLSAILNR) carrying the modification by the biotin dye without
FDR-filtering. Corresponding MS/MS spectra of the probe-modified peptide were further verified
manually. This modified peptide was observed as [M + 3H]4+ ions at 723 m/z (Figure 2.6a). Insource fragmentation of the attached probe was also observed; a cluster of quadruply charged ions,
captured within the 706-732 m/z window at the same retention time, shared a significant number
of y ions (Figure 2.7). ICG molecule is prone to gas-phase fragmentation.182 However, due to the
stochastic sampling of precursor ions for MS/MS in profiling experiments, some intense in-source
fragments of the modified peptide were missed for sequencing. Additional forms of the same
peptide carrying the intact probe were also observed (Figure 2.6b to 2.6d): [singly-oxidized M +
3H]4+ at 727 m/z, [M + 2H + Na]4+ at 729 m/z, and [doubly-oxidized M + 3H]4+ at 731 m/z.
Importantly, all these forms of modified peptide shared a series of y ions (Figure 2.8).
Following the same analytical workflow (Scheme 2.3), another modified AlbM peptide
with a sequence of DTCFSTEGPNLVTR was also discovered (Figure 2.9 and Figure 2.10).
Initially, this modified peptide was observed as triply charged ions at m/z 927 (Figure 2.9).
However, the mass increase of this modified peptide matched only a reduced form (loss of the 2nitro group) of the probe, a known reduction product of 2-nitroimidazole in hypoxic
environments.183 The extraction of ion chromatograms for this peptide, interestingly, also indicated
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the presence of several other modified forms of the same peptide (Figure 2.11). Their mass
increases over the native peptide were all smaller than that of the reduced probe (Figure 2.10 vs.
Figure 2.9). Unlike peptide LPCVEDYLSAILNR, those modified forms of peptide
DTCFSTEGPNLVTR had different elution times and thus were not in-source fragments.
Mutable modifications of peptide DTCFSTEGPNLVTR were less likely attributed to the
degradation of the ICG moiety as part of the reduced probe carried by the peptide. Although ICG
was prone to degradation during sample preparations,176 similar modifications as partial probes
were not observed on peptide LPCVEDYLSAILNR. Rather, adducts as partial probes on peptide
DTCFSTEGPNLVTR were produced in vivo, likely as a result of enzyme-catalyzed degradation
of the probe moiety on protein adducts177 or catabolic processes of the probe in hypoxic tumor
preceding or succeeding its conjugation with the protein. Additional ambiguity (Figure 2.10)
existed for assigning partial probe attachment to the peptide. Mass increases for the peptide
overlapped the mass increase for peptide AADKDTCFSTEGPNLVTR, which had a miscleaved
site compared to the fully digested peptide DTCFSTEGPNLVTR.
For a few reasons, modification sites for both peptides were assigned to a cysteine residue
near the N-terminus, C472 and C591, respectively. First, MS/MS spectra for the modified peptides
encompassed y ions up to the C-side residue of cysteine. The sequential y ions denoted both
peptides as unique hits against the entire mouse proteome. Second, the cysteinyl thiol (C472) was
the only nucleophile in the N-terminal region of peptide LPCVEDYLSAILNR and the most
nucleophilic one (C591) in the N-terminal region of peptide DTCFSTEGPNLVTR. Third, no b
ion was observed, in agreement with the cysteine modification in the N-terminal region.
Additionally, numbers of fragment ions remained unassigned (Figure 2.8 and Figure 2.9), which
could be attributed to probe (or probe fragment)-carrying ions generated in the gas phase.182,184
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Additional experiments can further validate identified peptides and identify additional probemodified peptides and their precursor proteins. These experiments include targeted proteomics
analysis using selected reaction monitoring-tandem mass spectrometry and the all-ionfragmentation (AIF) for an unbiased measurement of any product ion.185 DDA spectra and AIF
spectra can be explored simultaneously to identify rare protein targets with improved efficiency
and confidence. Incorporation of alternative techniques for sample preparation, for instance, onresin trypsin diegstion186 and affinity pull-down of probe-modified peptides,174 is also worth
pursuing.

2.3.5 Albumin microenvironment steering pathways for the formation of
differential adducts with biotinyl 2-nitroimidazole-ICG
To analyze the probe-protein interaction and visualize the structural significance of peptide
LPCVEDYLSAILNR and DTCFSTEGPNLVTR within the folded AlbM, we conducted a
computational docking experiment for the biotin dye and AlbM. Although the X-ray
crystallographic data of AlbM was not available, the 3D structure was effectively modeled using
SWISS-MODEL.169 SWISS-MODEL is a web-based package for protein structure homology
modeling that builds protein models at different levels of complexity. In this study, as the
automated mode for modeling was selected, SWISS-MODEL searched for suitable templates
against the database of proteins with known 3D structures and identified a list of top hits based on
the protein sequence homology. By ranking the identified templates according to the GMQE score,
the top hit, rabbit serum albumin (3V09), was selected. The GMQE score described the estimated
template-target sequence alignment quality of a specific template and reflected the expected
accuracy of its resulting target model and the target’s sequence coverage. Afterward, the 3D model
of AlbM was downloaded as a PDB file and appended hydrogen atoms. Meanwhile, all chemical
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bonds in the biotin dye model except those forming ring and planar structures were defined as
flexible bonds. Finally, the prepared AlbM and biotin dye models were used together with a
defined search space at either the center or the peripheral subdomain of the protein model as the
docking input for AutoDock Vina.171 Subsequently, AutoDock Vina computed the free energy of
various ligand-bound protein models and searched for the best docking mode with its relative free
energy at the local minimum. By placing the ligand at various locations on the protein, an affinity
value regarding binding energy was calculated for each docked model. AutoDock Vina reported
nine docked modes with the ligand affinity ranging from -8.0 to -8.5 kcal/mol for peptide
LPCVEDYLSAILNR and -5.4 to -6.1 kcal/mol for peptide DTCFSTEGPNLVTR. Such energy
differences were equivalent to 20- to 100-fold differences in the dissociation constant (Kd). The
structure and location profiles of the docked ligand were saved as the output (Figure 2.12).
Intriguingly, locations of peptide LPCVEDYLSAILNR containing C472 and
DTCFSTEGPNLVTR containing C591 were significantly distinct on the 3D model of AlbM.
Peptide LPCVEDYLSAILNR (with C472 in red, Figure 2.12) was located in a deep pocket, where
the biotin dye was docked with a higher binding affinity. In contrast, peptide
DTCFSTEGPNLVTR (with C591 in yellow, Figure 2.12) was located on the surface of the
protein, where the biotin dye was docked with a lower binding affinity. The homology analysis
(Table 2.6) of these sequence regions validated their relevant template-deduced conformational
features of the AlbM model. Hence, different locations of the two cysteine residues could explain
the differential formation of probe adducts: the intact biotin dye molecule modified the inner
peptide while a reduced probe or probe fragments modified the surface peptide (Scheme 2.4).
Upon intravenous administration, the biotin dye could exist in two hypothetical forms as
complexed with the high-abundance AlbM in the circulatory system of the mouse subject: (1)

77

AlbM peripheral subdomain-bound form and (2) AlbM core pocket-buried form.187,188 The AlbM
might carry the probe in both forms through the mouse circulatory system to the tumor site. The
high affinity of the probe to the pocket increases the effective molarity189 of the probe, thus
amplifying its apparent electrophilicity, i.e., making the otherwise inert 2-nitroimidazole ring
reactive towards the reduced cysteine residue (C472) that is made available by the compromised
redox homeostasis190 at the hypoxic tumor site.
On the other hand, the peripheral subdomain-interacting or surface-adsorbed 2nitroimidazole probe was exposed to the solvent environment, prone to dynamic dissociation and
re-association, accessible to oxidoreductases for enzymatic reduction. When nucleophilic thiol
groups become available from impaired disulfide bridges of AlbM at the hypoxic tumor site, the
thiol group on cysteine (C591) reacts with the activated imidazole ring on the reduced probe and
metabolic fragments via the nucleophilic addition or substitution mechanism,156,188 leading to
observed modifications of different mass increases on peptide DTCFSTEGPNLVTR (Figure 2.9
and Figure 2.10). Modifications of this peptide exemplify a general pathway for 2-nitroimidazole
modification of proteins in the hypoxic tumor (Scheme 2.4).
Besides the hypoxic condition, the biodistribution of albumin could play another
significant role in the fluorescence detection of solid tumors in this study. While 49% of the total
albumin population is located within the plasma as intravascular albumin or “serum” albumin after
being synthesized and excreted by hepatocytes, a substantial 51% of it is found as extravascular
albumin at discrete levels of local abundance.191 Importantly, the tumor cell line 4T1-Luc used in
this study is a breast cancer cell line, which originates from malignant neoplasms of the mouse
mammary gland. With lactation as its unique function, the mammary gland can not only capture
albumin from the plasma for milk secretion via transcytosis192 but also synthesize nonhepatic
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albumin on its own193. In comparison to its scare intracellular abundance of most somatic cells,
albumin occupies 19% of cytosolic protein contents in breast cancer cells.194 In fact, the level of
this intracellular albumin has been utilized as a prognostic factor to evaluate the effect of adjuvant
tamoxifen (whose active metabolites can block estrogen receptors that sustain the growth of breast
cancer cells) treatment for ER+ (estrogen receptor-positive) breast cancer.195 Therefore, it is
conceivable that the malignant breast tumor behaves as a “hypoxic reservoir” of albumin, which
provides an exclusive extra- and intracellular environment where the low abundance of oxygen
and high abundance of albumin coexist. It is this unique pathophysiological environment that
enables the hypoxia-targeting capability of 2-nitro-ICG probes.
The probe molecule would likely to be transiently engaged by a protein carrier, such as
AlbM, transported through the cardiovascular system to various destinations, activated locally by
an oxidoreductase, and eventually bond to the protein carrier forming covalent adducts under
hypoxic condition. Overall, the discovery of two biotin dye-modified AlbM peptides did bestow
some valuable insights on the hypoxia-detection mechanism of 2-nitroimidazole derivatives
(Scheme 2.4).
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2.4 Conclusion
With the biotinyl 2-nitroimidazole-ICG probe, we have opened a proteomics gate to
explore the metabolic chemistry of 2-nitroimidazole and its hypoxia-targeting mechanism in the
hypoxic cellular condition. By applying our product-ion-oriented data-mining methodology, we
have successfully interpreted otherwise convoluted and indecisive data of proteomics profiling.
Accordingly, the biotinyl 2-nitroimidazole-ICG probe and its reduced forms modify the mouse
serum albumin as the primary protein target at two cysteine residues, C472 and C591, located in a
deep pocket and on the surface, respectively. At the hypoxic tumor site of the probe-injected mouse
subject, the chemical probe covalently links to these peptides probably via dissimilar mechanisms
(Scheme 2.4). On top of this constructive interpretation to the global insight on the hypoxiaprobing mechanism of 2-nitroimidazole compounds, our investigation illustrates a distinguished
analytical workflow that depicts a practical guideline for some foreseeable challenging cases in
the mass spectrometry-based chemical proteomics, especially during in vivo evaluation of drug
candidates, where the detectable chemical modifications on target and off-target proteins are
unknown or mutable.
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2.5 Chapter 2 Figures
Figure 2.1 Western Blot images.

Note: a) WB result for SDS-PAGE gel of unenriched probe-treated sample as Lane 1 and immobilized
avidin-enriched probe-treated sample as Lane 2. b) WB result for 2-DE gel of unenriched probe-treated
sample. The protein spot of interest is marked in the green ellipse. The WB experiments involve anti-biotin
primary antibody and alkaline phosphatase conjugate as the secondary antibody for chromogenic detection.
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Figure 2.2 Fluorescence imaging results.

Note: a) in vivo (top), ex vivo (bottom) fluorescence images of tumor sample labeled by the biotin dye. b)
Fluorescence (left) and Coomassie Blue G250-stained (right) gel images of SDS-PAGE-resolved tumor
lysate samples (lane “-” is control and lane “+” is biotin dye-labeled tumor sample). Refer to Figure 2.10
for additional gel images.

82

Figure 2.3 Quantitative comparison of in vivo tumor fluorescence peak values
of different groups of mice injected with different dyes.
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Figure 2.4 in vivo and ex vivo Fluorescence kinetics of individual mice before
dye injection and at different time points after dye injection.

Note: Each group of mice is injected with one of four dyes: (a) and (e) Bis-carboxylic ICG, (b) and (f)
Half-loaded ICG, (c) and (g) Pip-2nitroimidazole-ICG and (d) and (h) Biotin dye, with 100 µl at 25 µM
concentration solved in 9.25% sucrose solution. For each mouse, the tumor is located on top of the right
leg of the mouse.
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Figure 2.5 Venn diagram showing relations among the identification results.

Note: This Venn diagram shows relations among the identification results of both SDS-PAGE-resolved
avidin-enriched probe-treated sample (Sample 1) and 2-DE-resolved unenriched probe-treated sample
(Sample 2) by both MODa and MaxQuant. Refer to Table 2.5 for specific protein identities labeled with 4digit binary numbers.
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Figure 2.6 Example MS spectrum associated with the peptide
LPCVEDYLSAILNR modified by intact biotin dye.

Note: This example MS spectrum shows a cluster of quadruply-charged molecular ions (labeled) and their
in-source fragmented forms (unlabeled) associated with the peptide LPCVEDYLSAILNR modified by
intact biotin dye. a) The peak at m/z of 723 matching the probe-carrying peptide. b) The peak at m/z of 727
matching the oxidized (plus one oxygen atom) form of a probe-carrying peptide. c) The peak at m/z of 729
matching the one sodium adduct form (replacing one proton with one sodium) of a probe-carrying peptide.
d) The peak at m/z of 731 matching the doubly oxidized (plus two oxygen atoms) form of a probe-carrying
peptide.
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Figure 2.7 Alignment of extracted ion chromatograms for the MS ion cluster
associated with peptide LPCVEDYLSAILNR modified by the intact probe.

Note: The 706-732 m/z ion isolation window of interest is binned into smaller windows of 2 m/z. The
overlap of ion current peaks implies multiple ions share the same retention profile, suggesting the lability
of the probe modification and in-source fragmentation phenomenon of the original probe-carrying peptide.
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Figure 2.8 Annotated MS/MS spectra featuring the peptide
LPCVEDYLSAILNR modified by intact biotin dye.

Note: a) The spectrum matching the probe-carrying peptide. b) The spectrum matching the oxidized (plus
one oxygen atom) form of the probe-carrying peptide. c) The spectrum matching the one sodium adduct
form (replacing one proton with one sodium) of the probe-carrying peptide. d) The spectrum matching the
doubly oxidized (plus two oxygen atoms) form of the probe-carrying peptide. Oxidation of probe-carrying
peptides b and d was peculated to occur during sample preparation.
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Figure 2.9 Annotated MS/MS spectrum featuring the peptide
DTCFSTEGPNLVTR modified by a reduced form of the biotin dye.

Note: This triply charged precursor with an m/z ratio of 927 matches a proposed modified peptide carrying
a reduced probe with a loss of 2-nitro group on its imidazole ring. This peptide eluted at 40.3 min as shown
on the total ion chromatogram (TIC). Refer to Scheme 2.4 for the complete structural scheme of the
modification (fully protonated, R+).
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Figure 2.10 Annotated MS/MS spectrum featuring the probe-modified
peptide DTCFSTEGPNLVTR or its mis-cleaved form.

Note: This annotated MS/MS spectrum features either the probe-modified peptide DTCFSTEGPNLVTR
or its mis-cleaved form AADKDTCFSTEGPNLVTR. This triply charged precursor has a m/z ratio of 903.
This precursor eluted at 40.7 min as shown on the total ion chromatogram (TIC).
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Figure 2.11 Alignment of extracted ion chromatograms (XICs) for y ions of
interest.
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Note: a) Aligned y-ion XICs of peptide LPCVEDYLSAILNR. b) Aligned y-ion XICs of
(AADK)DTCFSTEGPNLVTR. The alignment shows both individual (y1 to y11) and stacked (showing as
summed y-ion current for MS/MS scans with at least five concurrent y ions) ion chromatograms. Y-axis
was zoomed for a better illustration with a scale of 1 x 107. On the stack chromatograms, one peak cluster
indicates either a single molecular ion or multiple molecular ions with similar precursor masses
(exemplifying in-source fragmentation) occurring at a specific retention window at 63 min, referring to
Figure 2.7. The dispersion of multiple peak clusters over the retention time (43 min, 48 min, 50 min, 55
min, and 59 min on b suggests the existence of multiple molecular ions associated with this peptide of
interest.
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Figure 2.12 Biotin dye docking results visualizing the pre-modification probeprotein interactions.

Note: The structure of AlbM was modeled using a template X-ray structure (rabbit serum albumin PDB
accession 3V09). a) Cartoon presentation of AlbM binding the biotin dye molecule in two distinct manners.
The cysteine residue is highlighted in yellow for the superficial peptide DTCFSTEGPNLVTR and red for
the conserved peptide LPCVEDYLSAILNR. b) Protein-surface presentation with docked biotin dye
molecules at both the surface and cavity of AlbM. c) A regional view of the biotin dye-protein interaction
on the binding surface. d) A regional view of the biotin dye-protein interaction in the binding pocket. The
2-nitroimidazole group is concealed inside the pocket and isolated from the extra-molecular environment.
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Figure 2.13 Additional gel images.
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Note: a) Visible bands in vIEF-PAGE gel after TCA-induced protein precipitation. Lane 1: denatured
control sample, Lane 2: denatured probe-treated sample, Lane 3: native control sample, and Lane 4: native
probe-treated sample. b) Fluorescence image of a. c) 2-DE fluorescence image of a denatured probe-treated
sample. d) 2-DE fluorescence image of a denatured control sample. e) Coomassie Blue-stained 2-DE gel
of denatured probe-treated sample. f) Coomassie Blue-stained 2-DE gel of denatured control sample. g)
Gel e post-excision of the protein spot of interest. h) Gel f post-excision of the protein spot of interest.
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2.6 Chapter 2 Schemes
Scheme 2.1 Evolution of nitroimidazole-indocyanine green derivatives as
fluorescent tumor hypoxia probes.
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Scheme 2.2 Overview of this investigation.

Note: a) Brief scheme showing proposed general reaction pathways of 2-nitroimidazole probes. Both smallmolecule metabolites and macromolecule adducts are anticipated as in vivo products. b) Structure of biotin
dye showing the reactive hypoxia-targeting 2-nitroimidazole group in red, ICG fluorophore in green, and
biotin affinity handle in blue. c) Experimental workflow of this study. Note the biotin dye is dual-functional
thus allows for flexible and orthogonal detection of target analytes at various stages (color-coded to indicate
related groups on the dye molecule).
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Scheme 2.3 Recommended data-mining workflow for the identification of
protein targets and their modification sites in chemical proteomics profiling
studies.

Note: The mass spectra acquired in data-dependent acquisition mode should be analyzed with
complementary tactics in parallel, regarding the identifiability of modified peptides. Using this study as an
example, the output corresponding to each step of data processing has been verified (✓). The dashed arrow
represents the prevalent restrictive search strategy relying on an input of defined modifications to assign
spectra featuring modified peptides, which has been proven inapplicable to this study. Traceable surrogate
probe fragment ions remain to be determined *(TBD), which requires a dedicated MS/MS study of the
biotin dye in the future.
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Scheme 2.4 Proposed AlbM-biotin dye in vivo reaction mechanism.

Note: The AlbM carries the biotin dye in two hypothetical forms (regardless of stoichiometry), the
peripheral subdomain-bound (surface-adsorbed) and core pocket-buried, to the hypoxic tumor site through
the circulatory system of the mouse subject. These two forms of the protein-probe complex theoretically
have a 20- to 100-fold difference in equilibrium constants for the probe binding (K1 vs. K2). Under hypoxic
condition, as the compromised redox homeostasis impairs proximate disulfide bridges of AlbM cysteine
residues, both forms of the probe can covalently modify AlbM. Note the high affinity of the probe to the
protein pocket elevates the effective molarity of the probe thus amplifying its apparent electrophilicity,
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which provides additional reactivity of the probe to the adjacent thiol in the binding pocket, leading to direct
addition of the intact probe to the cysteine residue (center a and b). In contrast, the surface-adsorbed probe
is only reactive to the adjacent thiol after the bio-reductive activation (top, b). Furthermore, post-covalentbinding bio-reductive reactions reduce 2-aminoimidazole (top, c) to imidazole (top, d) or other unknown
species (X, top, e) at the protein surface.
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2.7 Chapter 2 Tables
Table 2.1 Optical properties of the biotin dye in comparison with the previous
ICG-based fluorescence imaging probes.

λabsor
Name

Structure

Chemical Formula

λemiss

ption

ion

max

max

(nm)

(nm)

Extinctio
n
Coefficie
nt
(x1000
M-1cm-1)

Bis-carboxylic
ICG

C37H43N2NaO10S2

755

790

221

Half-loaded
ICG

C46H54N7NaO12S2

755

790

171

Pip-2nitroimidazoleICG
(Fully loaded)

C55H65N12NaO14S2

753

790

230

Biotin dye

C62H82N11NaO13S3

755

785

102
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Note: Optical properties of the biotin dye are compared with the previous ICG-based fluorescence imaging
probes.148,150 For the measurement of optical properties, 9.25% of sucrose was used as the solvent in
consistence with published results. The fluorescence signal was more stable in this solvent. The
fluorescence signal of ICG dye varies greatly in different solvents. See 2 for more detailed references.
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Table 2.2 AlbM peptides identified by MaxQuant.
Identified Sample1 (SDS-PAGE)
Peptide Sequence

Identified Sample2 (2-DE) Peptide
Sequence

AADKDTCFSTEGPNLVTR

AADKDTCFSTEGPNLVTR

AETFTFHSDICTLPEK

AETFTFHSDICTLPEK

AETFTFHSDICTLPEKEK

AETFTFHSDICTLPEKEK

AHCLSEVEHDTMPADLPAIAADFVED

AHCLSEVEHDTMPADLPAIAADFVEDQEV

QEVCK

CK

ALVSSVR

ALVSSVR

APQVSTPTLVEAAR

APQVSTPTLVEAAR

AWAVAR

AWAVAR

CCAEANPPACYGTVLAEFQPLVEEPK

CCAEANPPACYGTVLAEFQPLVEEPK

CCSGSLVER

CCSGSLVER

CCTLPEDQRLPCVEDYLSAILNR

CCTLPEDQRLPCVEDYLSAILNR

DVFLGTFLYEYSR

DVFLGTFLYEYSR

ECCHGDLLECADDR

ECCHGDLLECADDR

EFKAETFTFHSDICTLPEKEK

EFKAETFTFHSDICTLPEKEK

ENPTTFMGHYLHEVAR

ENPTTFMGHYLHEVAR

ENYGELADCCTK

ENYGELADCCTK

GLVLIAFSQYLQK

GLVLIAFSQYLQK

HPDYSVSLLLR

HPDYSVSLLLR

KQTALAELVK

KQTALAELVK

LCAIPNLR

LCAIPNLR

LCAIPNLRENYGELADCCTK

LCAIPNLRENYGELADCCTK

LGEYGFQNAILVR

LGEYGFQNAILVR

LPCVEDYLSAILNR

LPCVEDYLSAILNR
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LQTCCDKPLLK

LQTCCDKPLLK

RHPDYSVSLLLR

RHPDYSVSLLLR

RPCFSALTVDETYVPK

RPCFSALTVDETYVPK

RPCFSALTVDETYVPKEFK

RPCFSALTVDETYVPKEFK

SLHTLFGDK

SLHTLFGDK

SLHTLFGDKLCAIPNLR

SLHTLFGDKLCAIPNLR

SLHTLFGDKLCAIPNLRENYGELADC
SLHTLFGDKLCAIPNLRENYGELADCCTK
CTK
TVMDDFAQFLDTCCK

TVMDDFAQFLDTCCK

VCLLHEK

VCLLHEK

VNKECCHGDLLECADDRAELAK

VNKECCHGDLLECADDRAELAK

YNDLGEQHFK

YNDLGEQHFK

YTQKAPQVSTPTLVEAAR

YTQKAPQVSTPTLVEAAR

ATAEQLK

AADKDTCFSTEGPNLVTRCK

CCTLPEDQR

AFKAWAVAR

CSYDEHAK

ATAEQLKTVMDDFAQFLDTCCK

EAHKSEIAHR

DDNPSLPPFERPEAEAMCTSFK

KAHCLSEVEHDTMPADLPAIAADFVE
DTCFSTEGPNLVTR
DQEVCK
KYEATLEK

ECCHGDLLECADDRAELAK

LATDLTK

EFKAETFTFHSDICTLPEK

LQTCCDKPLLKK

EKALVSSVR

QTALAELVK

LCAIPNLRENYGELADCCTKQEPER

SEIAHR

LDGVKEKALVSSVR

TCVADESAANCDK

LSQTFPNADFAEITK

TNCDLYEK

LSQTFPNADFAEITKLATDLTK

YMCENQATISSK

LVQEVTDFAK
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NECFLQHKDDNPSLPPFERPEAEAMCTSF
K
NYAEAKDVFLGTFLYEYSR
QEPERNECFLQHKDDNPSLPPFERPEAEA
MCTSFK
QTALAELVKHKPK
SEIAHRYNDLGEQHFK
TNCDLYEKLGEYGFQNAILVR
VCLLHEKTPVSEHVTK
YNDLGEQHFKGLVLIAFSQYLQK

Note: The identified peptides shared in both SDS-PAGE-resolved avidin-enriched sample (Sample 1) and
2-DE-resolved unenriched sample (Sample 2) are labeled in red.

105

Table 2.3 Details of 29 shared proteins identified in both samples by
MaxQuant.
UniProt
Entry

Protein Names

Gene
Names

P01027

Complement C3 (HSE-MSF) [Cleaved into: Complement C3 beta
chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a
anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg);
Complement C3b alpha' chain; Complement C3c alpha' chain
fragment 1; Complement C3dg fragment; Complement C3g
fragment; Complement C3d fragment; Complement C3f fragment;
Complement C3c alpha' chain fragment 2]
Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain)

C3

P01942
P02088

P07724

Hemoglobin subunit beta-1 (Beta-1-globin) (Hemoglobin beta-1
chain) (Hemoglobin beta-major chain)
Tubulin alpha-1B chain (Alpha-tubulin 2) (Alpha-tubulin isotype Malpha-2) (Tubulin alpha-2 chain) [Cleaved into: Detyrosinated
tubulin alpha-1B chain]
Serum albumin

P07759

Serine protease inhibitor A3K (Serpin A3K) (Contrapsin) (SPI-2)

P07901

Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86)
(HSP86) (Tumor-specific transplantation 86 kDa antigen) (TSTA)

P11499

Heat shock protein HSP 90-beta (Heat shock 84 kDa) (HSP 84)
(HSP84) (Tumor-specific transplantation 84 kDa antigen) (TSTA)

P14824

Annexin A6 (67 kDa calelectrin) (Annexin VI) (Annexin-6)
(Calphobindin-II) (CPB-II) (Chromobindin-20) (Lipocortin VI)
(Protein III) (p68) (p70)
Endoplasmic reticulum chaperone BiP (EC 3.6.4.10) (78 kDa
glucose-regulated protein) (GRP-78) (Binding-immunoglobulin
protein) (BiP) (Heat shock protein 70 family protein 5) (HSP70
family protein 5) (Heat shock protein family A member 5)
(Immunoglobulin heavy chain-binding protein)
Carboxylesterase 1C (EC 3.1.1.1) (Liver carboxylesterase N) (Lung
surfactant convertase) (PES-N)
Transketolase (TK) (EC 2.2.1.1) (P68)

P05213

P20029

P23953
P40142
P50446

Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin6-alpha) (mK6-alpha) (Keratin-6A) (K6A)

P52480

Pyruvate kinase PKM (EC 2.7.1.40) (Pyruvate kinase muscle
isozyme)

Molecula
r Weight
(Da)
186,484

Hba Hbaa1
Hbb-b1

15,085

Tuba1b
Tuba2

50,152

Alb Alb-1
Alb1
Serpina3
k Mcm2
Spi2
Hsp90aa
1 Hsp86
Hsp86-1
Hspca
Hsp90ab
1 Hsp84
Hsp84-1
Hspcb
Anxa6
Anx6

68,693

Hspa5
Grp78

72,422

Ces1c
Es1
Tkt

61,056

Krt6a
Ker2
Krt2-6
Krt2-6a
Krt6
Pkm Pk3
Pkm2
Pykm

59,335

15,840

46,880

84,788

83,281

75,885

67,630

57,845
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P60710
P62737

Actin, cytoplasmic 1 (Beta-actin) [Cleaved into: Actin, cytoplasmic
1, N-terminally processed]
Actin, aortic smooth muscle (Alpha-actin-2) [Cleaved into: Actin,
aortic smooth muscle, intermediate form]

P63017

Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8)

P63260

Actin, cytoplasmic 2 (Gamma-actin) [Cleaved into: Actin,
cytoplasmic 2, N-terminally processed]
Actin, gamma-enteric smooth muscle (Alpha-actin-3) (Gamma-2actin) (Smooth muscle gamma-actin) [Cleaved into: Actin, gammaenteric smooth muscle, intermediate form]
Actin, alpha cardiac muscle 1 (Alpha-cardiac actin) [Cleaved into:
Actin, alpha cardiac muscle 1, intermediate form]
Tubulin alpha-1A chain (Alpha-tubulin 1) (Alpha-tubulin isotype Malpha-1) (Tubulin alpha-1 chain) [Cleaved into: Detyrosinated
tubulin alpha-1A chain]
Tubulin alpha-1C chain (Alpha-tubulin 6) (Alpha-tubulin isotype Malpha-6) (Tubulin alpha-6 chain) [Cleaved into: Detyrosinated
tubulin alpha-1C chain]
Keratin, type II cytoskeletal 73 (Cytokeratin-73) (CK-73) (Keratin73) (K73) (Type II inner root sheath-specific keratin-K6irs3) (Type-II
keratin Kb36)
Beta-actin-like protein 2 (Kappa-actin)

P63268

P68033
P68369

P68373

Q6NXH
9
Q8BFZ3
Q8BGZ
7
Q8VED
5
Q91X72
Q922U2
Q9Z331

Keratin, type II cytoskeletal 75 (Cytokeratin-75) (CK-75) (Keratin-6
hair follicle) (mK6hf) (Keratin-75) (K75) (Type II keratin-K6hf)
(Type-II keratin Kb18)
Keratin, type II cytoskeletal 79 (Cytokeratin-79) (CK-79) (Keratin79) (K79) (Type-II keratin Kb38)
Hemopexin
Keratin, type II cytoskeletal 5 (Cytokeratin-5) (CK-5) (Keratin-5)
(K5) (Type-II keratin Kb5)
Keratin, type II cytoskeletal 6B (Cytokeratin-6B) (CK-6B) (Keratin6-beta) (mK6-beta) (Keratin-6B) (K6B)

Actb

41,737

Acta2
Actsa
Actvs
Hspa8
Hsc70
Hsc73
Actg1
Actg
Actg2
Acta3
Actsg
Actc1
Actc
Tuba1a
Tuba1

42,009

Tuba1c
Tuba6

49,909

Krt73
Kb36

58,911

Actbl2

42,004

Krt75
Kb18

59,741

Krt79
Kb38
Hpx Hpxn

57,552

Krt5 Krt25
Krt6b K6beta Krt26b

61,767

70,871

41,793
41,877

42,019
50,136

51,318

60,322

Note: 29 proteins were identified in both samples (SDS-PAGE-resolved avidin-enriched sample and 2-DEresolved unenriched sample) by MaxQuant.
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Table 2.4 Peptides and their corresponding proteins identified by MODa.
Identified Peptides from Sample 1

Identified Peptides from Sample
2

DVFLGTFLYEYSR

Correspondi
ng Sample
1 Proteins
P07724

DVFLGTFLYEYSR

Correspondi
ng Sample 2
Proteins
P07724

ENPTTFMGHYLHEVAR

P07724

ENPTTFMGHYLHEVAR

P07724

GLVLIAFSQYLQK

P07724

GLVLIAFSQYLQK

P07724

LGEYGFQNAILVR

P07724

LGEYGFQNAILVR

P07724

QTALAELVK

P07724

QTALAELVK

P07724

FLEQQNQVLQTK

Q6IFZ6

FLEQQNQVLQTK

Q6IFZ6

VNSDEVGGEALGR

P02088

APQVSTPTLVEAAR

P07724

DLVVLLFETALLSSGFSLEDPQTHS
NR
GTGASGSFK

P11499

CCSGSLVER

P07724

Q07133

DTCFSTEGPNLVTR

P07724

GFSSGSAVVSGGSR

Q3TTY5

HPDYSVSLLLR

P07724

SADELENLILQQN

Q6DIB4

LPCVEDYLSAILNR

P07724

SGSEGPVLLLLHGGGHSALSWAVF
TAAIISR
SSAFDGLLPQQN

Q8BVQ5

LSQTFPNADFAEITK

P07724

Q8VBT3

LVQEVTDFAK

P07724

GVTHNIPLLR

Q91ZA3

PCFSALTVDETYVPK

P07724

HIEIQVLGDK

Q91ZA3

SLHTLFGDK

P07724

LVTYGSDR

Q91ZA3

TPVSEHVTK

P07724

SFGLPSIGR

Q91ZA3

YNDLGEQHFK

P07724

VVEEAPSIFLDPETR

Q91ZA3

DIPVDSPELK

O08677

YSSAGTVEFLVDSQK

Q91ZA3

ALLNVVDSAR

O35405

LYLGHNYVTAIR

Q921I1

IGGHGAEYGAEALER

P01942

SDIVIAVTYNR

Q99MR8

VITAFNDGLNHLDSLK

P02088

VFFSEGAQANR

Q99MR8

YFDSFGDLSSASAIMGNAK

P02088

LGLALNFSVFYYEILNSPEK

Q9CQV8

LHVDPENFR

P02089

SLQSVAEER

Q9CZM2

VVAGVATALAHK

P02089

NAFASVILFGTNNSSSISGVWVFR

Q9D8N0

LAQIHFPR

P07758

DLQILAEFHEK

P07759

ELISELDER

P07759

EVFTEQADLSGITETK

P07759

LSVSQVVHK

P07759

TMEEILEGLK

P07759

EADDIVNWLK

P09103

THILLFLPK

P09103

VDATEESDLAQQYGVR

P09103

ALELTGLK

P09405

ETLEEVFEK

P09405

FAISELFAK

P09405

GFGFVDFNSEEDAK

P09405
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TLVLSNLSYSATK

P09405

ATGVFTTLQPLR

P11276

GLTPGVIYEGQLISIQQYGHR

P11276

HFSVEGQLEFR

P11499

HLEINPDHPIVETLR

P11499

SLTNDWEDHLAVK

P11499

DAFVAIVQSVK

P14824

DLESDIIGDTSGHFQK

P14824

ENDDVVSEDLVQQDVQDLYE
AGELK
GIGTDEATIIDIVTHR

P14824

GSVHDFPEFDANQDAEALYTA
MK
ILISLATGNR

P14824

LVFDEYLK

P14824

SEIDLLNIR

P14824

SELDMLDIR

P14824

TLIEILATR

P14824

IINEPTAAAIAYGLDK

P16627

FEELNADLFR

P17156

LLQDFFNGK

P17156

DNHLLGTFDLTGIPPAPR

P20029

ELEEIVQPIISK

P20029

IEWLESHQDADIEDFK

P20029

NELESYAYSLK

P20029

SDIDEIVLVGGSTR

P20029

SQIFSTASDNQPTVTIK

P20029

IFNNGADLSGITEENAPLK

P22599

LVQIHIPR

P22599

SFNTVPYIVGFNK

P23953

NPDTNIVFSPLSISAALAIVSLG
AK
FATNFYQHLADSK

P29621

TSDQIHFFFAK

P32261

FAEAFEAIPR

P42932

LATNAAVTVLR

P42932

LFVTNDAATILR

P42932

VADIALHYANK

P42932

TLEAQLTPQVVER

P49182

YEVTTIHNLFR

P49182

FTGLQYLR

P51885

SLEYLDLSFNQMSK

P51885

GVNLPGAAVDLPAVSEK

P52480

IYVDDGLISLQVK

P52480

P14824

P14824

P32261
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VGWEQLLTTIAR

P57780

VGLQVVAVK

P63038

SPYQLVLQHSR

P82198

ISHLPLVEELR

P97310

GILLYGPPGTGK

Q01853

LDQLIYIPLPDEK

Q01853

LSQELDFVSHNVR

Q02819

DTPLTLTVLHK

Q06770

GFLDVVTR

Q3TW96

VQDPLAELVK

Q497V5

SYIHEVAR

Q5SYD0

GSVHQNFDDFTFVTGK

Q60963

TLQPLLFINSAK

Q60963

AYYHLLEQVAPK

Q61233

EGESLEDLMK

Q61233

LNLAFIANLFNK

Q61233

NEALIALLR

Q61233

NWMNSLGVNPR

Q61233

QFVTATDVVR

Q61233

TLTLALVWQLMR

Q61233

VYALPEDLVEVNPK

Q61233

YAFVNWINK

Q61233

DFFHLDER

Q61247

QEEDLANINQWVK

Q61247

GPLAHQISGLFLPSK

Q61503

AISHEHSPSDLEAHFVPLVK

Q76MZ3

LAGGDWFTSR

Q76MZ3

SEIIPMFSNLASDEQDSVR

Q76MZ3

VLELDNVK

Q76MZ3

EIISEVQR

Q7SIG6

LHFFMPGFAPLTSR

Q7TMM9

SHIDQLVLIFAGK

Q8R317

QTPTFWILAR

Q8VBW6

CSPDPGLTALLSDHR

Q91X72

FNPVTGEVPPR

Q91X72

GATYAFTGSHYWR

Q91X72

GPDSVFLIK

Q91X72

WFWDFATR

Q91X72

ANDDIIVNWVNR

Q99K51

AYFHLLNQIAPK

Q99K51

HVSPAGAAVGVPLSEDEAR

Q9CWJ9

SLASLGLSLVASGGTAK

Q9CWJ9

LQLLNLSR

Q9DBB9
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APLVPPGSPVVNALFR

Q9JHU9

SVLVDFLIGSGLK

Q9JHU9

QHFEWLLK

Q9QUR6

LVVLPFPGK

Q9QXC1

Note: AlbM peptides are highlighted in yellow. Shared peptides and their corresponding proteins (shown
as UniProt accession numbers), are labeled in red. Sample 1 is the SDS-PAGE-resolved avidin-enriched
sample. Sample 2 is the 2-DE-resolved unenriched sample.
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Table 2.5 Venn data table showing relations among the identification results.
(0001)

(0010)

(0100)

(0101)

(1000)

(1010)

(1011)

(1100)

(1110)

(1111)

Q07133

O35405

A0JP43

A2ASS6

O08677

Q6IFZ
6

P01027

Q6DIB4

P16627

E9Q286

A6X935

P02089

P05213

Q8VBT
3
Q9CZM
2

P29621

P01872

C8YR32

P07758

P07901

P02301

O35969

P09103

P40142

Q497V
5
Q5SYD
0
Q7SIG
6

P02535

Q99MR
8
Q9CQV
8
Q9D8N
0

O55055

P09405

P50446

O70318

P11276

P60710

O88491

P17156

P62737

P0194
2
P0775
9
P1482
4
P2002
9
P2395
3
P5248
0
Q91X7
2

P0208
8
P0772
4
P1149
9

P97310

Q3TTY
5
Q8BVQ
5
Q91ZA
3
Q921I1

P08071

O89110

P22599

P63017

P0C6F1

P04104

P32261

P63260

P10126

P04441

P42932

P63268

P12382

P05214

P49182

P68033

P14148

P08003

P51885

P68369

P15864

P0CG49

P57780

P68373

P26041

P0CG50

P63038

P35700

P10077

P82198

P35980

P10711

Q01853

P43274

P16045

Q02819

P43276

P16301

Q06770

P43277

P17182

P46662

P18529

Q3TW9
6
Q60963

Q6NXH
9
Q8BFZ
3
Q8BGZ
7
Q8VED
5
Q922U
2
Q9Z331

P47857

P20152

Q61233

P47911

P20918

Q61247

P47915

P21614

Q61503

P47962

P24527

P49962

P27005

P53026

P29699

Q76MZ
3
Q7TMM
9
Q8R317

P54310

P42859

P62631

P48036

P62806

P59240

P06151
P07744

Q8VBW
6
Q99K51
Q9CWJ
9

112

P62849

P61979

P62855

P62983

P62918

P62984

P63101

P68134

P68433

P68368

P84228

P68372

P84244

P80316

P86048

P83626

Q05920

P97386

Q3USH
1
Q3UV17

P97504

Q5DTX
6
Q5SWU
9
Q61881

Q00896

Q6ZWV
3
Q8BMK
4
Q8BQM
9
Q8BRH
4
Q8BTI8

Q01514

Q8C341

Q9DBB
9
Q9JHU
9
Q9QUR
6
Q9QXC
1

P99024

Q00897
Q00PI9

Q03526
Q3TLH4
Q3UMC
0
Q3UTQ
7
Q3UXZ6

Q8VEK
3
Q91YQ
5
Q9CR5
7
Q9CTN
5
Q9CXB
8
Q9CY62

Q4VA45

Q9D8E6

Q61702

Q9DBN
5
Q9DCV
7
Q9QYB
2

Q62255

Q569L8
Q60674
Q61316
Q61329
Q61576

Q64438
Q684R7
Q6IFZ9
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Q6P8J2
Q6P9J9
Q7TNG
5
Q7TNP2
Q7TPR4
Q80TK0
Q80X19
Q80YV3
Q811F1
Q8BGA
8
Q8BGC
4
Q8BKI2
Q8BND
5
Q8BTF7
Q8BTY8
Q8BVK9
Q8C145
Q8C166
Q8C551
Q8C5W
4
Q8K0D2
Q8K3V4
Q8R0W
0
Q8R2S9
Q8VCT9
Q8VDC
1
Q8VDW
0
Q8VIM9
Q91WB
4
Q91WG
0
Q99J45
Q99K95
Q99KC8
Q99KD5
Q99KW
3
Q9CQB
5
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Q9CQW
3
Q9CWF
2
Q9CXV9
Q9D0F9
Q9D281
Q9D3R6
Q9D4B1
Q9D554
Q9D6F9
Q9DC60
Q9EP96
Q9ERC
8
Q9ERD
7
Q9JJN2
Q9JKF1
Q9JLC8
Q9JMA1
Q9JMH6
Q9R0H5
Q9WU7
9
Q9WUP
0
Q9WVE
8
Q9Z0G7
Q9Z1N5
Q9Z1X4
Q9Z247

Note: This Venn data table shows detailed identification results of both SDS-PAGE-resolved avidinenriched sample (Sample 1) and 2-DE-resolved unenriched sample (Sample 2) by both MODa and
MaxQuant. Column titles refer to the specific areas on the Venn diagram above in Figure 2.5.
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Table 2.6 Homology analysis of serum albumin from multiple species showing favored conservation of the
inner peptide.
Species
SALSA
SALSA
CHICK
MERUN
MESAU
MOUSE
RAT
RABIT
PIG
BOVIN
SHEEP
EQUAS
HORSE
MACFA
MACMU
HUMAN
PONAB
FELCA
CANLF
BOMMX
XENLA
XENLA

Albumin
ID
Q03156
P21848
P19121
O35090
A6YF56
P07724
P02770
P49065
P08835
P02769
P14639
Q5XLE4
P35747
A2V9Z4
Q28522
P02768
Q5NVH5
P49064
P49822
Q3T478
P14872
P08759
Output

Legend.
Alignment output symbol
*

Ntermi
nus …
… 459
… 459
… 465
… 462
… 461
… 461
… 461
… 461
… 460
… 460
… 460
… 460
… 460
… 461
… 453
… 461
… 461
… 461
… 461
… 460
… 460
… 459

Sequence region 1
(showing the inner peptide)
CCKDEPGHFVLPCAEEKLTDAIDATCDDYDPSSINPHIAHCCNQSYSMRR
CCKDEQGHFVLPCAEEKLTDAIDATCDDYDPSSINPHIAHCCNQSYSMRR
CCQ-LGEDRRMACSEGYLSIVIHDTCRKQETTPINDNVSQCCSQLYANRR
CCA-LPEKKRLPCVEDYLSAILNRVCLLHEKTPVSEQVTKCCSGSLVERR
CCV-LPEAQRLPCVEDYISAILNRVCVLHEKTPVSEQVTKCCTGSVVERR
CCT-LPEDQRLPCVEDYLSAILNRVCLLHEKTPVSEHVTKCCSGSLVERR
CCT-LPEAQRLPCVEDYLSAILNRLCVLHEKTPVSEKVTKCCSGSLVERR
CCK-HPEAERLPCVEDYLSVVLNRLCVLHEKTPVSEKVTKCCSESLVDRR
CCK-RPEEERLSCAEDYLSLVLNRLCVLHEKTPVSEKVTKCCTESLVNRR
CCT-KPESERMPCTEDYLSLILNRLCVLHEKTPVSEKVTKCCTESLVNRR
CCA-KPESERMPCTEDYLSLILNRLCVLHEKTPVSEKVTKCCTESLVNRR
CCK-LPESERLPCSENHLALALNRLCVLHEKTPVSEKITKCCTDSLAERR
CCK-LPESERLPCSENHLALALNRLCVLHEKTPVSEKITKCCTDSLAERR
CCK-LPEAKRMPCAEDYLSVVLNRLCVLHEKTPVSEKVTKCCTESLVNRR
CCK-LPEAKRMPCAEDYLSVVLNRLCVLHEKTPVSEKVTKCCTESLVNRR
CCK-HPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRR
CCK-HPEPKRMPCAEDYLSVVLNQLCVLHEKTPVSERVTKCCTESLVNRR
CCT-HPEAERLSCAEDYLSVVLNRLCVLHEKTPVSERVTKCCTESLVNRR
CCK-KPESERMSCAEDFLSVVLNRLCVLHEKTPVSERVTKCCSESLVNRR
CCA-LPNTQKMPCAEGGLSLIIGEFCEMEKTHPINEHVKNCCWKSYSNRR
CCA-VPENQRMPCAEGDLTILIGKMCERQKKTFINNHVAHCCTDSYSGMR
CCA-VPENQRMPCAEGDLTILIGKMCERQKKTFINNHVAHCCTDSYSGMR
**
: * * :: :
*
.
:. .: :**
*

Omitted
region (…)
508
508
513
510
509
509
509
509
508
508
508
508
508
509
501
509
509
509
509
508
508
507

…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…

580
580
585
580
581
581
581
581
580
580
580
580
580
581
573
581
581
581
581
580
580
579

Sequence region 2
(showing the surface peptide)
KCCAAEDQAACFTEEAPKLVSESAELVKV-KCCAAEDQAACFTEEAPKLVSESAELVKV-KCCKQSDINTCFGEEGANLIVQSRATLGIGA
KCCKQEDKEACFSTEGPKLVAESQKALA--KCCKAEDKEACFSEDGPKLVASSQAALA--TCCKAADKDTCFSTEGPNLVTRCKDALA--KCCKAADKDNCFATEGPNLVARSKEALA--KCCSAEDKEACFAVEGPKLVESSKATLG--KCCAAPDHEACFAVEGPKFVIEIRGILA--KCCAADDKEACFAVEGPKLVVSTQTALA--KCCAADDKEGCFVLEGPKLVASTQAALA--KCCGAEDKEACFAEEGPKLVASSQLALA--KCCGREDKEACFAEEGPKLVASSQLALA--KCCKADDKEACFAEEGPKFVAASQAALA--KCCKADDKEACFAEEGPKFVAASQAALA--KCCKADDKETCFAEEGKKLVAASQAALGL-KCCKADDKETCFAEEGKKLVAASQAALGL-KCCAAEDKEACFAEEGPKLVAAAQAALA--KCCAAENKEGCFSEEGPKLVAAAQAALV--KCCAAEDHQACFNAEEPILIEHCKQLAA--KCCTADEHQPCFDTEKPVLIEHCQKLHP--KCCTADEHQPCFDTEKPVLIEHCQKLHP--.**
:
** :
::

Ctermi
nus
608
608
615
609
608
608
608
608
607
607
607
607
607
608
600
609
609
608
608
607
607
606

Indication
Fully conserved residue positions

:

Strongly conserved residue positions (shared by groups of amino acids with similar chemical properties)

.

Weakly conserved residue positions (shared by groups of amino acids with slightly distinct chemical properties)

Note: The in silico tryptic peptides are highlighted. Note the intact-probe-modified peptide in the deep pocket (yellow) contains more conserved
residues than reduced-probe-modified peptide on the AlbM surface (turquoise). The cysteine residues (in red and orange) of both peptides are fully
conserved. The sequence alignment was performed with a popular algorithm Clustal Omega. 196
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Chapter 3 Measuring Proteome-wide Live-cell Actions of
Small Molecules Using α-Methylene-β-lactone and Mass
Spectrometry
This chapter reports novel utilities of the α-methylene-β-lactone (MeLac) moiety as a
chemical probe warhead of multiple electrophilic sites. This study demonstrates that MeLacalkyne is a competent covalent probe and reacts with diverse proteins in live cells. Proteomics
analysis of affinity-enriched samples identified probe-reacted proteins, resolved their modified
peptides/residues, and thus characterized probe-protein reactions. Unique methods have been
developed to evaluate confidence in identification of the reacted proteins and modified peptides.
Tandem mass spectra of the peptides have uncovered that MeLac reacts with nucleophilic cysteine,
serine, lysine, threonine, and tyrosine residues, through either Michael addition or acyl addition.
As a broad-spectrum measurement probe, MeLac-alkyne has successfully analyzed orlistat and
parthenolide selectivity in live HT-29 cells within a unique peptide-centric proteomics platform.
As a scaffold, MeLac-alkyne has created a selective β-lactone probe with glutathione via
proteome-assisted probe-ligand assembly in biological matrices. The MeLac-alkyne-empowered
chemical proteomics platform is widely adaptable for measuring the live-cell action of reactive
molecules. The assembly of MeLac-alkyne glutathione adduct exemplifies a scalable route to
develop selective probes. It also provides an unprecedented opportunity to probe the glutathione
S-transferase P1 (GSTP1) responsible for multi-drug resistance in cancer patients. Overall, MeLac
is a versatile warhead bearing enormous potential in expediting the development of chemical
probes and targeted covalent inhibitors. MeLac-based probes are novel chemical tools making
easier interrogating protein (re)activity and developing new medicine.
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Part of this study has been published on ChemRxiv under the title “α-Methylene-β-Lactone
Probe for Measuring Live-Cell Reactions of Small Molecules” as a preprint.197

118

3.1 Introduction

3.1.1 Significance of chemical proteomics in drug development
Bioactive small molecules have always been the focus of interest for developing diagnostic
and therapeutic agents to elucidate and alter biochemical pathways. Drug discovery pipelines
typically involve two approaches for screening bioactive small molecules: target-based screening,
where compounds are developed to target a disease-causing enzyme, and phenotypic screening,
where libraries of small molecules are screened against model organisms to revert a disease-related
phenotype.198,199 In general, the target-based approach, which operates at a lower level, is targetspecific, thus reliable and low-risk. However, the implementation of target-based screening is
usually restricted by the progress of biological understanding of the disease and throttled by the
unforeseeable ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity)
profile. On the other hand, phenotypic screening, which operates at a higher level and factors in
drug delivery and toxicity, rarely provides opportunities to discover and validate the mode of
action of a drug candidate.200 Although expeditable and scalable, phenotypic screening is always
riskier to perform due to the fact that chemically distinct drug candidates may function on different
modes of action in different contexts or organisms beyond the experimental expectation.
Fortunately, the fast-advancing field of chemical proteomics provides a suitable middle-ground
between target-based and phenotypic screening approaches for unbiased exploration of drugtarget-phenotype relationships.201
Chemical proteomics is a progressive subfield of chemical biology. Chemical proteomics
tactically integrates synthetic chemistry to generate investigational small molecules to study and
manipulate whole sets of proteins, known as proteomes, and bioanalytical chemistry to establish
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bioanalytical platforms. These platforms investigate modes of action for bioactive small molecules
and functions of proteins.74 Chemical proteomics analysis of drug-protein reactions expedites the
development of new drugs by revealing selective inhibitors early, identifying toxicity liabilities,
and mitigating the risk of late-stage failures.74 In a typical chemical proteomics workflow, direct
chemical perturbation is usually introduced as a measure of treatment to a model proteome at a
specific level of biological relevance, such as cell lysates, living cells, tissues, and animal
specimens. Afterward, latent measurements of biochemical changes are performed. Offering
multiplexed analyses on, these chemical proteomics platforms often facilitate quantitative studies
of target engagement, off-target effect, and cytotoxicity for a compound of interest
simultaneously.202-204

3.1.2 Chemical probes and chemical proteomics methodologies
The measurement of post-treatment biochemical changes of a proteome relies on an
elaborate set of analytical and chemical tools. The analytical tools can be either optics-based or
mass spectrometry-based. The chemical probes are either covalent or non-covalent. Although
affinity capture approaches for target protein profiling are used with both types of chemical probes,
each type of chemical probes denotes a distinguishable analytical and biochemical methodology
of the underlying chemical proteomics experiments. Compound -centric approaches feature
chemically modified, either tagged 71 or immobilized 72 , compounds of interest as either covalent or
non-covalent chemical probes. Also known as boutique probes, these chemical probes are
introduced directly as baits to capture target proteins from a complex proteome. I n contrast,
activity-based approaches depend on meticulously designed covalent chemical probes. These
activity-based probes are capable of irreversibly binding, reacting with, and labeling target proteins
from a complex proteome, which is pre-treated with compounds of interests. The subsequent
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elucidation of target activity relies on the indirect measurement of probe-target adducts as
competitive binding assays.
Presumably, compound-centric chemical proteomics is the most straightforward strategy
for studying the proteome-wide activity of a known drug molecule. It mandates a boutique probe
created by installing a reporting group on the drug molecule. However, the construction of a drugderived probe often bears high synthetic costs. The application of such a boutique probe also
suffers from the consequence of chemical modifications. Because any structural changes made to
the drug molecule may significantly alter the parent molecule’s potency and selectivity profile.73
The more sophisticated strategy is activity-based chemical proteomics, which emphasizes the use
of a broad-spectrum covalent probe. Activity-based chemical proteomics, technically referring to
competitive ABPP, offers a nearly universal bioanalytical platform.74,75 Such a platform can
effectively decipher the proteome-wide action of underivatized drugs, as well as other reactive
molecules like environmental toxins and reactive metabolites from the human microbiota. 76-79
In contrast to boutique probes, ABPs are designed to carry less specificity to their protein
targets or are not specific at all. They capture proteome-wide “snapshots” visualizing drug-protein
interactions by permanently occupying available active sites post drug treatment on the model
proteome. As illustrated in Scheme 3.1, a competitive ABPP platform depends on its ABP to
measure the proteome-wide action of an underivatized drug.80,81 The distinctive technological
advantage of competitive ABPP is that a single ABP with broad proteome coverage can establish
a versatile analytical platform capable of evaluating multiple drugs or drug candidates on different
subsets of a single proteome. Therefore, ABPs with a broad spectrum of reactivity can fully
unleash the enormous potential of competitive ABPP technology.
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An ABP normally consists of three chemical components: a reactive group that is
commonly known as the “warhead,” a recognizing group that is commonly established as a
chemically inert binding moiety, and a reporting group that is commonly devised as an
affinity/fluorophore tag. (top, Scheme 3.1) An ABP’s warhead dictates the probe’s reactivity while
the recognizing group mainly determines the probe’s specificity towards a subset of proteins within
a proteome. In principle, when a broad reactivity spectrum is desired, an ABP should incorporate
(1) no recognizing group that may direct pre-reaction probe-protein complexation and (2) a
warhead of broad reactivity spectrum. While fluorophosphonate-based probes provide a successful
example of exploiting the first option of this principle,205 the second option is rarely explored due
to the limited availability of broad-reactivity warhead. It has always been a challenge to design a
warhead that covers the diverse reactivity space of a proteome. Individual proteins differ in
molecular composition and structure. Their reactions with small molecules are distinct from site
to site, domain to domain, and protein to protein. The diversity of these reactions rapidly multiplies
due to the large number and abundance range of proteins in a proteome.

3.1.3 The emerging need for novel warheads of broad reactivity
Existing warheads are far from ideal for universal platforms of competitive ABPP. To date,
a diverse collection of reactivity of warheads has been implemented on ABPs, including Michael
addition, non-Michael nucleophilic addition, addition-elimination, nucleophilic substitution, and
oxidation.124,206,207 Unfortunately, these conventional warheads typically react with only one
functional group on amino acid residues: cysteine,119,208,209 serine,205,210,211 threonine, tyrosine,212
lysine,79,212,213 and histidine,212 resulting in limited proteome coverage. Their reactivity depends
on either a specific reaction mechanism or a single electrophilic site.79,122-124,214-216 After all, a
widely adaptable platform of competitive ABPP requires a versatile probe equipped with a
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warhead of broad reactivity. To broaden the reactivity spectrum further, ABPs should adopt a
warhead with multiple electrophilic sites, which can extend the coverage of diverse functional
groups on amino acid residues. Nonetheless, due to the lack of warheads consisting of multiple
electrophiles, such an ideal broad-spectrum ABP is still absent.
This study employed α-methylene-β-lactone (MeLac) as a novel warhead with broad
reactivity and live-cell compatibility. Small and rigid, MeLac couples the Michael acceptor
functionality of acrylate217,218 with β-lactone reactivity.219-221 MeLac was proposed to be
susceptible to nucleophilic attacks at three distinct sites, as shown on Scheme 3.2, which would
result in a broad reactivity spectrum covering multiple nucleophilic side chains on different amino
acid residues. Therefore, this hypothesis was tested as follows: when used on a chemical probe as
the warhead for proteomics profiling, MeLac would react with different nucleophilic groups on
proteins via different mechanisms. This new warhead is prone to reactions with nucleophilic thiol
(Cys), hydroxyl (Ser, Thr, and Tyr), and amino (Lys) groups on the protein. Also, MeLac can
provide separate sites for regioselective reactions with spatially arranged protein nucleophiles.
Thus, the reactivity of the small and rigid MeLac is projected to be broad. A MeLac-equipped
chemical probe would make a competent measurement probe for building a widely adaptable
platform of competitive ABPP.
Using a MeLac-alkyne as a probe without recognizing group, the probe-protein reactions
in live cells were examined and characterized using both gel-based and mass spectrometry-based
proteomics profiling. New methods for the confident identification of protein adducts were
developed. A peptide-centric live cell compatible platform of competitive ABPP was built using
MeLac-alkyne. This platform was used for analyzing the selectivity profiles of protein reactions
with three chemically distinct compounds (Scheme 3.3): orlistat, parthenolide, and alkyl MeLac,
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which were used as model inhibitors with the β-lactone, Michael acceptor, and MeLac reactivity,
respectively.

3.1.4 The versatility of a chemical scaffold
On the other hand, MeLac was also introduced as a useful scaffold in developing selective
probes. MeLac offers separate electrophilic sites allowing not only regioselective reactions with
spatially arranged protein nucleophiles but also scalable development of selective probes to protein
targets of interest. Derivatization of one electrophilic site on the MeLac scaffold with an affinity
ligand can introduce a recognizing group in-situ for its pre-reaction complexation with the active
site on a protein. In this study, the in-cell conjugation of reduced glutathione (GSH) to MeLac was
also discovered. This surprising intracellular process produced a highly selective β-lactone
boutique probe for GSH. Overall, this study demonstrates utilities of the MeLac scaffold in
developing (1) broad-reactivity ABPs for measuring proteome-wide actions of underivatized small
molecules and (2) selective boutique probes for specific affinity ligands targeting small groups of
proteins.
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3.2 Experimental

3.2.1 Overview
To investigate the intriguing broad reactivity aspect of MeLac, the 4-(but-3-ynyl)-3methyleneoxetan-2-one (MeLac-alkyne probe, Scheme 3.3)222,223 was studied for its protein target
and labeling site-specific profile. After reactivity and target characterization of MeLac-alkyne, it
was then implemented as a competitive ABP for analyzing proteome-wide reactions of three
compounds in live HT-29 cells. These three compounds were 4-decyl-4-methyleneoxetan-2-one
(alkyl MeLac inhibitor), orlistat, and parthenolide. (Scheme 3.3) Both MeLac-alkyne and alkyl
MeLac inhibitor were synthesized and characterized at Howell group at Department of Chemistry.
Orlistat and parthenolide were purchased commercially. MeLac-alkyne probe-protein reactions
were initially evaluated using gel-based ABPP. Next, as illustrated in Scheme 3.4, probe-reacted
proteins were conjugated to azide-(desthio)biotin tags and enriched with immobilized avidin. This
affinity enrichment allowed the selective release of probe-reacted proteins and probe-modified
peptides for the following MS-based probe reactivity characterization, target profiling, structural
elucidation of probe-modified peptides, and dose-dependent target site-specific profiling of
benchmark inhibitors using MeLac-alkyne in competitive ABPP.

3.2.2 HT-29 cell culture
HT-29 cells were cultured to a confluency of 90-95%, as shown on Figure 3.1 in either
T75 or T175 cell culture flasks (CELLTREAT Scientific; about 8 million cells/ T75 flask or 23
million cells/T175 flask) with appropriate amount of growth medium (GM). The GM was prepared
by supplementing Dulbecco's Modified Eagle Medium (DMEM, Gibco) with 10% (v/v) fetal
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bovine serum (FBS, Gibco) and 1% (v/v) Pen/Strep antibiotics (FBS, Gibco). Sterile disposable
filter units (with a pore size of 0.22 μm or 0.45 μm) were used to sterilize the GM before its use
for cell culture. The incubation of cell culture flasks was performed in a humidified incubator at
5% of CO 2 and 37 °C.
To initiate the culturing of HT-29 cells, a vial of cryogenically preserved cells (seeds) was
thawed and washed with GM at 37 °C. The washed cells were then transferred to a proper cell
culture flask at a proper seeding density, as suggested in Table 3.1. GM change (replacing old GM
with fresh GM) was performed three to four times per week, depending on the cell growth and
viability. To maintain a healthy HT-29 cell line, cells were routinely passed at a confluency of
above 75%. For each passage, cells were detached from the supporting surface of the vessel by
trypsin/EDTA solution (Gibco). The detached culture suspension was then split at a ratio of 1:3 or
1:4 into new vessels of the same size. Cell viability (the number of living cells divided by the
number of total cells) was checked on a small aliquot of the culture suspension treated with trypan
blue on a hemocytometer under a microscope.

3.2.3 In vitro probe-proteome reaction for competitive ABPP using
MeLac-alkyne probe and HT-29 cells
Before reaction, cells were washed twice with 10 mL (for cells in each T75 flask) or 20
mL (for cells in each T175 flask) of phosphate-buffered saline (PBS, 1X, pre-heated at 37 °C,
Gibco).
For inhibitor-free probe treatment of the cells, either 10 or 20 µL of a pre-aliquoted stock
solution of MeLac-alkyne probe (dissolved in dimethylacetamide, DMAC, Sigma-Aldrich) or its
diluate in situ was added to each flask containing pre-washed cells and 10 or 20 mL of PBS,
resulting in working probe concentration of 0.01, 0.05, 0.1, 0.5, 1, 5, 10, or 50 μM. To incubate
126

cells, the flasks were placed on a rocking platform at 37 °C for 30 minutes. After the reaction, 10
or 20 mL of ice-cold tris-buffered saline (TBS, 1X, pre-heated at 37 °C, Pierce) was added to each
flask to quench the reaction. Cells in each flask were then gently scraped off the flask surface. The
subsequent suspension was transferred to either a 15-mL or 50-mL conical tube, centrifuged at
500 xg, 4 °C for 3 min to pellet the cells. Cells in each conical tube were washed with 10 or 20 mL
of PBS. Cell pellets were either used immediately or stored at -80 °C.
For the competitive activity-based proteomics profiling, the inhibitor (orlistat,
parthenolide, or alkyl MeLac) treatment of the cells was performed before the MeLac-alkyne probe
treatment at a working probe concentration of 20 μM. Briefly, a pre-aliquoted storage stock
solution of 20 mM, 50 mM, or 100 mM inhibitor (dissolved in DMSO, stored as aliquots at -80
°C) was diluted with DMSO to suitable concentrations to prepare working stock solutions if
necessary. At each inhibitor concentration, an appropriate volume of each inhibitor working stock
solution was then added to each prepared cell culture flask for each biological replicate (10 µL per
T75 flask with 10 mL of PBS or 20 µL per T175 flask with 20 mL of PBS). Various inhibitor
concentrations were investigated (1 μM vs. 10 μM for orlistat and parthenolide; 10 μM vs. 100 μM
for alkyl MeLac). The inhibitor-treated cells were subject to similar quenching and washing steps,
as described above.

3.2.4 Cell lysis and protein extraction
An appropriate volume of ice-cold PBS lysis buffer (6 to 10X of pellet volume) containing
1X EDTA-free protease inhibitor cocktail (Thermo Scientific) and phosphatase inhibitor cocktails
(Thermo Scientific) was added to each cell pellet. The subsequent cell suspension was
homogenized using an ultrasonic cell disruptor (VCX 130, Vibra-Cell) at 40% power on ice for
three pulses of 5 seconds. The homogenized lysate in each conical tube was split and transferred
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to multiple 2-mL microcentrifuge tubes for centrifugation at 16,000 g for 30 min at 4 °C. The
lysate supernatants in microcentrifuge tubes were recombined for each original lysate sample,
followed by BCA (Pierce) assay quantitation for total protein content. Finally, the cleared cell
lysates were diluted with PBS lysis buffer to give a final protein concentration of 1.5 mg/mL for
copper-catalyzed azide-alkyne cycloaddition (CuAAC) click reactions.

3.2.5 CuAAC click conjugation of probe-reacted proteins with azide
tags
A click reagent cocktail was prepared in situ by mixing tris(benzyltriazolylmethyl)amine
(TBTA, TCI) with a final concentration of 100 μM, copper(II) sulfate (Sigma-Aldrich, at a final
concentration of 1 mM), TCEP (tris(2-carboxyethyl)phosphine, Pierce, at a final concentration of
1 mM), and the azide fluorescence or affinity tag of choice [at a final concentration of 25 μM;
tetramethylrhodamine biotin azide (TAMRA), desthiobiotin azide (Des, Scheme 3.5), Dde biotin
picolyl azide (Dde, Scheme 3.6), or diazo biotin azide (Dia, Scheme 3.7) from Click Chemistry
Tools], in a tri-solvent system consisting of DMSO (Sigma-Aldrich), tert-butanol (Fisher
Scientific), and water (MS-grade, Fisher Scientific). The click reagent cocktail was added to each
sample of diluted probe-reacted lysate containing 1.5 mg/mL of protein. The reaction mixtures
were incubated at room temperature for 1 hour with constant agitation. After the reaction, proteins
were precipitated using cold acetone at -20 °C overnight. The resulting protein precipitate was
pelleted by centrifugation, resuspended once in cold methanol using ultrasonic cell disruptor, repelleted, and washed with cold methanol two more times without sonication. The slightly air-dried
pellet was then re-dissolved in 500 μL to 1mL of a reconstitution buffer (pH 8.0) containing 50
mM Tris-HCl (Fisher Scientific), 8 M urea (Pierce), and 10 mM 2-mercaptoethanol (Bio-Rad).
Next, the protein samples were incubated with 10 mM d ithioerythritol (DTE, ACROS Organics)
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at room temperature for 45 minutes, followed by 18.8 mM iodoacetamide (G-Biosciences) at room
temperature in the dark for 30 minutes. Finally, sodium dodecyl sulfate (SDS, Fisher Scientific)
was added to each protein sample to a final concentration of 2%. Samples were directly used for
either SDS-PAGE or affinity enrichment or stored at -80 °C.

3.2.6 Trypsin digestion of probe-reacted proteins and affinity enrichment
of probe-modified analytes
For each probe-treated sample, affinity enrichment was performed at either the protein
level (for the enrichment of probe-reacted proteins before trypsin digestion, performed for all three
affinity tags) or peptide level (for the enrichment of probe-modified tryptic peptides after trypsin
digestion, only performed for Des).
3.2.6.1 Affinity enrichment at the protein level
500 μL (containing about 0.75 mg of total protein) of each sample was transferred to a
centrifuge column and diluted with 12 mL of 100 mM Tris-HCl buffer (diluting SDS to less than
0.1%, urea to less than 0.3 M). Next, 200 μL of pre-washed 50% NeutrAvidin-agarose resin
(Pierce) slurry was added to each centrifuge column and incubated with constant agitation at 4 °C
overnight. For each sample, the protein-bound resins were washed twice with 10 mL of washing
buffer A (100 mM Tris-HCl, 0.1% SDS), three times with 10 mL of washing buffer B (100 mM
Tris-HCl), and twice with 10 mL of LC-MS-grade water. Afterward, the probe-reacted proteins
were eluted with one of three corresponding elution buffers prepared fresh. The Des elution buffer
consisted of 0.1% SDS (or 4 M urea), 5 mM biotin (Sigma-Aldrich), and 20 mM TEAB; the Dia
elution buffer consisted of 4 M urea, 37.5 mM sodium dithionite, and 20 mM TEAB; the Dde
elution buffer consisted of 4 M urea, 3% hydrazine, and 20 mM triethylammonium bicarbonate
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(TEAB, Sigma-Aldrich). The subsequent eluates were concentrated by a vacuum concentrator,
extracted and digested using a tip-based solid-phase extraction/trypsin digestion protocol.
3.2.6.2 In-tip trypsin digestion of affinity enriched proteins
Solid-phase extraction/trypsin digestion (SxTd) tips were prepared in-house. To prepare
each SxTd tip, two lays of Empore C18 material (two pre-stacked 3M Empore C18 Extraction
Disks), and ten lays of glass fiber material (packed twice of five pre-stacked Whatman glass
microfiber filters) into a 300 μL pipette tip (Fisherbrand, SureOne, Micropoint Pipette Tips,
Universal Fit, Non-Filtered). After packing the SxTd tip, the sorbent was pre-wet twice with 200
μL of 0.1% trifluoroacetic acid in 80% acetonitrile, spun at 1000 xg, RT, for 2 min. The sorbent
was then conditioned twice with 200 μL of freshly prepared 0.1M TEAB in 90% methanol, spun
at 1000 xg, RT, for 2 min. The maximal loading capacity of each SxTd tip was 50 μL (containing
up to 20 μg of total protein) affinity enrichment eluate sample.
For all protein samples with 5 to 20 μg of total protein in each, the total amount of needed
trypsin was determined on the theoretical NeutrAvidin-agarose resin binding capacity (8 mg
biotinylated protein per 1 mL of settled resin) and a trypsin:protein ratio (w/w) of 1:30. Fresh
precipitation buffer (PrecB) was prepared by mixing methanol and 1 M TEAB at a ratio (v/v) of
9:1. Trypsin suspension was prepared by mixing 1.0 μg/μL trypsin stock with ice-cold PrecB at a
volume ratio of 1:850. After brief vortexing, 280 μL of trypsin suspension was mixed with each
50 μL protein sample. Each suspension was then loaded to an SxTd tip, spun at 1000 xg for 3 min.
The loaded SxTd tips were washed with 200 μL of ice-cold PrecB for three times, 200 μL of dry
ice-cold acetone twice, and 200 μL of ice-cold PrecB once; all steps were followed by
centrifugation at 1000 xg for 3 min. Afterward, 20 μL of freshly prepared ice-cold trypsin in 20
mM TEAB solution (containing 0.34 μg of trypsin) was added to each loaded SxTd tip to submerge
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the sorbent fully (no air bubble). Finally, the loaded SxTd tips were placed in an appropriate pipette
tip box with deionized water at the bottom (pipette tip not touching the water), sealed in a clean
plastic bag, and incubated in a cell culture incubator at 37°C for 16 hrs. On the second day, each
SxTd tip was quenched with 200 μL of 0.1% trifluoroacetic acid twice. The digest was eluted with
60 μL of 50% acetonitrile, spun at 1000 xg for 5 min, concentrated in SpeedVac (Thermo),
lyophilized on a FreeZone Freeze Dry System (Labconco), and reconstituted in a solvent
containing 0.1% formic acid (Fisher Scientific), 2.5% acetonitrile in LC-MS grade water for LCMS/MS analyses.
3.2.6.3 Affinity enrichment at the peptide level
Buffer exchange was performed using Zeba spin desalting columns (7K MWCO, Pierce)
according to the manufacture’s instruction manual. After buffer exchange, the eluates (containing
50 mM ammonium bicarbonate, 2 M urea, and 1 mM calcium chloride, Sigma-Aldrich) from the
spin columns were diluted to a resulting urea concentration of 0.8 M. The protein samples were
then digested at a trypsin (sequencing grade, Pierce, or TPCK-treated, bioWORLD)-to-protein
ratio of 1:50 or 1:25 and incubated at 37 °C for 16 hours. Next, pre-washed 50% NeutrAvidinagarose resin slurry (100 μL per 0.75 mg of protein) was mixed with each digested sample,
followed by 1-hour incubation at room temperature with constant agitation. The resins were then
washed three times with 500 μL of Pierce IP Lysis Buffer, four times with 500 μL of PBS, and
four times with 500μL of LC-MS-grade water. The captured peptides were eluted by the elution
solvent (1.5X volume of the resin slurry, 50% acetonitrile, 0.1% trifluoroacetic acid, Fisher
Scientific) with 3-minute incubation for three times. The subsequent eluate fractions were pooled
in microcentrifuge tubes, concentrated in a SpeedVac, lyophilized, and reconstituted in a solvent

131

containing 0.1% formic acid (Fisher Scientific), 2.5% acetonitrile in LC-MS grade water for LCMS/MS analyses.

3.2.7 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
Western Blot
The gel-based analysis was performed on all the probe-reacted and avidin-enriched protein
samples. A small portion of each sample (10 µL) was loaded onto a Mini-PROTEAN® TGX™
precast gel (1.0-mm, 10-well, Bio-Rad). Together with the samples, 5 µL of either SeeBlue™
Plus2 pre-stained protein standard (Life Technologies) or Precision Plus Protein™ dual color
protein standards (Bio-Rad) was loaded to the gel as molecular weight references. The gels were
prepared in duplicates for performing analytical electrophoresis and Western Blot in parallel. The
subsequent electrophoresis was performed using Tris/Glycine/SDS premixed electrophoresis
buffer (Bio-Rad) either at constant 120 V for 90 min until complete migration of the fronting dye
band to the bottom of the gel. After electrophoresis, the protein bands were fixed with a solution
of 10% acetic acid and 50% methanol in water. For the analytical electrophoresis, gels were stained
with QC Colloidal Coomassie Stain (Bio-Rad), placed in a clear resealable plastic pouch, and
imaged with a document scanner. For the Western Blot, the gel was removed from the
electrophoresis cassette immediately after electrophoresis, rinsed with water, and accommodated
in a sandwich assembly of pre-wet fiber pads, filter paper, PVDF membrane (Life Technologies;
pre-soaked in methanol), and gel holder cassette. The sandwich assembly was then placed together
with a pre-frozen cooling pack and a magnetic stirrer in the buffer tank containing freshly prepared
transfer buffer (10% methanol in Tris/Glycine/SDS premixed electrophoresis buffer). The transfer
was performed at constant 30V overnight. After completion of the transfer, the PVDF membrane
was removed from the sandwich assembly and placed in a clean square petri dish provided by the
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WesternBreeze kit (Invitrogen). Solutions for chromogenic immunodetection were prepared
according to the WesternBreeze instruction manual. Briefly, the membrane was incubated on an
orbital shaker (Thermo Fisher Scientific) at 1 rev/s with: 1) 20 mL of water for 5 min; 2) 10 mL
of blocking solution for 30 min; 3) 20 mL of water for 5 min (twice); 4) 10 mL of primary antibody
(diluted to 1 mg/mL from original 8.17 mg/mL solution, mouse monoclonal anti-biotin IgG,
Fitzgerald) solution (0.05 μg/mL, 1:20000) for 1 h; 5) 20 mL of antibody wash solution for 5 min
(4 times); 6) 10 mL of secondary antibody- alkaline phosphatase conjugate (anti-mouse IgG, Life
Technologies) for 30 min; 7) 20 mL of antibody wash solution for 5 min (4 times); 8) 20 mL of
water for 2 min (3 times); 9) 5 mL of chromogenic substrate solution for 1 h; and 10) 20 mL of
water for 2 min (3 times). Finally, the blotted PVDF membrane was dried in air and scanned with
a document scanner.

3.2.8 Liquid chromatography-tandem mass spectrometry methods
For each sample, enriched and reconstituted tryptic digests were analyzed on a Q Exactive
Plus mass spectrometer equipped with the nanospray ionization (EASY-Spray nano) source
coupled with an EASY-nLC 1200 system (Thermo Fisher Scientific). For the LC part, peptides
were separated on a fused silica capillary (30 cm x 100 um I.D) packed with Halo C18 (2.7 um
particle size, 90 nm pore size, Michrom Bioresources). The autosampler temperature was 4.0 °C.
Column oven temperature was 50.0 °C. Sample injection volume was 2.0 µL. Mobile phase flow
rate was set as 300 nL/min. Solvent A was 0.1 % formic acid in water, and solvent B was 0.1 %
formic acid in acetonitrile. A gradient of 0 to 40% solvent B over 180 min was applied. For the
mass spectrometer part, the Xcalibur v2.8 software was used to control the instrument. The mass
spectrometer operated in DDA mode for monitoring positive ions at a spray voltage of 2200 V.
For MS1, the mass range was from 350 to 1700 m/z. The Orbitrap mass analyzer was set with a
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resolution of 70,000, an AGC target of 1E6, and a maximum ion time of 100 ms. For data
dependent MS2, the quadrupole was set with an isolation window of 2.0 m/z. The Orbitrap was set
with a resolution of 17,500, an AGC target of 1E5, and a maximum ion time of 50 ms. This DDA
method allowed up to 10 MS/MS scans per duty cycle, and a stepped normalized collision energy
(NCE) of 27. Precursors that triggered MS/MS scans were dynamically excluded from repetitive
MS/MS scans for 40 s. Charge state exclusion was enabled to reject precursor ions with charge
states outside the range of +2 to +4. The peptide match option was set as preferred. MS/MS spectra
were collected as the profile data type.

3.2.9 Mass spectrometry data qualification and analysis
For peptide and protein identification, the data was initially searched against a canonical
human reference proteome database (a FASTA file, Swiss-Prot, Homo Sapiens, UP000005640,
last modified on January 26th, 2019) containing 20,425 protein sequences. DDA raw files were
analyzed with both FragPipe224 (Version 12.2, with MSFragger Version 2.3) for unrestricted
database search (open-search) and MaxQuant 225 (Version 1.6.5.0) for restricted database search
with distinct settings. For more comprehensive identification and quantitation of probe
modification site-specific peptides, the same MaxQuant database search was also performed with
an extended proteome database (a FASTA file, UniProt, Homo Sapiens, UP000005640, last
modified on May 7th, 2020) containing 210,599 protein sequences compiled of both canonical and
isoform protein entries.
3.2.9.1 Unrestricted database search for a global illustration of MeLac and MeLac-related
chemical modifications
The open search of processed data was performed on all the samples using MSFragger.
The raw DDA data files were first centroided and converted to mzXML open-source format using
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ProteoWizard 167 . To perform the search, a set of default open-search parameters was then used
except for the items as follows: a precursor m/z tolerance (DeltaMass) window of 0 to 1000 Da, a
peptide length range of 5 to 50 residues, a peptide mass range of 500 to 5000, a maximum missed
peptide cleavage of 1. Both variable and fixed modification inclusion lists were disabled. Finally,
mass shifts (of precursor ions, caused by chemical modifications in samples) in the open-search
results were visualized using the DeltaMass226 software tool.
3.2.9.2 Restricted database search for identification of MeLac-reacted proteins
For the identification of target proteins for MeLac-alkyne probe 1, the MaxQuant search
was performed on probe-treated samples that underwent the protein-level enrichment procedure.
The corresponding search parameters were less than 1% peptide-level false discovery rate (FDR),
less than 1% protein-level FDR, less than 1% modification site FDR, a minimum peptide length
of 5, a minimum score of 0 for unmodified peptides, a minimum score of 40 for modif ied peptides,
a minimum unique peptide number of 2, a minimum razor (+ unique) peptide number of 2, a
minimum peptide number of 2, an MS/MS mass error tolerance of 20 ppm, a peptide length range
of 8 to 25 for unspecific search, a maximum missed peptide cleavage of 1, a maximum peptide
mass of 4600 Da, and a revert decoy mode. A basic modification inclusion list (variable oxidation
on methionine, variable acetylation on protein N-terminus, and fixed carbamidomethylation on
cysteine) was used with up to 3 modifications per peptide.
3.2.9.3 Restricted database search for identification of MeLac-modified peptides
For the identification of MeLac-alkyne probe-modified peptides and their modification
sites, the MaxQuant search was performed on probe-treated samples that underwent peptide-level
enrichment procedure. To limit the search space, a separate search was performed on each dataset
of these samples for each expected reactive amino acid residue (cysteine, lysine, serine, threonine,
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or tyrosine, respectively). Apart from the common settings reported above, the distinct search
parameters were a minimum unique peptide number of 0, a minimum razor (+ unique) peptide
number of 1, a minimum peptide number of 1. The modification inclusion list was set according
to the expected residue to be modified. For cysteine-specific search, a customized modification
inclusion list covering variable oxidation on methionine, variable acetylation on protein Nterminus, variable carbamidomethylation on cysteine, variable original Des-MeLac (+550.3115)
on cysteine, and variable hydrolyzed Des-MeLac (+568.3221) on cysteine was used with up to 5
modifications per peptide. For non-cysteine-specific search, a customized modification inclusion
list was used with up to 5 modifications per peptide, covering variable oxidation on methionine,
variable acetylation on protein N-terminus, fixed carbamidomethylation on cysteine, variable
original Des-MeLac (+550.3115 on either lysine, serine, threonine, or tyrosine), and variable 2mercaptoethanol-quenched Des-MeLac (+628.3254 on either lysine, serine, threonine, or
tyrosine). Two reported desthiobiotin-PEG 3 -specific fragment ions were set as diagnostic peaks
(197.1285 Da and 240.1707 Da).227,228 Example spectra were visualized and modified for formal
presentation using IPSA.229
3.2.9.4 Identification of glutathione Des-MeLac-modified peptides
For the identification of glutathione Des-MeLac-modified peptides and their modification
sites, the MaxQuant search was performed on probe-treated samples that underwent peptide-level
enrichment procedure. A separate custom human proteome database (a FASTA file, Swiss-Prot,
Homo Sapiens, UP000005640, last modified on April 9th, 2020, appended with GSTP1-I105 →
V105) containing 20,351 protein sequence entries was used (before the switching to the extended
UniProt database) as the reference proteome for covering the isoform-specific peptide
YVSLIYTNYEAGK, which was discovered by the manual examination of previous database
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search results. Reactive amino acid residues: cysteine, lysine, serine, threonine, and tyrosine were
included. Other settings were a minimum unique peptide number of 0, a minimum razor (+ unique)
peptide number of 1, a minimum peptide number of 1. For the customized modification inclusion
list covering variable oxidation on methionine, variable acetylation on protein N-terminus, variable
carbamidomethylation on cysteine, and variable glutathione Des-MeLac (+857.3953) on cysteine
with up to 5 modifications per peptide. Two reported desthiobiotin-PEG 3 -specific fragment ions
were set as diagnostic peaks (197.1285 Da and 240.1707 Da). 227,228
3.2.9.5 Label-free quantitation of probe-modified peptides and visualization of orlistat,
parthenolide and alkyl MeLac competitive ABPP data
The relative abundance of each identified/sequenced tryptic peptide was quantified and
calculated as the extracted chromatogram peak area of its corresponding precursor at the MS1 level
as part of the MaxQuant database search workflow. The MaxQuant search output was then
processed and summarized as tables of fold change vs. p-value by the in-house developed R
package maxabpp. The data was finally visualized as volcano plots.

3.2.10 Quantum mechanical modeling
All computational studies were performed using Gaussian 09 (Revision D.01). All the input
model structures were built with GaussView 5.0.9.
3.2.10.1 MeLac reaction paths
MeLac reaction paths were modeled with three different protein nucleophiles: thiol,
hydroxyl, and amino groups. Simplified model structures, methyl MeLac, methanethiol, methanol,
and methylamine, as well as their corresponding six transition states (TS) and six products, were
built for either Michael addition or acyl addition reaction path. Geometric optimization of these
structures was then performed with a range-separated DFT functional ωB97XD, employing a
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correlation-consistent Dunning basis set aug-cc-pVTZ for effective modeling of Michael addition
reaction path for the thiol.230 The Self-Consistent Reaction Field (SCRF) used Polarizable
Continuum Model (PCM) as an implicit method to account for the polarizable solvent effect of
water on reactions. Afterward, intrinsic reaction coordinate scan (IRC) computation was
performed on each TS structure to ensure its energy saddle point location on the reaction path.
Finally, vibrational frequency computation was performed on all optimized structures to determine
thermal corrections to their Gibbs free energy.
3.2.10.2 Des signature ions
The geometry minimization of Des signature ions was performed with a basic DFT
functional B3LYP, employing a Pople basis set 6-311+g(d, p) of moderate size. The output
structures of the lowest total energy (f 1 and f 2 ) were consistent with the previously reported
fragments.228

3.2.11 Computational protein-ligand modeling
The computational protein-ligand modeling (molecular docking) experiment was
performed using Schrödinger Suite (2020-1 Release).
3.2.11.1 Ligand and protein preparation
Four GSH-Lac β-lactone stereoisomers, 3R,4R-, 3R,4S-, 3S,4R-, and 3S,4S- were generated
on ChemDraw (version 19.0) as two-dimensional (2D) structures with specified chirality on both
the β-lactone and the GSH moieties. Their corresponding SDF files were imported to the Maestro
(version 12.3) workspace as ligands. Next, three-dimensional (3D) coordinates of all ligands were
generated by the LigPrep module with protonation states dominant within a pH range of 7.0 ± 2.0,
preserving their tautomeric forms. The LigPrep output then served as starting ligand geometries
for docking.
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The crystal structure of a human glutathione S-transferase P dimer (GSTP1) complexing
two hydrolyzed piperlongumine ligands (PDB ID: 5J41)231 obtained from Protein Data Bank
(PDB) was subjected to several preparation steps on the Protein Preparation Wizard in Maestro
before used as protein model for docking: removal of surface water molecules, assignment of bond
orders, and addition of missing hydrogen atoms. Next, the orientation of amide (Asn and Gln),
hydroxyl (Ser, Thr, and Tyr), and thiol groups (Cys) and the protonation and tautomeric state of
His residues on the protein model were also optimized. In the final preparation step, restrained
minimization of the protein model was applied using 0.3 Å RMSD constraint and OPLS3e force
field. The Protein Preparation Wizard output then served as the starting protein geometry for
receptor grid generation.
3.2.11.2 Receptor grid generation
For the starting protein geometry, a ligand-enclosing box was centered on one of the
piperlongumine ligands so that the ligand to be docked (GSH-Lac) would be confined to the
enclosing box. The size of the enclosing box was set to be dependent on the piperlongumine
ligand.
3.2.11.3 Ligand docking
Docking calculations involved Glide Extra Precision (XP) with default sampling, preprocessing, and postprocessing. The preprocessing refers to the restrained minimization of the
model GSTP1-piperlongumine complex in the OPLS3e force field, which is part of the protein
preparation process. Postprocessing refers to post docking minimization of the GSTP1-GSH-Lac
complex. Glide was set to write the 5 best poses per ligand.

3.3 Results and Discussion
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3.3.1 Broad reactivity of MeLac delivering wide proteome coverage
The broad reactivity of MeLac was characterized at four levels of resolution according to
the resolving power of each specific analytical method and scope of data interpretation applicable
throughout the workflow of this study. These resolution levels were the gel-based proteome
resolution, MS-based protein resolution, MS-based peptide resolution, and MS-based amino acid
residue resolution. First, the fluorescent TAMRA tag provided a gel-based shortcut to reveal the
in-proteome reactivity of MeLac. Upon CuAAC conjugation to MeLac-alkyne probe-reacted
proteins, the TAMRA fluorophore enabled direct detection of those proteins after gel
electrophoresis. As a result, the fluorescence gel image of in vitro probe-treated cellular proteome
(Figure 3.2A) displayed multiple fluorescent protein bands throughout gel lanes. This gel image
suggested the successful labeling of various proteins by the MeLac-alkyne probe. The labeled
proteins had a wide range of molecular weight from 250 kDa to 10 kDa, implying a wide proteome
coverage of the MeLac-alkyne probe and broad reactivity of the MeLac warhead. Full lanes of
protein bands were observed for proteome samples treated by the MeLac-alkyne probe at a probe
concentration as low as 0.5 µM, indicating the in-cell applicability of the probe. The extent of
background probe-protein reactions, where the probe labeled surface residues instead of ligand binding/active site residues on proteins, was unclear. However, by comparing the rate of darkness
diminishing of individual protein bands over the decline of probe concentration, the probe did
potentially offer some selectivity towards certain proteins with molecular weight around 50 kDa.

3.3.2 Interpreting MS-based profiling data: probe-protein reactions
characterized at multiple levels of resolution
Over the gel-based analysis, MS-based proteomics profiling provides more details of
probe-protein reactions. In chemical proteomics, complex protein samples are preferentially
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analyzed as tryptic digests via the bottom-up approach by HR/AM mass spectrometers. As part of
the affinity capture methodology and sample processing workflow, biotin-avidin-based affinity
enrichment techniques are indispensable. These affinity enrichment techniques can significantly
improve the detectability of low-abundance analytes. In practice, the enrichment of analytes can
be performed either before the trypsin digestion of protein samples (at the protein level) or after
trypsin digestion of those samples (at the peptide level). If captured at the protein level, the
enriched analytes are mapped to a comprehensive picture of the whole target protein candidate
pool of the chemical probe. For each target candidate in the pool, multiple tryptic peptides are
measured both qualitatively and quantitatively. According to the sequence coverage and number
of detected unique peptides, indistinguishable proteins (usually isoforms or homologous proteins
within the same family) are aggregated as a single identification hit. Once defined by the
proteomics database search engine, these aggregated identification hits are usually treated as
indivisible protein groups for downstream qualitative and quantitative analyses. Therefore, the
identification of individual proteins is more straightforward and less proteins are grouped if the
sequence coverage is high and number of sequenced unique peptides is large for each protein. On
the flip side, the protein-level enrichment process almost always produces less-than-ideal
preparations adulterated with non-probe target background proteins. The double aggravated
sample complexity, by both tryptic peptides from background proteins and unmodified peptides
from probe-reacted proteins, usually fails the detection of probe-modified peptides. In contrast to
protein-level enrichment, the peptide-level enrichment process concentrates probe-modified
peptides further at the cost of sequence coverage and uniqueness enforcement of individual target
proteins.
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For this study, the MS-based characterization of protein reactions with the MeLac-alkyne
probe is defined at three levels of resolution according to the assignability of reaction sites on
specific proteins, residues, or peptides. Complete characterization of a protein reaction with a
covalent chemical probe ultimately requires localizing the probe modification on a specific amino
acid residue of a protein (residue resolution). Both the protein-level and peptide-level affinity
enrichment were performed on MeLac-alkyne treated samples. When the affinity enrichment was
performed at the protein level, few probe-modified peptides were detected. Consequently, the
assignment of probe-protein reactions could solely depend on the identification of reacted proteins
(protein resolution) in enriched samples. There are two reasons. Some probe-reacted proteins may
not produce probe-modified peptides that are suitable for bottom-up proteomics, the method-ofchoice for chemical proteomics. Not all precursor ions of suitable peptides are sampled for MS/MS
analysis in proteomics profiling. When the affinity enrichment was extended to the peptide level,
for a few target proteins, it remained challenging to localize their probe modification sites because
of several issues. A probe-modified peptide, in comparison to its native counterpart, does not
always produce adequate sequence ions during its gas-phase fragmentation within the mass
spectrometer. For each peptide precursor ion acquired for gas-phase fragmentation and MS/MS
scans, the whole set of these sequence ions is essential evidence to localizing the probe reaction
site at a specific residue. When the observable set of sequence ions is truncated as the probe
modification perturbs the gas-phase fragmentation behavior232 of probe-modified peptide, the site
localization can be ambiguous. In this case, it is plausible to only assign the probe reaction site to
the modified peptide (or its fragment) instead of a specific residue on the corresponding protein.
Consequently, the corresponding protein reaction is characterized at a moderately reduced
resolution of the peptide level.
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Depending on chemical properties of the chemical probe and affinity enrichment method
of choice in various chemical proteomics studies, not all probe-protein reactions can be
characterized based on probe-modified peptides. In some cases, probe-protein reactions can only
be characterized at a heavily reduced resolution of the protein level. For instance, when a labile
covalent probe is used in compound-centric chemical proteomics, target proteins are universally
characterized at the resolution of the protein level. With decreasing resolution from the residue to
protein level, tightened constraints must be set to determine confidence in reporting reactivity of
the probe, which demands new analytical methods to evaluate confidence in the identification of
the probe-reacted proteins.

3.3.3 Affinity tagging triplication differentiating target candidates at the
protein level
To confront the analytical challenge in identifying and reporting probe-reacted proteins at
the protein-level resolution, a novel method named affinity tagging triplication was developed to
differentiate MeLac-alkyne probe-reacted proteins with discrete analytical confidence, even
without detection of any probe-modified peptide. In each of three separate preparations (step 3,
Scheme 3.4), a different (desthio)biotin tag was used for avidin-based affinity enrichment of
probe-reacted proteins from one lysate sample of MeLac-alkyne probe-treated HT-29 cells. The
rationale was that the tagged proteins underwent different releasing conditions to recover MeLacalkyne probe-reacted proteins. Consequently, the resulting sample matrices and background
proteins in the preparations obtained would be significantly different. When a protein was
identified in more than one enrichment preparation, the confidence of it being a true MeLac-alkyne
probe-reacted protein was increased. Specifically, the MeLac-alkyne probe-reacted proteins were
tagged, using CuAAC click chemistry, with desthiobiotin azide (Des, Scheme 3.5), Dde biotin
143

picolyl azide (Dde, Scheme 3.6) azide or diazo biotin azide (Dia, Scheme 3.7). Tagged proteins
were captured by NeutrAvidin-agarose resins and then released using different elution conditions
for preparing trypsin digests.
Subsequently, a unique three-tier system was set based on the number of reproduced
identifications of a particular protein in the differentially tagged preparations f rom a common
lysate sample. The lysate was prepared from HT-29 cells upon in-live-cell reactions with MeLacalkyne. In total, a protein target candidate pool of 1,505 canonical proteins (distinguished by gene
names)—related to 2,074 protein groups (distinguished by aggregated UniProt accession
numbers)—was identified by proteomics profiling and MaxQuant 225 database search (Table ia, ib,
and ic, Appendix) at a threshold of 1% maximal peptide/protein FDR and two minimal unique
peptides. The identified proteins were categorized in Tier I, II, or III (Figure 3.2B and 3.2C) with
decreasing confidence in being true probe-reacted proteins, accordingly. Proteins in Tier I were
identified in all the three tagged samples; Tier II in two; Tier III for only one. Analogous to the
minimum requirement of two unique peptides for identifying a precursor protein within a
proteome, Tier I and II proteins are reported as confident identifications; Tier III proteins need
further investigation. Notably, the three-tier categorization of identified proteins was performed
with either gene names or protein groups of aggregated UniProt accession numbers. When
categorized with gene names which did not annotate protein isoforms (Figure 3.2B), 17.5%
proteins (264 out of 1,505) were identified as Tier I proteins, 25.1% proteins (378 out of 1,505)
were identified as Tier II proteins, and 57.3% proteins (863 out of 1,505) were identified as Tier
III proteins. When categorized with UniProt protein accession numbers, which annotated protein
isoforms (Figure 3.2C), isoform-specific proteins in each protein group were compared across
confidence tiers using maxabpp. In contrast to the convention where protein IDs are treated as a
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series of characters and compared for exact matches, the maxabpp matching algorithm treats
aggregated protein IDs as a group of individual entries. When comparing two protein groups, if
maxabpp detects the existence of one or more shared individual protein(s), it will mark these two
protein groups as related. Consequently, if unequal numbers of aggregated protein isoforms are
identified in all three differentially tagged samples of unique sample matrices, these related protein
isoforms will be categorized as Tier I proteins. With the implementation of this matching
algorithm, higher numbers of intersecting proteins were observed as identified isoforms and
homologous sequences. 34.3% proteins (711 out of 2,074) were identified as Tier I proteins, 31.5%
proteins (653 out of 2,074) were identified as Tier II proteins, and 34.2% proteins (710 out of
2,074) were identified as Tier III proteins (Figure 3.2C and Table ii, Appendix). Overall,
proteomics profiling of enriched MeLac-alkyne probe-reacted proteins supported the broad
reactivity of the MeLac warhead with proteins in the proteome, as observed in gel-based ABPP
(Figure 3.2A), but offered limited information for understanding protein reactions with MeLac.

3.3.4 Reactivity investigation to deepen at peptide the level
Proteomics profiling of enriched MeLac-alkyne probe-modified peptides confirmed the
broad reactivity of MeLac. A total of 751 MeLac-alkyne probe-modified peptides with 1,430
modification sites were identified by MaxQuant 225 , resulting in the identification of 562 canonical
proteins (Figure 3.2D and 3.2E; Table iii, Appendix). The Andromeda233 peptide-spectrum
match (PSM) scoring algorithm of MaxQuant was set to filter PSM hits with a minimum score
cutoff of 40 and 1% false discovery rate threshold for both peptide and protein identification.
Consequently, for most peptides, alternative PSM assignments with lower scores were discarded.
Among all 1,430 MeLac modification sites, a fraction of sites had ambiguity in localization on
peptides; reactions could only be assigned to fragments of modified tryptic peptides.
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Approximately 1,000 peptides had localized modification sites. Moreover, MeLac-alkyne probemodified peptides originated from functionally diverse proteins, covering enzymatic reactions of
all seven general types; these proteins were modified at either catalytic or non-catalytic residues
(Figure 3.3, Figure 3.4, and Table 3.2). Interestingly, in comparison with 1,505 gene nameannotated canonical proteins identified in samples from protein-level enrichment experiments, a
significant number (292 out of 1,505) of proteins were identified only from samples of enriched
MeLac-alkyne probe-modified peptides. Apart from the existence of background peptides, this
observation implied that the detection of low-abundance peptides, upon probe modification,
required further concentration at the peptide level. The affinity pull-down of these peptides
successfully reduced sample complexity and achieved higher identification rate of probe-modified
peptides.
Identification of MeLac-alkyne probe-modified peptides had its own challenge in
confidence, differing from the confidence challenge for enriched samples of MeLac-alkyne probereacted proteins. The identification of the modified peptides depended only on a single amino acid
sequence. Higher-energy collisional dissociation (HCD) of peptide ions used in the mass
spectrometer of this work generated incomplete sequence ions, preventing de novo sequencing of
the peptides. Therefore, additional constraints should be imposed for verifying MS/MS spectra
and identifying MeLac-alkyne probe-modified peptides. These constraints were particularly
important because a relatively low PSM score of 40 was set for the database search and
identification of modified peptides. The verification of a spectral match would require the presence
of two signature ions from Des as the modification-specific fragment ions (labeled on spectra as
f 1 and f 2 , Figure 3.2F and Scheme 3.8). Specificity of these two fragment ions was high (Table
3.3), enabling verification of identified MeLac-alkyne probe-modified peptides because Des was
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introduced to the modified peptide as a xenobiotic moiety via CuAAC attachment of the Des tag
for enriching modified peptides. However, not all identified spectra of probe-modified peptides
had a lower mass cutoff to detect the signature ions, due to the dynamic mass range setup during
MS analysis (white vs. red areas in Figure 3.2E). The gene name-annotated canonical proteins
identified based on probe-modified peptides (red slides in Figure 3.2D) were compared to the
identified ones from protein-level enrichment samples (Figure 3.2B). A decreasing trend on the
percentage of identifiable probe-reacted proteins from Tier I to III (30.6% to 21.4% to 12.5%,
respectively) supported the effectiveness of the affinity tagging triplication strategy for identifying
true MeLac targets. Although the Tier III proteins should be treated with lower confidence,
observing probe-modified peptides provided a means to separate the protein targets from the
remaining pool of proteins, which had the largest fraction of background proteins. Proteomics
profiling of enriched peptide samples also identified significant numbers of proteins in each tier
(orange slides, Figure 3.2D) based on peptides, which did not carry MeLac modifications in the
samples; 36.4% for Tier I, 21.2% for Tier II and 18.4% for Tier III, respectively. The decreasing
percentages were consistent with the declining confidence levels of Tier I, II, and III proteins being
true MeLac targets. Overlapping sequences between probe-modified and non-probe-carrying
peptides indicated a possible loss of the MeLac modification during sample preparation. For
instance, acyl addition by nucleophilic thiol produces labile thioesters. 220 Non-specific peptides
carried through the peptide enrichment preparation could also contribute to the observed nonprobe-carrying peptides. However, the fact that more than one third (inner orange slide, Figure
3.2D) of the Tier I proteins were also identifiable based on the non-probe-carrying peptides
suggested that the non-specific peptides could be a minor concern.
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MS/MS spectra of MeLac-alkyne probe-modified peptides provided direct and detailed
information for characterizing probe-protein reactions. MS/MS spectra with unambiguously
localized sites for modification were used to explain the MeLac chemistry. Modification of
peptides by MeLac-alkyne was attributable to both Michael addition and acyl addition of MeLac
by Cys, Ser, Thr, Tyr, and Lys (Scheme 3.9 and Appendix). Despite being uncommon and
thermodynamically unfavorable based on computation results (Figure 3.5), Michael addition
modifications of Lys and Thr have been reported for proteins.234,235 Possible nucleophilic
substitutions of the lactone ring of MeLac (mechanism 2b on Scheme 3.2), whose reaction
products would have degenerate masses as those from acyl addition, were not considered in this
work. Upon chemical modification by MeLac-alkyne and downstream CuAAC tagging with Des,
the modified peptides had three distinct mass shift values. A global view of MeLac modifications
on peptides was apparent on a DeltaMass plot based on unrestricted MSFragger search226 (Figure
3.6A). Upon CuAAC attachment of the Des tag, the modification of a residue by MeLac-alkyne
led to a total mass shift of 550.3115 Da (Des MeLac, top of Figure 3.6B). Depending on the
reaction site on MeLac, further modifications by Des MeLac on reacted peptides occurred during
sample preparation: hydrolysis of the lactone ring causing an additional increase of 18.0106 Da
(568.3221 Da in total, bottom of Figure 3.6B) and quenching of the Michael receptor with 2mercaptoethanol adding a further increase of 78.0139 Da (628.3254 Da in total) as in Figure 3.6C.
Modified peptides with a mass increase of 550.3115 Da were attributed to the products of Michael
addition (Scheme 3.9), but not acyl addition; an excessive amount of 2-mercaptoethanol was used
for quenching the Michael acceptor and the thioester bond formed via acyl addition of the β-lactone
ring is labile.220 Indeed, few modified peptides could be assigned as quenched adducts from the
acyl addition of Des MeLac by Cys.
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3.3.5 Advantages of MeLac-alkyne in probing reactive cysteine
Cys residues had the largest number of MeLac modification sites (Figure 3.2E). The
cysteinome provides many important targets for covalent drugs. 119 The majority of MeLac-alkyne
probe-modified peptides carried a localized site of Cys modification. This observation was not a
surprising fact considering the large numbers of reactive cysteines under physiological conditions.
The profiling results of MeLac-alkyne were compared with those of iodoacetamide (IA)-alkyne, a
routinely used broad-spectrum cysteine-reactive probe in chemical proteomics. Localized IA
reaction sites on 6143 cysteinyl peptides had been reported, among which 758 sites were
ligandable.77 Although sharing 128 ligandable peptides with the IA-alkyne pool, 224 out of the
653 peptides with probe modification, either catalytic or non-catalytic cysteines, were unique to
MeLac (Figure 3.7). It is important to note that besides the chemical difference between MeLac
and IA, MDA-MB-231 and Ramos cells were used in the IA study. Although known as highly
cytotoxic and incompatible with live cells, the IA-alkyne probe was used at a concentration of 100
µM to treat live cells.77 In comparison, HT-29 cells were treated with MeLac-alkyne at
concentrations up to 50 µM for gel-based analysis and 20 µM for MS-based analysis in this work.
A significant advantage of MeLac over IA probes comes from differences in cytotoxicity.
IA has high cytotoxicity,236 limiting the application of IA probes mainly to lysates. 237 In contrast,
MeLac compounds were used with live cells at concentrations up to 100 µM for MeLac-alkyne
and 300 µM for alkyl MeLac inhibitor in this work. Cells remained adhered to culture flask surface
under these concentrations for incubation times up to 1 hour. Two important analytical advantages
from the live-cell application of a measurement probe are (1) decreased background reactions and
(2) enabled analysis of proteases whose activity must be blocked during cell lysis. Additionally,
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MeLac-based competitive ABPP for analyzing the action of non-covalent inhibitors in live cells is
a unique potential.

3.3.6 Establishing a versatile competitive ABPP platform using MeLacalkyne probe and peptide-centric quantitation approach
This study then proceeded to test the major designed utility of MeLac probes in competitive
ABPP platforms for analyzing proteome-wide reactions of reactive molecules. Three inhibitors:
orlistat, parthenolide, and alkyl MeLac inhibitor, were analyzed the competitive ABPP platform
using the MeLac-alkyne probe. The orlistat and parthenolide were selected as model covalent
inhibitors, while the alkyl MeLac was introduced as a MeLac parent compound or putative MeLacbased inhibitor for studying the chemoselectivity of the MeLac warhead.
Orlistat is a β-lactone compound capable of forming covalent adducts with nucleophilic
hydroxyl and thiol groups on proteins. It is an FDA-approved drug that targets lipases for weight
management. Extensive chemical proteomics analysis has revealed many off-target proteins,73,220,
which are linked to anti-tumor activities238 and organ toxicity239 for this over-the-counter drug.
Most of the covalent orlistat-protein adducts are formed via a labile thioester bond. 220 Confident
identification of off-target proteins of orlistat, especially orlistat-modified peptide, is extremely
challenging due to the fact that the thioester or ester bond is not stable during sample preparation
for proteomics analysis. This is a common problem for β-lactone based probes. Live-cell
competitive ABPP using MeLac-alkyne as the measurement probe provides a valuable solution to
this analytical challenge.
Parthenolide is an α-methylene-γ-lactone natural product with anti-inflammation and antitumor activity.240-243 Parthenolide has a Michael acceptor subject to nucleophilic addition as well;
both exist in the MeLac warhead. Unlike β-lactone, which is prone to nucleophilic attacks and
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ring-opening reactions, γ-lactone is significantly more stable and inert.244 Although a systematic
chemistry study comparing the reactivity of the Michael acceptor and γ-lactone of parthenolide is
unavailable, the existing cysteine-dominant parthenolide reactivity profile240 suggests that
parthenolide would only react with protein nucleophiles as a Michael acceptor for nucleophilic
addition reactions.
Proteome-wide inhibitor selectivity and protein dose responses were first explored with
gel-based competitive ABPP at various inhibitor concentrations over a wide concentration
window. Subsequently, two reasonable concentrations were selected based on the gel-based ABPP
results (Figure 3.8) for MS-based quantitative experiments for each inhibitor. Orlistat,
parthenolide (1 vs. 10 µM), or alkyl MeLac (10 vs. 100 µM) treatment, live HT-29 cells were
incubated with MeLac-alkyne at 20 µM. The probe-modified peptides were then enriched for MSbased profiling. In total, 395 probe-modified peptides from 316 proteins were quantified for
samples from the orlistat competition experiment (Figure 3.9A); 320 probe-modified peptides
from 276 proteins were quantified for parthenolide (Figure 3.9B); 44 probe-modified peptides
from 41 proteins were quantified for alkyl MeLac (Figure 3.9C). Pairwise quantitative comparison
of enriched probe-modified peptide samples from cells pre-treated with either orlistat, parthenolide
at 10 μM vs. 1 μM, or alkyl MeLac at 100 μM vs. 10 μM was performed using a method of labelfree quantitation (LFQ). For each quantified probe-modified peptide, the relative amount was
determined as the mean of normalized areas of MS1 chromatographic peaks of precursor ions for
the peptide in six replicates (two biological replicates with three analytical replicates each). The
normalization was performed against the total ion intensity of all quantified ions of probe-modified
peptides to correct run-to-run variations. In addition, if a longer miscleaved sequence was observed
for a particular tryptic peptide with the probe modification, the peak area for this peptide was
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calculated as the sum of the miscleaved and fully cleaved. Volcano plots of Log 10 p-value vs. Log2
FC were based on quantified probe-modified peptides (Figure 3.9). An FC cutoff threshed was
not set for selecting protein targets of orlistat, parthenolide, or alkyl MeLac due to two reasons.
The quantitative comparison was only performed within a tentative dose window, 10 μM vs. 1
μM, or 100 μM vs. 10 μM, which could be at any location on a dose-response curve for the
inhibitory potency of the two inhibitor molecules. LFQ is less precise than isotope-labeling based
quantitation by design. At the 5% statistical level of significance (p-value ≤ 0.05), 40
peptides/proteins responded to the increased orlistat concentration, and 16 peptides/proteins
responded to the increased parthenolide concentration. Intriguingly, the parthenolide target
candidate pool highlighted six previously reported protein targets, DCTN4, RPL4, RPL14, RPL18,
RPS2, and PRKDC, (high-lighted in red, Figure 3.9B) from a label-based competitive ABPP
experiment using a different human cell line and IA-alkyne probe.240 Remarkably, the DNAdependent protein kinase catalytic subunit (PRKDC) was reported as one of three major kinase
targets showing high dose response (with a log 2 FC value of -5) to parthenolide.
In contrast to orlistat and parthenolide, the alkyl MeLac competition experiment had the
smallest number of quantified proteins. This could be explained with: (1) Cells were treated with
alkyl MeLac at concentrations 10-fold higher than the other two inhibitors, resulting in a less
informative dose window capturing the region of dose saturation on the dose response curve; (2)
alkyl MeLac shared the same reactivity with MeLac-alkyne, thus completely labeled and occupied
all possible sites on protein targets of MeLac-alkyne at a higher concentration, resulting in
detection of few MeLac-alkyne probe-modified peptides. In addition, probe-modified peptides
were not detected for a group of proteins at the higher inhibitor concentration, particularly for alkyl
MeLac, where 15 out of 16 statistically significant proteins were not detected at 100 μM. These
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proteins formed an off-chart list of protein targets of the inhibitor used in the competition
experiment. It was highly likely that these proteins were the best targets for the corresponding
inhibitor. However, this statement would require further experimental verification considering the
stochastic sampling of peptide ions during MS analysis. Notably, the selectivity profiles for
orlistat, parthenolide, and alkyl MeLac differed significantly, exemplifying that the broadly
reactive MeLac-alkyne probe assembles a versatile peptide-centric platform of competitive ABPP
capable of analyzing reactive molecules with different chemical properties. The capability of
MeLac reacting with multiple nucleophilic residues and measuring enzymes of all classes (colored
dots in Figure 3.9) endorsed its foreseeable versatility.

3.3.7 MeLac warhead recruiting glutathione in live cells to assemble a
selective β-lactone probe
Intriguingly, multiple electrophilic sites on the MeLac scaffold made it possible for MeLacalkyne to conjugate a reactive affinity ligand on one site and use another site to react with protein
nucleophiles. Considering the diversity of intracellular reactive metabolites, the unrestricted
database search was initially used to screen for unknown protein modifications. Surprisingly, the
MeLac-alkyne probe recruited endogenous glutathione to form a β-lactone probe that had much
increased selectivity as the DeltaMass plot highlighted an unexpected modification with an
unusual mass shift of 857 Da (Figure 3.10A). The high mass region of the DeltaMass plot also
showed several other mass shifts with noticeable peptide spectra matching densities. The mass
shift of 857 Da, being the most significant one, was attributed to the direct addition of GSH
presumably at the Michael acceptor on MeLac to form a new β-lactone probe, namely GSH-Lac
in live cells (Scheme 3.10). A dedicated MaxQuant search (with 857 Da as the input modification
parameter) identified 70 GSH-Lac-modified peptides, 22 of which were also previously identified
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as MeLac-alkyne probe-modified peptides (Figure 3.11; Table iv and v, Appendix). The search
results also revealed a modification site preference shift. As shown in Figure 3.12, compared to
MeLac-alkyne that modified proteins mostly on cysteine (more than 50% of modifications sites
were cysteine), GSH-Lac modified proteins mostly on non-cysteine residues (less than 20% of
modifications sites were cysteine). This discovery confirmed the proposed reaction routes of
MeLac with amino acids, as MeLac and GSH-Lac differed significantly in the reaction route
preference (the Michael addition reaction path for thiol with MeLac vs. acyl addition reaction path
for amino and hydroxyl groups with GSH-Lac).
Modified peptides observed for glutathione S-transferase P1 (UniProt ID P09211, GSTP1)
provided evidence for processes of in-cell assembly of GSH-Lac as well as its reactions with
proteins (Figure 3.10; Scheme 3.10). Peptide YISLIYTNYEAGK together with its miscleaved
counterpart YISLIYTNYEAGKDDYVK was observed with both MeLac-alkyne and GSH-Lac
modifications at Y108; a natural variant 245 with 104I → V was also identified to carry the same
modifications. Because the GSH-Lac modification initially appeared to be a mass shift of 843 Da
on the 104I → V variant peptide from the unrestricted database search using only the canonical
proteome sequence database (Figure 3.10A). The peptide ASCLYGQLPK, located in a narrow
cavity (green, Figure 3.10B), was modified at C47 only by MeLac-alkyne. The N-terminal tryptic
peptide PPYTVVYFPVR was only modified at Y7 by GSH-Lac. Y7 (red, Figure 3.10B) and Y108
(blue, Figure 3.10B) are located in a wide-open cavity. During the GSTP1 detoxification activity
of xenobiotics, Y108 and Y7 are involved as electrophilic participants in the addition of GSH to
exogenous molecules.246 This catalytic mechanism is related to multidrug resistance in cancer
therapy.247 Anticancer prodrugs, which are activated by Y7, have thus targeted GSTP1. 248,249

154

Therefore, a selective probe targeting GSTP1 has a direct impact in developing drugs regulating
the protein activity.
The formation of observed GSTP1 adducts with MeLac-alkyne and GSH-Lac could be
explained by different routes, as shown on Scheme 3.11. The first route initiated from MeLacalkyne reacting with GSH-bound GSTP1 to form the MeLac-alkyne GSTP adduct at Y108 (and
C47) through steps A and B; additional probe modifications on nearby residues were also observed
(Figure 3.12). Further attachment of GSH to the Y108 adduct formed the same product as the
directed reaction product with GSH-Lac (step D and E, Scheme 3.11). Consequently, the Y108
peptides were detected with both MeLac-alkyne and GSH-Lac modifications. The formation of
GSH-Lac or in-live-cell installation of GSH to MeLac-alkyne was likely to be catalyzed by
GSTP1. When GSH-Lac reacted locally with GSTP1, both Y108 and Y7 were modified (steps E
and F, Scheme 3.11). It was also plausible that newly formed GSH-Lac could diffuse away from
GSTP1 and react with other intracellular proteins (step G and H, Scheme 3.11), resulting in the
detection of 48 modified peptides unique to GSH-Lac. In contrast to the reactions between MeLacalkyne and its protein targets corresponding to the identified 640 unique peptides, the reaction
between GSH-Lac and its protein targets had substantial selectivity, which was indicated by it
smaller target pool of proteins corresponding to only 48 unique modified peptides. (Figure 3.11;
also see Table v on Appendix for more details of these peptides)
GSH-Lac, not MeLac-alkyne modified Y7. The accessibility of Y7 and Y108 to the βlactone C2 (acyl) carbon on GSH-Lac was evaluated via computational protein-ligand docking
using Schrödinger Suite. Up to five energetically favorable protein-ligand interacting models were
calculated for all four possible β-lactone stereoisomers of GSH-Lac. The GSH-Lac docked protein
models showed stereoisomer (3S,4S) and (3S,4R) stereoisomers of GSH-Lac had relatively lower
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docking energy (Glide energy) and closer distances to the oxygen atoms of both Y7 and Y108
compared to the other two stereoisomers. These docking results implied possible stereoselectivity
on GSH-Lac by the GSTP1 catalytic cavity featuring Y7 and Y108 (Figure 3.14). Comparing
(3S,4S) and (3S,4R), the latter was docked with the shortest distances to both Y7 and Y108 (red
projection dots highlighted in the green ellipse, Figure 3.14A), while the former had slightly
longer distances to Y108 (blue projection dots highlighted in the yellow ellipse, Figure 3.14A)
but the lowest Glide energy. This observation suggested Y7 favored the reaction with (3S,4S), but
Y108 was closed to (3S,4R). Nevertheless, validation of the GSTP1 stereoselectivity on GSH-Lac
would require future dedicated experiments using stereo-purified synthetic GSH-Lac.
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3.4 Conclusion
MeLac is a novel chemical probe warhead that couples a Michael acceptor with a β-lactone
moiety. This small, rigid warhead’s broad reactivity allows it to react with different protein
nucleophiles through distinct mechanisms. Multiple reactive sites on MeLac extend the scope of
these reactions and provide a potential means of conjugating recognizing moieties for ligand directed chemistry250 in live cells. With its broad reactivity, the MeLac warhead also offers a
unique possibility to convert non-covalent inhibitors to measurement probes targeting different
enzymes,251 as well as to broaden druggable targets by identifying new binding sites. 77,78 MeLac
probes, being useful for live-cell applications, potentially have an immense impact on drug
discovery and further expand the analysis of the reactions with proteins that can deactivate during
cell lysis. MeLac-based competitive ABPP platforms are highly adaptable and are appropriate for
measuring the live-cell action of a wide array of small reactive molecules.
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3.5 Chapter 3 Figures
Figure 3.1 HT-29 cells under microscope.

Note: (A) Seeds and (B) Target confluency (90 to 95%).
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Figure 3.2 Multi-level characterization of protein reactions with α-methyleneβ-lactone (MeLac) alkyne probe.
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Note: (A) Gel-based activity-based protein profiling showing broad reactivity of the MeLac-alkyne probe.
(B) Triplicated selective enrichment (Affinity Tagging Triplication) of probe-reacted proteins resulting in
discrete identification confidence (Tier I > Tier II > Tier III) of probe-reacted proteins annotated with gene
names. (C) Three-tier identification confidence ranking of isoform-specific proteins annotated with UniProt
accession numbers. (D) Comparison of identification numbers of protein-level vs. peptide-level enrichment.
(E) MeLac modification sites on nucleophilic amino acid residues identified at a residue-level resolution
from peptide-level enrichment workflow. (F) Signature ion-based reduction of data complexity and
validation of identification of probe-modified peptide; insert comparing total ion chromatogram of peptide
fragment ions and extracted ion chromatograms for highly specific fragment ions of desthiobiotin-PEG3 (f1
and f2; structures of minimized geometry with the lowest total energy shown).
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Figure 3.3 Example protein models showing probe-modified catalytical
residues.

Note: The identified/sequenced probe-modified peptides are highlighted in orange. The probe-modified
residues are highlighted in red. (A) Aldehyde dehydrogenase, mitochondrial (ALDH2, PDB ID: 1o04).252
(B) Methylated-DNA-protein-cysteine methyltransferase (MGMT, PDB ID: 1eh6). 253 (C) Caspase-8
(CASP8, PDB ID: 1qtn). 254
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Figure 3.4 Example protein models showing probe-modified non-catalytic
residues.

Note: The identified/sequenced probe-modified peptides are highlighted in orange (or cyan). The probemodified residues are highlighted in red. The reported catalytical residues are highlighted in blue. (A)
Calpain-2 catalytic subunit (CAN2, PDB ID: 1kfu). 255 (B) Ribonuclease inhibitor (RINI, PDB ID: 1a4y).256
(C) Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCHL3, PDB ID: 6qml).
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Figure 3.5 Theoretical MeLac reaction paths with nucleophiles.
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Figure 3.6 Global and residue-specific illustration of MeLac modifications on
peptides.

Note: (A) A DeltaMass plot showing identified global modification of peptides with mass shifts
accountable to the conjugation with MeLac. (B) Representative MeLac modifications on peptides at Cys
residue. (C) Representative MeLac modification on peptides at Ser residue.
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Figure 3.7 Venn diagram comparison of MeLac vs. IA alkyne77 probemodified tryptic peptides.

MeLac-modified peptides

224

126

300

2

628

5086
1

IA-modified peptides (ligandable)

IA-modified peptides (non-ligandable)

165

Figure 3.8 Competitive activity-based protein profiling displaying broad
reactivity of the alkyl MeLac inhibitor.

Note: HT-29 Cells were first incubated with the alkyl MeLac inhibitor or orlistat at the corresponding
concentration for 30 minutes. Cells were then incubated for 30 minutes with the MeLac-alkyne probe at 5
µM for 1 hour. Cells were washed and lysed. The subsequent lysate underwent CuAAC with TAMRA
biotin azide as the fluorescent reporting tag or Des as the affinity tag. (See Experimental 3.2.5 for detailed
procedure) Approximately 100 µg of total protein was loaded to each well without affinity enrichment. Gel
images were acquired to show fluorescent protein bands (probe-reacted proteins) and Coomassie Bluestained protein bands (all proteins).
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Figure 3.9 MeLac-alkyne quantitively probing protein selectivity/reactivity
profiles of chemically distinct molecules.
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Note: The volcano plots show that (A) orlistat, (B) parthenolide, and (C) alkyl MeLac selectively reacted
with different proteins. These reactions were detectable by changing the inhibitor concentrations, 10 vs. 1
µM for orlistat and parthenolide, 100 vs. 10 µM for alkyl MeLac, using the MeLac-alkyne as the
measurement probe. Inert tables showing proteins of quantified probe-modified peptides at the lower
inhibitor concentration with p-value ≤ 0.05, but not detected at the higher inhibitor concentration (zero
intensity for all samples at the higher inhibitor concentration).
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Figure 3.10 Identification of GSH-Lac adducts.

Note: (A) The DeltaMass plot showing identified global modification of peptides with mass shifts
accountable to the conjugation with GSH-Lac. (B) GSH-bound GSTP1 dimmer (PDB ID: 5j41)231 with
three reactive residues labeled: Y7 in red, Y108 in blue, and C47 in green. MS/MS spectra for a GSTP1
peptide with modifications of MeLac-alkyne uniquely at C47 (C), GSH-Lac uniquely at Y7(D), and
peptides with modifications of both MeLac-alkyne and GSH-Lac detected at Y108 (E and F). Spectra for
peptides of a mutant GSTP1 isoform carrying modifications of both MeLac-alkyne and GSH-Lac detected
at Y108 (G and H).
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Figure 3.11 Selectivity comparison of GSH-Lac vs. MeLac-alkyne at the
peptide level.
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Figure 3.12 Summary of probe modification sites.
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Figure 3.13 Additional MS/MS spectra observed different MeLac
modification sites on peptide YISLIYTNYEAGKDDYVK of glutathione Stransferase P.

B

C

E

F

Note: sw = Des MeLac warhead modification (+ 550.3115 Da), sh = Des MeLac hydrolyzed modification
(+ 568.3221 Da).
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Figure 3.14 MeLac-alkyne recruiting endogenous glutathione to assemble a
selective β-lactone probe.

Note: (A) Selectivity comparison, ID numbers of probe-modified peptides, GSH-Lac vs. MeLac-alkyne
(B) Minimized docking pose of GSH-Lac probe in GSTP1 for selective reaction with Y108 with possible
general acid catalysis by Y7. (C) Docking energy comparison indicating differentiation of GSH-Lac
stereoisomers by the reaction site of GSTP1.
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3.6 Chapter 3 Schemes
Scheme 3.1 Illustration of the “3-R” anatomy of an activity-based probe and
general design an activity-based protein profiling experiment.
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Scheme 3.2 Proposed reactivity of MeLac towards different protein
nucleophiles via distinct mechanisms.
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Scheme 3.3 Structures of MeLac-alkyne probe, alkyl MeLac inhibitor,
orlistat, and parthenolide.
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Scheme 3.4 Overview of the experimental workflow featuring affinity tagging
triplication and dual-level enrichment
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Scheme 3.5 Desthiobiotin azide tagging.
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Scheme 3.6 Dde biotin picolyl azide tagging.
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Scheme 3.7 Diazo biotin azide tagging.
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Scheme 3.8 Signature ions of Desthiobiotin-PEG3.
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Scheme 3.9 Observed MeLac modifications by mass spectrometry.
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Scheme 3.10 Observed GSH-Lac modifications by mass spectrometry.
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Scheme 3.11 Proposed MeLac and GSH-Lac reaction routes with GSTP1.
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3.7 Chapter 3 Tables
Table 3.1 Seeding density and confluency for various cell culture vessels.
Vessels

Dishes
35mm
60mm
100mm
150mm
Well
plates
6-well
12-well
24-well
48-well
96-well
Flasks
T-25
T-75
T-175
T-225

Surface
area
(cm 2)

Seeding
density
(number
of cells in
millions)

Cells at
confluency
(in millions)

8.8
21.5
56.7
145

0.3
0.8
2.2
5.0

9.6
3.5
1.9
1.1
0.32
25
75
175
225

Trypsin
(mL of 0.05% trypsin, 0.53 mM EDTA).
Approx. volume

Growth
medium
(mL). Approx.
volume

1.2
3.2
8.8
20.0

1
3
5
10

2
5
12
30

0.3
0.1
0.05
0.03
0.01

1.2
0.5
0.24
0.12
0.04

1
0.4 to 1
0.2 to 0.3
0.1 to 0.2
0.05 to 0.1

1 to 3
1 to 2
0.5 to 1.0
0.2 to 0.4
0.1 to 0.2

0.7
2.1
4.9
6.3

2.8
8.4
23.3
30

3
5
17
22

3–5
8–15
35–53
45–68

Note: Table adapted from Ryan, John A. (2005). Growing more cells: A simple guide to small volume
cell culture scale-up (Application Note No. CLS-AN-064). Retrieved from Corning Inc. website:
https://www.corning.com/catalog/cls/documents/application-notes/CLS-AN-064.pdf
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Table 3.2 Probe-reacted proteins with reported active sites according to MCSA.
|Unipr
ot
ID|Gen
e
name

Protein
name

PD
B
mo
del

Known
catalytical
residues*
(roles)

Known
catalytical
residues*
(role type)

MaxQu
ant
PSM
score
52.247
48.513

|P05091|
ALDH2_
HUMAN

Aldehyde
dehydroge
nase,
mitochond
rial

1o04

Lys192
(electrostatic
stabilizer) and
Cys302
(covalent
catalysis,
proton shuttle)

Lys192
(spectator)
and Cys302
(reactant)

114.58

114.58

89.793
61.703
|P13489|
RINI_HU
MAN

Ribonucle
ase
inhibitor

1a4y

Lys40
(electrostatic
stabilizer)

Lys40
(spectator)

72.876
47.392
111.13

176.69

|P15374|
UCHL3_
HUMAN

Ubiquitin
carboxylterminal
hydrolase
isozyme
L3

56.54
1uch

Cys95
(covalent
catalysis,
proton shuttle)

Cys95
(reactant)

165.3

100.97
176.69
84.249

|P16455|
MGMT_
HUMAN

|P17655|
CAN2_H
UMAN

Methylate
d-DNA-proteincysteine
methyltran
sferase
Calpain-2
catalytic
subunit

1eh6

1kfu

Tyr114
(hydrogen
bond donor,
proton donor)
and Cys145
(nucleophile,
proton donor)
Cys105
(covalently
attached,
proton shuttle,
electrostatic
stabilizer)

Tyr114
(interaction,
reactant) and
Cys145
(interaction,
reactant)
Cys105
(interaction,
reactant,
spectator)

60.49

Modifica
tion
mass
(Da)

Modi
fied
resid
ue

LLC(1)GGGIAADR

550.3115 +
18.0106

Cys

LLC(1)GGGIAADR

550.3115

Cys

550.3115

Cys

550.3115

Cys

550.3115

Cys

550.3115 +
18.0106

Cys

550.3115

Cys

550.3115 +
18.0106

Cys

550.3115

Cys

550.3115 +
18.0106

Thr

550.3115

Thr

550.3115 +
18.0106

Thr

550.3115

Thr

550.3115 +
18.0106

Ser

550.3115

Ser

550.3115 +
18.0106

Cys

Modification
localization
(Probabilities)

SPNIIMSDADMDW
AVEQAHFALFFNQ
GQC(0.085)C(0.45
4)C(0.461)AGSR
SPNIIMSDADMDW
AVEQAHFALFFNQ
GQC(0.106)C(0.26
5)C(0.629)AGSR
SPNIIMSDADMDW
AVEQAHFALFFNQ
GQC(0.419)C(0.41
9)C(0.161)AGSR
ELDLSNNC(1)LGD
AGILQLVESVR
ELDLSNNC(1)LGD
AGILQLVESVR
SNELGDVGVHC(1
)VLQGLQTPSCK
SNELGDVGVHC(1
)VLQGLQTPSCK
VT(0.153)HET(0.84
7)SAHEGQTEAPSI
DEK
VT(0.475)HET(0.52
4)SAHEGQT(0.001
)EAPSIDEK
VT(0.911)HET(0.08
9)SAHEGQTEAPSI
DEK
VT(0.979)HET(0.02
1)SAHEGQTEAPSI
DEK
VTHETS(1)AHEG
QTEAPSIDEK
VTHETS(1)AHEG
QTEAPSIDEK
GNPVPILIPC(1)HR

65.842

GNPVPILIPC(1)HR

550.3115

Cys

51.495

VVC(1)SSGAVGN
YSGGLAVK

550.3115

Cys

550.3115 +
18.0106

Cys

550.3115

Cys

69.594
85.77

WNDNC(1)PSWNT
IDPEER
WNDNC(1)PSWNT
IDPEER
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|Q05086|
UBE3A_
HUMAN

Ubiquitinprotein
ligase E3A

|Q14790|
CASP8_
HUMAN

Caspase8

|Q93009|
UBP7_H
UMAN

Ubiquitin
carboxylterminal
hydrolase
7

1c4z

Cys86
(nucleofuge)
and Cys 820
(covalent
catalysis)

1qtn

Cys360
(covalently
attached)

1nbf

Cys223
(covalently
attached,
electrostatic
stabiliser)

GAPNNSC(1)SEIK
Cys86
(reactant) and
Cys 820
(reactant)

69.01

550.3115 +
18.0106

Cys

550.3115

Cys

550.3115 +
18.0106

Cys

VFFIQAC(1)QGDN
YQK
Cys360
(intereaction)

51.875

GTC(1)VEGTIPK
Cys223
(interaction,
spectator)

51.092

Note: *Catalytical residue information was obtained from Mechanism and Catalytic Site Atlas (M-CSA)257
data repository. According to M-CSA, a total of 667 human proteins were reported to have catalytical
residues with their side chains involved. As shown above, among these 667 proteins, 8 proteins were
identified as MeLac-modified ones. Among these 8 proteins, 3 proteins had MeLac modification on
reported catalytical residue side chains (highlighted in red).
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Table 3.3 Specificity of Des signature ions.
f1
Molecular formula

Monoisotopic mass

Unsaturation

Error (ppm)

C10H 17N2O2+

197.1284542

3.5

-0.2323

C8H 15N5O+

197.1271115

4

-7.0434

f2
Molecular formula

Monoisotopic mass

Unsaturation

Error (ppm)

C12H 22N3O2+

240.1706534

3.5

-0.1941

C14H24O3+

240.1719961

3

5.3964

C17H22N +

240.1746761

7.5

16.5552

Note:
Element composition range: C0-30, H0-60, N0-5, O0-10, S0-5.
Error range (ppm): 20.
Formula calculation used software from
http://www.cheminfo.org/Spectra/Mass/MF_from_monoisotopic_mass_and_PubChem/index.html.
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Table 3.4 Geometry optimization results of Des signature ions.
Ion

2D structure

Minimized geometry

Total energy
(B3LYP, Hartree)

Des1-1

-651.170362939

Des1-2
(f 1)

-651.174790289

Des1-3

-651.172576173

Des2-1

-785.206684442

Des2-2
(f 2)

-785.237450827

Note: The geometry minimization of Des signature ions was performed using Gaussian 09 (Revision D.01)
at b3lyp/6-311+g(d,p) level of theory. Input ion structures were built with GaussView 5.0.9. The minimized
structures (f1 and f 2) were consistent with the previously reported fragments.228
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Chapter 4 maxabpp as an R Package for Augmented
Visualization of Peptide-centric Competitive Activity-based
Protein Profiling Data from MaxQuant
4.1 Introduction
ABPP platforms are powerful chemoproteomics tools for analyzing proteome-wide
perturbation introduced to living systems by foreign small molecules. 74,75 ABPP platforms are used
routinely to measure the proteome-wide action of underivatized covalent drugs, environmental
toxins, and reactive metabolites from the human microbiota. 76-79 When conducted for analyzing
selectivity, target engagement, and off-target effects of a small molecule, an ABPP experiment
usually uses competition strategy for indirect measurements of small molecule pre-occupied
protein sites by comparing the probe modification difference of small molecule pre-treated sample
and the control. The mass spectrometry readout of these samples can be tandem mass spectra of
either probe-modified plus unmodified peptides from proteolysis of probe-labeled proteins or
probe-modified peptides only.
MaxQuant is the most appreciated free software suite for analyzing MS-based proteomics
profiling data163 . The MaxQuant suite offers an easy-to-use graphic user interface (GUI), a robust
peptide-spectrum matching and scoring algorithm named Andromeda, 135 and various userconfigurable search parameters for tunable sensitivity and accuracy. The output of a MaxQuant
run is a “txt” folder consisting of several tab-delimited tables, formatting the processed data
according to different aspects of downstream analysis. These tables are intended to be read by
MaxQuant and its sister software package Perseus258 for browsing, manual validation, processing,
and visualization of the database search output.
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In a conventional proteomics profiling experiment, such as comparing two sets of
proteomes from two different biological conditions for their qualitative and quantitative
differences in expression of individual proteins, the “MaxQuant plus Perseus” workflow is usually
an excellent choice for deriving the statistical inference and biological interpretation from the data.
Unfortunately, this workflow does not meet some special demands in analyzing the data from
various competitive ABPP experiments.197 Without additional software support for processing
ABPP data, most MaxQuant users are often forced to explore the “txt” folder manually using
Microsoft Excel. These users eventually find themselves overwhelmed and frustrated by these
error-prone manual steps of data manipulation.
Herein, we introduce the maxabpp package that provides a practical software tool for
comprehensive downstream analysis of MaxQuant output in the R environment 259 . It is built for
practicability, simplicity, flexibility, and transparency. The maxabpp package is open-source and
actively maintained at https://github.com/devradiumking/maxabpp. It does not depend on any
bioinformatics package, which ensures its compatibility with most user’s R environments. With
maxabpp and minimal efforts, novice users can perform highly reproducible and scalable data
analysis that summarizes and visualizes ABPP results ready for biological interpretation. All the
essential data analysis only requires a few files from the MaxQuant “txt” folder as the input, a
user-created metadata.txt, and a few lines of code following the tutorial as the instruction. On the
other hand, experienced R programmers can customize most functions in maxabpp to generate
personalized reports. Biostatisticians and bioinformaticians can also test and implement more
sophisticated statistical models on existing functions in the maxabpp package.

4.1.1 Data analysis using maxabpp
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The maxabpp package contains two modules: a qualitative analysis module for crosssample comparisons of identified proteins and a quantitative analysis module for label-free
quantitation (LFQ) of probe-modified peptides.
As shown in Figure 4.1A, the qualitative module begins with reading the proteinGroups.txt
files generated from multiple separate MaxQuant runs on the MS raw data files from samples
processed in different conditions. Proteins labeled by different covalent probes or tagged by
different affinity handles can be compared within and across sample groups. The proteinGroups.txt
files are renamed and placed in a user-specified folder under the R working directory. Reverse
sequences automatically are rejected. Proteins can be compared according to the specified column
of either Protein IDs, Majority protein IDs, Protein names or Gene names on the proteinGroups.txt
files as a function argument:
#read .txt files as datasets, for instance, condition1.txt, condition2.txt, and condition3.txt,
from a folder named #“proteinGroups” under the R working directory
datasets <- read_proteinGroups(folderName = "proteinGroups")
#extract the Protein IDs column from each file and combine as setList
setList <- make_custom_setList(datasets, “Protein IDs”)
The maxabpp package naturally supports the conventional approach that visualizes the
intersections of identified protein sets on a Venn Diagram. In addition to the Venn Diagram,
maxabpp plots the Target Diagram as a novel alternative for visualizing the intersecting protein
sets:
#generate a Venn object by calling Max_Venn function on the setList
Venn_object <- Max_Venn(setList, IndividualAnalysis = FALSE)
#plot Venn Diagram by calling plot_Max_Venn function on the Venn object
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plot_Max_Venn(Venn_object)
As shown on Figure 4.1B, the quantitative module begins with reading the
ModificationSpecificPeptides.txt file generated from a single MaxQuant run on multiple MS raw
data files from samples treated with inhibitor(s) at various inhibitor concentrations. A user-created
metadata.txt file listing all the raw data files and their corresponding experimental conditions is
also required:
#read the .txt file as a dataset
dataset <- read_tsv("ModificationSpecificPeptides.txt")
#read the metadata.txt file
metadata <- read_tsv(“metadata.txt”)
#call pairwise_LFQ function to generate a LFQ table
LFQ_table <- pairwise_LFQ(
raw = dataset,
metadata = metadata,
name_probe_mod = c("Mod"),
max_each_mod = 1,
max_total_mods = 1,
quantitation_level = "peptide",
background_check = FALSE,
normalize_to = "sum_all")
#append additional information to the LFQ table
LFQ_table <- append_ec_sites(LFQ_table, quantitation_level = "peptide")
#generate the volcano plot
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plot_volcano(LFQ_table,

"InhibitorConcentration1

_vs_

InhibitorConcentration2

_log2fold_change" , " InhibitorConcentration1 _vs_ InhibitorConcentration2 _-log10p-value",
xlim = c(-5.5, 2), ylim = c(0, 4), "Gene Names", pCutoff = 1.3, FCcutoff = 0,
"InhibitorConcentration1 _vs_ InhibitorConcentration2/Probe Name")
Notably, the pairwise_LFQ function is highly versatile and flexible. Users can toggle
parameters such as “quantitation_level”, “background_check” and “normalize_to” to perform
additional analysis on the same set of data. For instance, when quantitation_level = “protein” is
set, the pairwise_LFQ will perform quantitation at the protein level by aggregating/summarizing
the intensity of all the probe-modified peptides belonging to individual protein groups. When the
background_check = “TRUE” is set, the pairwise_LFQ will perform quantitation on background
peptides (peptides without any probe modification) so that the user can assess the run-to-run
variation of each sample and decide if it would be necessary to apply the normalization to the final
LFQ output.
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4.1.2 maxabpp Enables specialized MaxQuant data analysis for
competitive ABPP platforms.
Occasionally, the cross-sample comparison of identified proteins can be a frustrating task.
As part of the search algorithm, MaxQuant aggregates indistinguishable sequences, usually protein
isoforms and homologous sequences, into protein groups. The aggregation of these proteins results
in concatenated protein IDs, delimited by a semicolon. For example, the 5-AMP-activated protein
kinase subunit gamma-1 is identified as a protein group of five isoforms/homologous sequences,
“F8VYY9; A0A024R125; P54619-2; P54619; P54619-3; F8VPF5”. When comparing multiple
sets of protein IDs for intersections, the conventional approach simply treats each protein group as
a sequence of characters (string). Consequently, when related by slightly different protein groups
(scrambled or missing protein ID components) from different sets are compared, the st ringmatching algorithm would return FALSE, which reports these protein groups are totally different,
for instance, “F8VYY9; A0A024R125; P54619-2; P54619; P54619-3; F8VPF5” vs. “P54619;
A0A024R125; P54619-2; P54619-3; F8VPF5; F8VYY9” (scrambled components) vs. “F8VYY9;
P54619-2; P54619; P54619-3; F8VPF5” (missing component A0A024R125) vs. “P54619-3”
(single isoform). Alternatively, users often use gene names or protein names for protein IDs
comparison, which drops the isoform-specific protein IDs and treats protein groups as a single
canonical protein or a smaller group of homologous canonical proteins. This simplification is not
ideal for processing ABPP data because protein isoform selectivity of both chemical probes and
inhibitors is also considered valuable information and should be preserved. In the case of peptidecentric and site-specific analysis, distinguishable protein isoforms should be treated as individual
entities rather than part of protein groups.
Therefore, a protein group-compatible alternative to Venn Diagram is needed to illustrate
the intersection and exclusion relationships among various protein ID profiles obtained from
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distinct sample processing methods. The qualitative module of maxabpp features the Target
Diagram as a novel alternative for visualizing the intersecting protein sets. For instance, during the
development of a new chemical probe, multiple distinct affinity tags may be used to explore its
reactivity within a model proteome. After the CuAAC and affinity pulldown, probe-labeled
proteins are enriched from each sample within a unique sample matrix. Each pulldown sample
produces a unique LC-MS/MS profile. At the protein level, MaxQuant identified proteins are
compared for similarities and differences. Proteins commonly identified in multiple differentially
tagged samples are considered as target candidates with higher analytical confidence. 197
On the other hand, the affinity enrichment of analytes can also be performed on probemodified peptides after the trypsin digestion instead of probe-labeled proteins before the trypsin
digestion. In this case, the maxabpp data analysis is focused on probe-modified peptides; data of
probe-modified peptides needs to be filtered from the background peptides, annotated,
summarized, and compared across different samples.
In summary, maxabpp is a powerful R package that integrates unique functions processing
both qualitative and quantitative proteomics data, and thus provides a reliable software solution
for MaxQuant downstream data analysis and visualization of competitive ABPP experiments.
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4.2 Chapter 4 Figures
Figure 4.1 Overview of maxabpp workflows.

Note: (A) Qualitative workflow performing cross-sample comparisons of identified proteins. (B)
Quantitative workflow performing pairwise LFQ of probe-modified peptides from competitive ABPP
experiments for profiling inhibitor dose response.
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Chapter 5 Conclusion and Impact
Chemical proteomics is attracting a growing amount of attention chemical biology research
and beyond. Over the years, various chemical tools and analytical methods have been developed
for chemical proteomics and thus significantly expediting numerous studies of small molecule
modes of action and protein functions. Compared to traditional ligand binding assays, chemical
proteomics methods uniquely highlight the omics methodology of holism and create systemic
solutions to complex problems in chemical biology. Chemical proteomics is a multidisciplinary
subject. The rapid expansion of chemical proteomics d epends on its multiplying knowledge base
and evolving technology, which touches a wide range of scientific subjects. The technological
advancement of chemical proteomics has been discussed in three domains: chemical tools, mass
spectrometry-based analytical methods, and bioinformatics support. The domain of chemical tools
contains both chemical probes for protein reactivity profiling and chemical reagents for enhancing
analytical performance. The former is discussed independently while the latter is considered part
of the method development in mass spectrometry-based analysis.
This dissertation has presented the implementation of chemical proteomics and utilization
of chemical probes for biochemical measurements in two disparate directions. The 2-nitro-ICG
probe exemplifies a novel compound-centric chemical probe that answers how 2-nitroimidazole
targets tumor hypoxia. This study concludes that 2-nitro-ICG and its reduced fragments modified
mouse albumin as the primary protein target, but at two structurally distinct sites, possibly via two
different mechanisms. The development and application of 2-nitro-ICG also demonstrates various
analytical benefits, challenges, and pitfalls in the compound-centric methodological branch of
chemical proteomics.
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In contrast to the 2-nitro-ICG probe, the MeLac-alkyne probe is an innovative activitybased chemical probe with multiple electrophilic sites. This study of MeLac warhead and MeLacalkyne probe explores the significance of broad reactivity in activity-based probes for their
analytical versatility. The characterization of MeLac reactions concludes it is reactive to amino,
hydroxyl, and thiol groups on different types of amino acid residues. It also leads to the discovery
of MeLac-alkyne glutathione adduct, which reveals a potential scalable route towards rapidly
conversion of a multi-electrophile activity-based probe into a large variety of compound-centric
probes. These traits make the multi-electrophile a feature of greater significance on novel warheads
like MeLac. Chemical probes equipped with these warheads afford distinct advantages of being
both activity-based probes and scaffolds for assembling compound-centric probes simultaneously.
In addition to the exploration of chemical probes and their reactivity profiles, the
development of analytical methods in mass spectrometry plays another crucial role in chemical
proteomics. Mass spectrometry is intrinsically a qualitative analytical approach while biological
inferences are often derived from quantitative analysis of small molecule-treated proteomes in
chemical proteomics. Although label-free quantitation is a viable option in some cases of
proteomics profiling, accurate quantitative mass spectrometry primarily relies on the introduction
of various forms of stable isotope-based labels and internal standards. Quantitation-oriented
sample preparation methodologies such as metabolic labeling on proteins, chemical tagging on
peptides, and stable isotope dilution have made mass spectrometry technology amenable for
accurate and precise quantitation of protein targets throughout the chemical proteomics pipeline.
Another focus in analytical method development is reduction of sample complexity.
Biological samples have complex matrices. The introduction of chemical probes and click
chemistry reagents to these samples further exacerbates the complexity of their matrices. Although
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the affinity capture technology can significantly reduce sample complexity and efficiently enrich
analytes, the final proteomics profiling data may still contain a large number of ambiguous spectra.
This spectrum ambiguity issue has been demonstrated and addressed in two aspects: sample
preparation and bioinformatics. In the preparation of MeLac-treated protein samples, the affinity
tagging triplication technique has exposed a novel methodology for enhancing the analytical
implications. On the other hand, the modification-specific data processing principle has provoked
awareness and thoughts on tailoring bioinformatics tools for chemical proteomics.
Despite a few limitations, chemical proteomics has established its irreplaceable position in
chemical biology. Researchers continue to exert efforts to make chemical proteomics technologies
more universally applicable. The chemical tools, analytical workflows, and bioinformatics support
continue to improve. As more innovations emerge at the cutting edge of chemical proteomics, we
may only anticipate a faster expansion of this field.
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